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INTRODUCTION AND THESIS OUTLINE
General 
The treatment of disease has changed over the last decennia from population-
based treatments to personalized medicine, with no exception to cancer therapy. 
The focus on personalized treatment in oncology is mainly based on our growing 
understanding of the pathophysiology of cancer. Molecular imaging has played 
a major role in this. Molecular imaging can be defined by the noninvasive, real-
time visualization of biochemical events at the cellular and molecular level 
within living cells, tissues, and/or intact subjects.1 Molecular imaging can be 
performed in patients during the entire treatment process, with the potential to 
provide a movie of the patient’s disease instead of separate snap-shots. In the 
diseased state, one can choose to image chemical processes in the body or a 
target of interest, such as a cell surface receptor. The form of molecular imaging 
that is currently widely applied, is positron emission tomography using fluor-
18-deoxyglucose (FDG-PET), where areas of the body with increased uptake of 
glucose are highlighted. 
The use of molecular imaging could potentially improve the accuracy of cancer 
detection especially when combined with conventional imaging modalities 
such as ultrasound and CT, by improving sensitivity and specificity. When 
performing tissue-specific molecular imaging with a highly specific target and 
a sensitive imaging system, one should be able to see all involved lesions, even 
micrometastases. One of the cancer types that is in great need of improved 
detection and treatment is pancreatic cancer. Pancreatic cancer has a dismal 
prognosis due to late onset of symptoms and therefore most patients present 
with advanced stage of disease, resulting in less than 30% of patients to 
undergo a potentially curative surgical resection. Of those patients, the rate of 
irradical resections is high, mainly due to invisible tumor boundaries due to the 
perineural and perivascular growth pattern of the tumor. The most commonly 
performed surgical procedure for pancreatic cancer is the pylorus-preserving 
pancreatico-duodenectomy or the classic Whipple procedure. This surgery 
has a high morbidity with a long recovery period. Since the life expectancy 
of this disease is low, even after surgery, there is a high need to select only 
those patients for surgery that will actually benefit from a resection. This 
highlights the need for a tool able to detect this disease earlier, to properly 
stratify patients for the optimal primary treatment modality, either surgery 
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or neoadjuvant chemo- and/or radiotherapy, and in addition, improve results 
during the actual surgical resection. Tumor-specific molecular imaging has the 
potential do to this.
Molecular imaging techniques
Molecular imaging can be done in the diagnostic process in the form of tumor-
specific PET imaging, or during surgery using near-infrared fluorescence (NIRF) 
and photoacoustics. Fluorescence imaging is based on adding an exogenous 
contrast agent (a fluorophore) into the patient that can create contrast to the 
dark background, and permits detection of the desired tissue of interest in 
the surgical field.2 Fluorescence light in the near-infrared window (NIR) (700-
900 nm) has the advantage over visible light in several ways. First, there is 
an increased depth penetration and decreased autofluorescence compared to 
light in the visible range since NIR light is impaired by absorbance and scatter. 
This results in a depth penetration of around 5-8 mm in tissue. Second, since 
tissue has almost no light excitation in the NIR range, the signal-to-background 
contrast can be maximized in this range. Lastly, NIR light is invisible for the 
human eye, and therefore, it will not change the surgical field.3 This requires 
specialized cameras that can make the light visible for the surgeon on a screen.4 
The advantage of fluorescence imaging is that it can be used during open and 
minimally invasive surgery, such as laparoscopy and robotic surgery, depending 
on the used camera. Currently, there are several cameras that can be used for 
this purpose. The difficulty of developing a camera is the high dependency on 
an available imaging agent and vice versa. Choosing the right combination will 
determine the success of both the agent and the camera, since the failure of 
an agent to identify tumor in a specific manner could be due to agent failure of 
because the camera was not sensitive enough to detect the signal.5
As described above, NIRF imaging is superior for the detection of superficial 
lesions < 8 mm of depth. However, to improve the rate of radical resections in 
pancreatic cancer surgery, a depth of around 5 cm needs to be achieved, since 
the deep vascular margin is mainly affected. Photoacoustic imaging is based 
on ultrasound and uses the “light in, sound out”- principle. This technique can 
image at clinically relevant depths (up to 5 cm). The conversion of light to sound 
is called the photoacoustic effect, being introduced first by Alexander Graham 
Bell in 1881.6 In photoacoustic imaging, tissue absorbs pulsed laser light and 
emanates ultrasound waves as a result of transient thermoelastic expansion. 
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Because photoacoustic imaging relies on light only one-way and detection 
is based on sound waves, deeper tissue penetration is possible. Resulting in 
two to three orders of magnitude weaker ultrasound scattering than optical 
scattering in tissue.7 The key strengths of PAI are its ability to collect functional 
and molecular information from most tissues, and the high spatial resolution, 
without the use of non-ionizing radiation.8
Imaging agents
Both for NIRF imaging and photoacoustic imaging, fluorescent dyes are needed 
to enhance the optical signal. Currently, extensive experience is obtained with 
the non-specific fluorescent dyes indocyanine green (ICG) and methylene blue 
(MB). These dyes are approved by the U.S. Food and Drug Administration (FDA) 
for perfusion imaging, and are proven safe. Therefore, these agents were prefect 
candidates for off-label use in the first fluorescent imaging studies. When 
injected intravenously these agents migrate to the tumor using the enhanced 
permeability and retention (EPR) effect of neovasculature. The dye leaks to the 
tumor due to low interstitial pressure in the tumor microenvironment and is 
retained there. This method works well for hypervascular tumors, but it is well-
known that pancreatic cancer is hypovascular, has minimal leaky vessels and 
almost no EPR effect. This is also shown in a study of Hutteman et al. were ICG 
was used to image pancreatic cancer, without successful tumor demarcation.9
Based on the variable results obtained with the non-specific agents, the field 
changed to developing tumor-specific agents, targeting a specific feature of the 
tumor or it’s microenvironment. These targeted agents consist of a targeting 
ligand and a signalling moiety. This signalling moiety can either be a fluorescent 
or photoacoustic dye, or a radionuclide in case of PET imaging. Over the last 
years, tremendous amounts of literature have been published describing the 
development and preclinical validation of these novel agents. However, only 
a few of these agents make it into clinical trials and show successful results. 
This is mainly due to the extensive approval process to perform clinical trials 
with new agents, and because preclinical results are hard to translate to the 
human situation. Currently, a few successful first-in-human trials are conducted 
for tumor-specific intraoperative imaging with targeted agents in ovarian, and 
colon cancer.10-13 
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Potentially, molecular imaging in pancreatic cancer could be successful 
when using a tumor-specific targeted agent, in contrast to the unsuccessful 
attempt seen with the non-specific ICG. There has been scepsis in the field 
on whether or not this imaging technique would work for pancreatic cancer. 
Pancreatic carcinomas have a the dense stroma surrounding the tumor, which 
could potentially prevent imaging tracers from actually reaching their tumor 
cell targets. This has been put forward as an explanation for the unpromising 
results with targeted antibody therapy in pancreatic cancer.14 In this thesis, we 
describe the first results and show proof of tumor penetration by tumor-specific 
imaging agents. 
There is a large range of potential targeting ligands, such as small molecules, 
peptides, aptamers, antibodies, engineered protein fragments, nanoparticles, 
or micro-sized contrast agent. Each of these types of agents are different in 
size and thus possesses different pharmacokinetic characteristics. In this thesis, 
tumor-specific imaging of pancreatic cancer is performed using both an antibody 
and a peptide, showing the different characteristics of these agents, and their 
respective advantages.
Imaging targets for pancreatic cancer imaging
For molecular imaging to be of an additional value in detection and treatment 
of pancreatic cancer, a highly specific imaging signal is needed. In the case of 
pancreatic cancer, in order to achieve a high tumor-to-background ratio, one 
needs to identify a target that is only present on pancreatic cancer, and not or 
in minimal amount on chronic pancreatitis and/or the surrounding unaffected 
pancreatic tissue For imaging purposes, the ideal target is a cellular-membrane 
receptor that is also present in tumor-positive lymph nodes and retains 
expression in vital tumor cells after neoadjuvant therapy. In this thesis several 
targets for pancreatic cancer are described, together with the advantages and 
disadvantages. Important to notice is that, at least, at this point there is no 
optimal biomarker for pancreatic cancer imaging which also ensures all of the 
above described features. An agent, or multiple agents, directed against more 
targets, also known as multiplexing, would probably be ideal. However, at this 
point the process to receive FDA approval for one novel agent is challenging, 
since no precedent is available yet. Therefore, a situation where one can inject 
multiple novel imaging agents into one patient will probably not be realized in 
the near future.
01
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The experimental parts of this thesis focus on two targets, namely integrin 
alphavbeta6 (αvβ6) and the epidermal growth factor receptor (EGFR). For 
now, integrin αvβ6 seems to be the most promising target of the two, due 
to the low expression in chronic pancreatitis, and the high and homogenous 
expression in tumor, tumor-positive lymph nodes, and retained expression after 
neoadjuvant therapy. A disadvantage of this target is that expression in chronic 
pancreatitis and normal pancreatic tissue is not completely absent, due to very 
low expression in the normal ductal tissue. Other promising targets that are 
mentioned in this thesis, but not further studied are CEA,12,13 and uPAR. The 
advantage of uPAR is that it is not only present on the tumor tissue, but also 
on the tumor microenvironment, which is abundantly expressed in pancreatic 
cancer. A disadvantage is that abundant stroma is also present on chronic 
pancreatitis, making it harder to differentiate between the two entities.
Translation from molecule to man
As described above, one of the most challenging aspect of this research is the 
translation of results generated in the preclinical setting to the clinic. A large 
amount of the conducted research will not even make it to this stage and will 
therefore not directly benefit the patient. For this thesis, a unique collaboration 
was put into place between Stanford University Medical School, the LUMC and 
the Center for Human Drug Research (CHDR), to ensure an optimal roadmap for 
promising preclinical agents to make it into the clinic. All of the partners have 
their unique knowledge and experience, providing the possibility to develop 
a roadmap from molecule to man. The Gambhir Lab at Stanford University is 
world-leader in the development and preclinical validation of novel targeted 
imaging agents. The CHDR on the other hand has the unique position to 
perform first-in-human studies in a safe and controlled environment, and the 
Image-Guided Surgery Group at LUMC has the most experience in conducting 
oncologic trials with fluorescence guided surgery.
Regulatory aspects
One of the main struggles to get a novel imaging agent into the clinic in the USA 
are the regulatory aspects set by the FDA. To be able to request for a new drug 
application (NDA), large clinical trials are needed, and patient benefit needs to 
be shown. These trials are costly, and clinically relevant and objective endpoints 
are hard to reach with imaging studies. Especially the costs of these large trials 
make it impossible for an academic partner to pursue this alone. In addition, 
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industry partners are less willing to participate since the expected profit of 
imaging agents is minimal, compared to the development of pharmaceuticals. 
Another problem is that the FDA sees these agents as diagnostics agents, which 
means that no adverse events are allowed. However, the field argues that some 
minor grade I-II adverse events should be allowed, since these agents are used 
in oncologic patients that generally have a worst prognosis compared to the 
general population. Another challenge for approval is that at this point no real 
precedence exists for the products used in tumor-specific optical imaging (e.g. 
camera’s and imaging agents). For optical imaging systems this is challenging, 
because this makes it hard to get 510(k) approval based on equal performances 
compared to predicate devices.
 
THESIS OUTLINE
The thesis consists of five parts describing the entire process from development 
of tumor-specific molecular imaging for pancreatic cancer to the clinical 
application and future directions of this novel method for cancer detection in 
general and in specific for pancreatic cancer. Part 1 focuses on the development 
of targeted molecular imaging for pancreatic cancer. Part 2 describes the 
validation of this technique in preclinical setting. Part 3 focusses on the clinical 
translation of targeted molecular imaging in general, and part 4 describes the 
first-in-human clinical use of tumor-specific imaging agents in pancreatic cancer 
patients. Part 5 provides an introduction into the future directions of targeted 
molecular imaging in general and for pancreatic cancer specific.
Chapter 2 introduces tumor-specific molecular imaging to improve both 
diagnostics and intra-operative management of pancreatic cancer. It summarizes 
the current data available, explains the need to push this field forward, and 
describes promising novel studies. Chapter 3 shows the results of a retrospective 
study on the outcome of pancreatic cancer patients, especially focusing on the 
effect of tumor margin-positive (R1) resection, and indicates where tumor-specific 
imaging can make a difference. Chapter 4 summarizes on optimal molecular 
targets to detect pancreatic cancer, based on an immunohistochemistry study. 
In part 2, the achieved results of part 1 are used to translate the use of targeted 
imaging from ex vivo experiments to preclinical setting. Chapter 5 shows the 
preclinical validation of a novel fluorescent imaging agent, targeting αvβ6, in 
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preclinical pancreatic cancer models. Chapter 6 focusses on different targeted 
imaging agents and methods to enhance imaging signal for early detection 
of cancer. In part two the possibility to use targeted imaging in pancreatic 
cancer in preclinical setting is shown. To be able to translate these promising 
preclinical results into humans, several crucial steps need to be taken, which 
are discussed in part 3. Chapter 7 describes the regulatory aspects to achieve 
approval for the use of both imaging systems and imaging agents. Chapter 8 
provides an overview for the successful clinical translation of optical imaging 
agents. In part 4, the clinical use of targeted molecular imaging in pancreatic 
cancer patients is shown for the first time describing several first-in-human 
studies. Chapter 9 describes the results of the clinical translation of targeted 
PET tracers for pancreatic cancer imaging. Chapter 10 shows the results of 
intra-operative identification of pancreatic cancer using fluorescently labelled 
cetuximab. Chapter 11 focuses on the detection of visually occult tumor-positive 
lymph nodes using molecularly targeted fluorescent imaging during surgical 
resection. Lastly, part 5 provides an insight into the future of this technique and 
discusses the steps needed to make this a widely used technique in the future. 
Chapter 12 describes the need to develop a standardized method in assessing 
agents for fluorescence-guided surgery. And in Chapter 13, a general discussion 
is provided and the future perspectives are discussed.
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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. In order to 
improve outcomes, there is a critical need for improved tools for detection, 
accurate staging and resectability assessment. This could improve patient 
stratification for the most optimal primary treatment modality. Molecular 
imaging, used in combination with tumor-specific imaging agents, can improve 
established imaging methods for PDAC. These novel, tumor-specific imaging 
agents developed to target specific biomarkers have the potential to specifically 
differentiate between malignant and benign diseases, such as pancreatitis. 
When these agents are coupled to various types of labels, this type of molecular 
imaging can provide integrated diagnostic, non-invasive imaging of PDAC as well 
as image-guided pancreatic surgery. This review provides a detailed overview 
of the current clinical imaging applications, upcoming molecular imaging 
strategies for PDAC, and potential targets for imaging, with an emphasis on 
intraoperative imaging applications.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) accounts for about 90% of all 
pancreatic neoplasms and is the fourth most common cause of cancer-related 
deaths in developed countries.1 PDAC has a dismal prognosis, with a five-year 
survival rate of less than 5%. Pain, jaundice and weight loss are the most 
common presenting symptoms but in the early stages of the disease, these 
symptoms may be subtle which often leads to delayed diagnoses.2 The median 
size of PDAC at the time of diagnosis is ~3.1 cm, and these statistics have not 
changed in the past three decades despite advances in imaging technologies, as 
well as in vitro diagnostic testing methods.3 Resection of tumors while they are 
small, well-defined and localized results in a higher chance of complete tumor 
clearance which translates into greater patient survival rates.3, 4 
Only 15% to 25% of patients are eligible for curative resection at their initial 
diagnosis, due to locoregional spread and metastasis.5, 6 More precise detection 
methods can lead to improved patient stratification for the most optimal 
primary treatment modality; either surgery or systemic (neoadjuvant) therapy. 
This selection can prevent patients from undergoing resections without any 
oncologic benefit. Another advantage of precise visualization of the tumor could 
be a more radical resection. Tumor margin-positive (R1) resections occur in up to 
70% of PDAC cases, leading to a high number of locoregional recurrence.7, 8 This 
means that for all patients diagnosed with PDAC, only 15% of these patients 
will receive a radical, tumor-margin negative resection and have a chance for 
prolonged survival. Therefore, improved tools for diagnosis, accurate staging, 
and more effective, tumor-margin negative pancreatic surgeries are crucial for 
improving patient outcomes.9 
Imaging techniques play an important role in the diagnosis of PDAC. Current 
clinical imaging protocols include transabdominal ultrasound, computed 
tomography (CT) and/or magnetic resonance imaging (MRI) for disease staging 
and prediction of resectability.1 Endoscopic ultrasound (EUS) can complement 
these imaging methods with valuable staging information as well as the 
opportunity of tissue diagnosis by fine-needle aspiration.10
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Molecular functional imaging has the potential to play an important role 
in PDAC management and be of complementary value to these conventional 
imaging techniques. It could be used for earlier tumor detection, and improved 
characterization, staging, and response assessment to neoadjuvant therapy. 
It could also serve as a guide for surgery during diagnostic laparoscopy and 
tumor resection. Possible imaging modalities for molecular imaging include 
molecularly-targeted contrast-enhanced transabdominal (CEUS) and EUS, 
CT, MRI, positron emission tomography (PET), photoacoustic imaging (PAI), 
fluorescence molecular imaging, and Raman optical imaging (figure 1). 
Recently, Laeseke et al. published a review focused on the role of molecular 
imaging in early detection of PDAC.11 The current review gives an overview of 
the status of clinical imaging applications, the advances of molecular imaging 
strategies, and most optimal imaging targets for PDAC, with a special emphasis 
on intraoperative applications. 
Figure 1. Schematic illustration of the key imaging modalities used for the diagnostics and po-
tential intraoperative modalities for pancreatic cancer. Ultrasound, (endoscopic) ultrasound; CT, 
computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography. 
Representative images are shown of pancreatic cancer with the displayed modalities, expect for 
photoacoustic and raman optical imaging.
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CURRENT DIAGNOSTIC IMAGING TOOLS FOR PDAC
Transabdominal and endoscopic ultrasound
Ultrasound (US) is often the initial diagnostic assessment used in patients 
presenting with jaundice, weight loss, and abdominal pain. US is a relatively 
inexpensive, portable, noninvasive, and widely available tool. However, the 
sensitivity and accuracy of US is highly dependent on the operator’s skills, 
degree of disease progression and body habitus of the patient. Therefore, 
sensitivity of conventional US for detecting PDAC varies widely and ranges from 
95% in tumors > 3 cm to 50% in tumors < 1 cm.12 In addition, it is difficult 
to differentiate between PDAC and inflammatory diseases such as pancreatitis 
using US technology. 
EUS has become a valuable diagnostic tool for PDAC since it allows for tissue 
sampling and cytological evaluation, both of which can provide a definitive 
diagnosis.13, 14 For the evaluation of solid pancreatic tumors, EUS detects lesions 
<2 cm with greater sensitivity (98%) than CT (86%). On the other hand, EUS 
also has important limitations in the evaluation of solid pancreatic lesions. 
First, there is substantial operator-dependence, resulting in variable sensitivity 
ranging from 57% to 81%.15, 16 Second, the sensitivity is relatively poor (80%) 
when detecting PDAC in patients with pancreatitis.17 And finally, the invasive 
nature of EUS is a significant disadvantage of this technique.
Computed Tomography
Multiphase multi-detector row CT (MDCT) with intravenous contrast is the 
diagnostic test of choice for suspected pancreatic lesions. MDCT has the highest 
accuracy in determining the extent of primary tumor, locoregional extension, 
vascular invasion, distant metastases and resectability.14 MDCT is used to predict 
resectability of PDAC with a positive predictive value (PPV), sensitivity and 
specificity of 89%, 96% and 33-72%, respectively.18, 19 An additional advantage of 
MDCT imaging is the possibility to detect extrapancreatic spread by perineural 
invasion.20 This is of great importance since these patients have significantly 
reduced survival after pancreaticoduodenectomy.21 CT perfusion can be used to 
differentiate between low and high grade PDAC, by using peak enhancement 
intensity values and blood volume parameters.22 Despite its sensitivity, MDCT 
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cannot reliably detect small lesions (<1cm), differentiate between malignant 
lesions and benign conditions, or detect isoattenuating primary tumors.23
Magnetic Resonance Imaging
MRI has a reported sensitivity and specificity for diagnosis of PDAC of 85-93% 
and 72-79%, respectively.24, 25 MRI has advantages over CT regarding improved 
soft tissue contrast resolution and the absence of ionizing radiation. This 
leads to several situations were MRI is preferred above CT; such as with small 
tumors, isoattenuating lesions, and fatty infiltration in the pancreatic head.26 
In addition, there are alternative sequences when using MRI, such as magnetic 
resonance cholangiopancreaticography (MRCP) which can be used to image the 
biliary and pancreatic ducts in detail. MRCP has comparable sensitivity to the 
more invasive endoscopic retrograde cholangiopancreaticography (ERCP) in 
diagnosing PDAC.27 Another potential sequence is diffusion-weighted images 
(DWI), with this technique the difference in diffusion of water molecules is 
visualized by using the apparent diffusion coefficient (ADC). PDAC tends to have 
low ADC values due to high levels of fibrosis. This methods is helpful for the 
identification of subtle lesions with diffusion restriction.26 Due to its high soft 
tissue contrast MRI is the preferred modality for assessing cystic lesions in the 
pancreas.28 Another important advantage of MRI over CT is the more precise 
detection of enlarged lymph nodes and distant metastases.28 A disadvantage 
of both CT and MRI, is that neither can reliably distinguish residual or necrotic 
tumor from fibrosis and radiation changes after treatment.
PET Imaging 
Currently, PET is the only molecular imaging technique used for PDAC. It enables 
whole body imaging to allow staging of diseases, similar to CT and MRI. [18F]-
2-fluoro-2-deoxy-glucose (18F-FDG)-PET has an established role in the work-up 
of various malignancies. The normal pancreas has low glucose usage compared 
to PDAC, so areas with increased uptake can be visualized and point towards 
potential lesions. Because the metabolic activity of a tumor is expressed by 
the degree of 18F-FDG uptake it is possible to predict tumor aggressiveness and 
even survival in patients by the degree of uptake.29, 30 The average sensitivity 
and specificity of 18F-FDG for PDAC are 94% and 90% respectively, compared 
to 82% and 75% for CT.31 Choi et al. reported the use of 18F-FDG-PET to 
detect biologically active tumor volumes and therefore to assess treatment 
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effectiveness.32 A recent multi-center trial in the UK with 550 patients looking at 
the diagnosis of PDAC showed a sensitivity of 92.7% for FDG PET/CT compared 
to 88.5% for MDCT (p=0.010) and a specificity of 75.8% compared to 70.6% 
(p=0.023).33 A problem of using 18F-FDG uptake, is that glucose metabolism is 
not specific for malignant processes, and physiologic uptake can be found in 
normal tissues as well as in inflammatory tissue which might lead to false-
positive findings, causing a similar appearance for pancreatitis and PDAC.34 
 
CURRENT INTRA-OPERATIVE IMAGING TOOLS
A major limitation of the aforementioned imaging techniques, such as CT, MRI 
or PET is the fact that these techniques cannot be applied as intraoperative 
imaging tools due to altered positioning of the body, and tissue manipulation 
by the surgeon.35 For brain cancer surgery, the use of MRI-guided resection 
has almost become standard practice.36 Unfortunately, this method is time-
consuming, costly. Therefore, chances are low that MRI-guided resection will 
be widely-implemented outside the field of brain cancer surgery. Currently, the 
only tools available for a pancreatic surgeon to ensure complete tumor resection 
are visual and tactile information, frozen-section analysis by a pathologist, and 
intra-operative ultrasound. 
Intra-operative frozen-section analysis (IFSA) is commonly performed to 
determine resectability when unanticipated locoregional spread is identified 
during surgery and to ensure negative final margins after resection.37 Although 
frozen section analysis is commonly used to determine successful ablation, it 
is time-consuming,and only samples a small fraction of the wound bed which 
could lead to false-negative results. During surgery, if the IFSA of the resection 
margin turns out to be positive, additional pancreatic tissue is often removed 
in an effort to clear the margin. Only a few single institutional studies have 
assessed the value of this surgical maneuver so far and it is shown that there is 
actually no improved overall survival when additional IFSA-guided resection is 
performed.38-40 IFSA has a reported low incidence of false-positive results, but 
the amount of false-negative results has ranged widely from 1.2% to 75%.41, 
42 This relatively high incidence of false-negative results could indicate that 
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preoperative imaging and possibly even surgical judgement are more reliable 
than a negative IFSA.
Intra-operative Ultrasound
Currently, the only intra-operative imaging technique to help the surgeon 
delineate PDAC from its surrounding structures is anatomical intraoperative 
ultrasound. The ability to provide high resolution real-time imaging, along with 
accurate lesion detection, has established the role of intraoperative ultrasound 
(IOUS) in PDAC surgery. IOUS can be used for intraoperative guidance and 
localization of lesions, for determining resectability, surgical planning, 
differentiation between cystic and non-cystic lesions, and metastatic survey.43, 44 
IOUS also has disadvantages since it is less reliable for detecting superficial and 
small lesions compared to visual and tactile methods.45 Another disadvantage is 
its operator dependence; substantial training and experience are essential for 
generating and interpreting useful images for intra-operative surgical decision-
making.12, 46
THE NEED FOR ADVANCED MOLECULAR IMAGING 
IN PDAC
To be able to improve detection and patient stratification for treatment, there 
is a critical need to develop and improve imaging methods that specifically 
recognize cancer.47 In current practice, the accurate identification of tumors is 
mainly subjective and relies heavily on the surgeon’s experience leading to a 
significant variability in surgical outcomes.48 This inability to exactly identify 
tumors intraoperatively could result in: 1) Incomplete resection of tumors that 
could otherwise have been resected completely; 2) Attempt to resect tumors 
which should have been identified as locally advanced tumors; 3) Incomplete 
lymph node clearance due to lack of knowledge of the involved or potentially 
involved lymph nodes, and 4) Resection of the primary tumor in the presence 
of visually occult micrometastasis. In each of these situations, patients 
undergo operations with little or no oncological benefit, but with a high risk 
of deterioration of quality of life due to surgery in their end stage of life. 
There are two other challenges a surgeon faces when resecting PDAC. First, 
both the benign pancreatitis and malignant PDAC have abundant stroma, and 
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therefore both entities are difficult to distinguish using conventional imaging 
techniques. Second, the introduction of neoadjuvant treatment regimens such 
as FOLFIRINOX, leading to a 51% increase in tumors becoming resectable 
after 4 months of neoadjuvant treatment.49 One of the major drawbacks 
after neoadjuvant treatment is that conventional imaging modalities, such 
as CT and MRI, are often not able to differentiate between viable tumor and 
chemoradiation-induced tumor necrosis and fibrosis, and, therefore, prediction 
of resectability is limited.50 Neoadjuvant treatment effects make differentiation 
between (vital) tumor and fibrotic pancreatic tissue even harder for surgeons 
during the operation.
Tumor-targeted molecular imaging could provide crucial information in these 
situations. Molecular imaging can either be performed by using conventional 
imaging techniques in combination with tumor-specific imaging agents, or by the 
development of novel imaging techniques, such as fluorescent, photoacoustic 
and Raman optical imaging. Currently, several first-in-human clinical trials are 
conducted using these techniques in pancreatic cancer patients.
TUMOR-TARGETED MOLECULAR IMAGING 
STRATEGIES FOR PDAC
A molecular imaging approach using imaging agents that target molecular 
features of cancer could lead to more precise diagnoses.13 The common 
consensus is that PDAC evolves from precursor lesions that transform into 
invasive carcinoma through a multistep process, that involves the progression 
from pancreatic intraepithelial neoplasia (PanIN) into PDAC.51 Genetic 
alterations, such as mutations in the KRAS oncogene or p53, DPC4, and BRCA2 
tumor suppressor genes affect a core group of signaling pathways. The processes 
that are altered in PDAC lead to the expression of specific biomarkers, and these 
changed biomarkers may serve as targets for tumor-specific imaging.52 Potential 
biomarkers for tumor-specific targeting must possess certain characteristics 
such as diffuse upregulation through tumor tissue, strong upregulation 
compared to the expression in normal and surrounding tissue, and localization 
on the cellular membrane.53, 54 An effective molecular imaging agent needs to 
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demonstrate a high ratio of specific to non-specific binding to make sure the 
signal truly reflects the molecular imaging target. 
There are numerous categories of available molecular imaging agents including 
small molecules, peptides, aptamers, antibodies, engineered protein fragments, 
nanoparticles, or micro-sized contrast agent. Each of these types of agents is 
different in size and thus possesses different pharmacokinetic characteristics 
(Table 1). It goes beyond the scope of this review to describe all the different 
molecular imaging agents in detail; however, please refer to the following 
review for further details.55 
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The most important groups of targeted imaging agents that are currently being 
explored are based on targeting specific receptors that are upregulated during 
the progress of PDAC development. For example, global expression analysis of 
PDAC has revealed that claudin 4 and prostate stem cell antigen (PSCA) are 
upregulated in the vast majority of PDACs.56, 57 Given the membrane localization 
and the presence of an extracellular domain, these proteins are attractive 
candidates for targeted imaging. Additionally, claudin 4 has a high expression 
in high grade PanIN lesions, indicating the potential to detect lesions before 
development into an invasive carcinoma.58 Other targets employed for tumor-
specific imaging of different cancer types are not applicable for PDAC due to 
co-expression of these receptors on normal pancreatic tissue (somatostatin, 
secretin, bombesin, cholecystokinin, vasoactive intestinal peptide).59-62 Another 
possibility for PDAC would be the use of a combined target, against both tumor 
and surrounding stroma, which can be of significant advantage because of the 
abundance of stroma in PDAC, such as the target uPAR.63 Since several potential 
imaging targets have been identified for normal pancreatic tissue, an alternative 
strategy could be to visualize normal tissue while abnormal/cancerous would be 
visualized by a lack of imaging signal. For example by targeting the bombesin 
receptor, PDAC would appear by a lack of contrast agent uptake.64 However, 
specificity of those potential molecular imaging targets compared to pancreatitis 
is still to be determined.
MOLECULARLY TARGETED IMAGING AGENTS FOR 
CURRENT CLINICAL IMAGING MODALITIES
Molecularly targeted (intra-operative) ultrasound
Contrast-enhanced US (CEUS) involves the use of targeted microbubble imaging 
agents and specialized imaging techniques. For the diagnosis and differentiation 
of pancreatic malignancies, transabdominal CEUS has generated test 
characteristics comparable to, or better than other diagnostic modalities such 
as conventional ultrasound and CT.65 CEUS with a non-specific agent showed 
similar sensitivity to contrast-enhanced CT for the detection of PDAC (91.7% 
and 97.2%, respectively) and of pancreatitis (82.1% and 67.9%, respectively).66 
Intra-operative CEUS is well established in liver surgery, but it has not yet found 
its place in PDAC. However, CEUS provides a potential for the detection of small 
02
30 | Chapter 2
tumors, since it shows improved sensitivity and specificity compared to multi-
detector CT (MDCT) for pancreatic lesions <2 cm; 91% vs 71% and 94% vs 92%, 
respectively.67
Ultrasound using molecularly targeted microbubbles would be a tool to increase 
sensitivity and specificity even further.68 Targeted imaging agents differ from 
those initially developed by the presence of a targeting moiety able to link the 
microbubble to the selected biomarker.68-72 A disadvantage of microbubbles 
is their relatively large diameter. Therefore, they remain within the vascular 
compartment after intravascular administration, which limits targeting to 
molecules that are overexpressed on the surface of endothelial cells of the 
tumor vasculature (Figure 2).73 
Molecular-targeted agents for ultrasound imaging
The formation of new blood vessels is a fundamental process during tumor 
progression. Under hypoxic conditions, which are required for effective tumor 
angiogenesis, expression of hypoxia-inducible factors is induced in endothelial 
vessels resulting in vascular endothelial growth factor receptor (VEGFR) 
expression.74 VEGFR is a receptor tyrosine kinase that mediates most of the 
proangiogenic activity of VEGF. Our group has previously shown that VEGFR2 is 
a promising target for detection of PDAC. In a cohort of 129 patients, VEGFR2 
was abundantly expressed in up to 72% of all PDAC cases.75 Microbubbles 
developed to recognize VEGFR2, integrin and endoglin were used to visualize 
tumor angiogenesis by ultrasound imaging in PDAC of genetically engineered 
mouse models.76, 77 Recently, first-in-human clinical trials using a VEGFR2-
targeted agent have been performed.72 and shown great potential in detecting 
breast and ovarian cancer.78 Foygel et al discovered and validated thymocyte 
antigen 1 (Thy1) as a new PDAC imaging target.79 Thy1 is a marker expressed on 
the neovasculature of PDAC and shown to be differentially expressed in PDAC 
versus pancreatitis and normal pancreatic tissue in humans.79 In vivo imaging 
studies with a genetically engineered mouse model of PDAC showed a 4-5.5-
fold increased signal in PDAC compared to normal parenchyma when using a 
novel Thy1-targeted microbubble.79 Clinical trials with these agents in PDAC 
patients have not yet been performed, but are planned for the future.
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Figure 2. A. Schematic overview of the principle of ultrasound molecular imaging. A molecular-
ly-targeted contrast agent (microbubble) is administered intravenously into the subject (in this 
case a mouse). Sound waves are transmitted into the subject by the transducer, the sound wave 
reflections are recorded and converted into images. Because of the size of microbubbles of several 
micrometers, the contrast agent remains intravascular and attaches to the target of choice (for 
example VEGFR2). Examples of in vivo molecular ultrasound images with microbubbles in B. trans-
genic mouse model of PDAC, showing a strong signal when targeting VEGFR2 in focus of PDAC 
compared to normal pancreatic tissue, even in small PDAC lesions [From Pysz MA et al. Radiology. 
2015 Mar;274(3):790-9], and C. in human with breast cancer using microbubbles targeting kinase 
insert domain receptor (MBKDR). Left panel: the anatomical image for reference, right panel: MBKDR 
accumulation in breast cancer lesion [Willmann JK et al. J Clin Oncol. 2017 Mar 14:JCO2016708594]
Molecularly targeted MRI
MRI has a fairly high sensitivity as described above, but increased sensitivity 
could be realized by increased enhancement of the tumors using molecularly-
targeted contrast agents. Pirollo et al. described a way to systemically deliver 
the imaging agent gadolinium in a tumor-targeted nanocomplex leading to 
better tissue penetration, and therefore better visualization of PDAC in an 
orthotopic animal model.80 
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Molecular-targeted agents for MRI
Studies using targeted MR imaging against biomarkers, such as plectin-1 and 
EGFR, showed tumor targeting both ex vivo and in vivo.81, 82 ScFvEGFR-IO injection 
lead to 4.8 fold specific decrease in MRI signal in the tumor area, compared to 
a non-targeted particle.81 Mucin-1 is a tumor-specific antigen that is one of the 
early hallmarks of carcinogenesis in a broad range of tumors, including PDAC.83 
Medarova et al. developed a dual-modality imaging agent targeting Mucin-1 
in an orthotopic PDAC model for both MRI and NIRF imaging.83, 84 A potential 
drawback for clinical use of mucin-1 as imaging target is that this antigen 
expression is down-regulated after neoadjuvant gemcitabine therapy.85
Molecularly targeted PET
The specificity of PET imaging could be improved by using a more disease-
specific imaging agent compared to FDG-PET (Figure 3). There are several 
preclinical examples of disease-specific PET imaging in PDAC, and recently, for 
the first time a first-in-human trial is performed by Kimura et al. using a tumor-
specific peptide targeting integrin αvβ6, [18F]FP-R01-MG-F2, for the detection 
of PDAC. This study shows proof even in this cancer type with dense stroma, an 
imaging agent can penetrate the tumor [Kimura RH, et al. under review]. 
Molecularly targeted agents for PET imaging
In preclinical setting, several targets are explored. Aung et al described the 
use of 64Cu-RAFT-RGD, targeting αvβ3, for imaging an orthotopic pancreatic 
tumor-bearing mouse model showing higher detectability of cancer cells as 
compared to 18F-FDG-PET.86 Carbohydrate antigen 19-9 (CA19-9) is widely used 
as a serum marker of PDAC, and it is known to be presented on the tumor cells 
of approximately 90% of all PDAC patients.87, 88 A dual-modal probe targeting 
CA19-9 using PET and near-infrared fluorescence imaging was developed 
by Houghton et al. This probe identified metastases and map sentinel lymph 
nodes in an orthotopic PDAC mouse model via both PET-computed tomography 
(PET/CT) and NIRF imaging.89 Unfortunately, CA19-9 is also presented on 
pancreatitis and therefore, this agent will be of limited value in the clinic.90 
The earlier mentioned cell surface receptor integrin αvβ6 is a well-known
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Figure 3. A. Schematic overview of the principle of tumor-targeted PET imaging, a suitable tracer 
will be administered into the subject (in this case a mouse). Depending on the size of the tracer, 
the tracer can target the cancer at multiple locations; e.g. intravascular, receptors on the cell 
membrane, or intracellular. B. Small-animal PET imaging. BxPC-3 (integrin αvβ6 pos) and 293 
(integrin αvβ6 negative) cells were xenografted in nude mice. PET images were acquired in tumor-
bearing mice using a αvβ6-targeted cysteine knot (
18F-fluorobenzoate-R01) [From Hackel, et al. J 
Nucl Med 2013; 54:1101–1105]. 
target for molecular imaging of PDAC since over 90% of human PDAC cases 
overexpress αvβ6.91-96 Hackel et al. used two version of an 18F-labeled integrin 
αvβ6–targeted cystine knot peptide for successful PET-imaging of PDAC 
xenografted tumors in mice.91 Tissue factor (TF), a transmembrane glycoprotein, 
is also known to be upregulated during tumor growth and metastasis. There 
is a strong correlation between the aberrant expression of TF, staging and 
overall survival in PDAC, making TF an attractive imaging target.97, 98 Hong et 
al. developed a PET tracer, 64Cu-NOTA-ALT-836, for imaging TF expression using 
the chimeric antihuman TF monoclonal antibody, ALT-836. Serial PET revealed 
that the uptake of (64)Cu-NOTA-ALT-836 was significantly higher in TF positive 
tumors compared to negative tumors.99 Activated leukocyte cell adhesion 
molecule (ALCAM) homotypic interactions promote primary tumor growth, and 
this cell-surface glycoprotein is upregulated on cancer cells relative to normal 
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cells.100 McCabe et al. imaged ALCAM expression by using a cysteine-modified 
diabody, CysDb, which binds specifically to ALCAM-positive cells with a binding 
affinity of 1-3 nM and microPET images showed specific targeting of positive 
tumors.101 Clinical translation of this probe seems unlikely due to its relatively 
short half-life and potential nephrotoxicity due to high renal exposure of the 
beta-emitting radionuclide. Alternatively, this agent could be labeled with 
18F, which would overcome these limitations. Lastly, the transferrin receptor 
(TfR) was investigated as a possible target for PET imaging in PDAC. TfR is a 
cell-surface receptor involved in iron uptake. It is overexpressed on cells with 
high proliferation rates, and about 80% of all PDAC patients show high TfR 
expression.102 Sugyo et al. developed a PET probe targeting TfR, with a mean 
tumor-to-muscle ratio of 9.8 at day 6 in a subcutaneous PDAC model. However, 
a major disadvantage of this probe is its high accumulation in the liver, which 
could hinder detection of tumor tissue in close proximity to the liver.103
 
INTRAOPERATIVE MOLECULAR IMAGING 
TECHNIQUES: POTENTIAL FOR IMPROVED INTRA-
OPERATIVE PERFORMANCE
Fluorescence molecular imaging
Over the last few years, intraoperative imaging technologies using near-infrared 
(NIR) fluorescence have made enormous progress. The volume of publications 
in this field has increased eightfold in the literature in the last 10 years.104 
Benefits of Fluorescence imaging using NIR fluorescent light include the 
ability to image in real time using an NIR fluorescence camera system without 
impeding the current clinical workflow. If surgeons were able to resect tumors 
and preserve normal structures more easily, time of surgery could be shortened, 
thereby reducing anesthesia time and its associated risks. Furthermore, this 
could subsequently lower rates of recurrence and complications, which would 
improve patient outcomes and even drive down costs.35 Fluorescence imaging 
using NIR fluorescent light has already been established as a powerful tool 
for guiding precise intra-operative positioning in other types of cancer such as 
liver metastases.105, breast cancer.106, 107, ovarian cancer.108, melanoma.109, vulvar 
cancer.110, 111, and cervical cancer.112, 113. Currently, only the non-specific dyes 
methylene blue (MB) and indocyanine green (ICG) are approved for clinical use 
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by the FDA and in order to determine the true clinical benefit of tumor-specific 
fluorescent imaging, developing and clinically assessing tumor-specific imaging 
agents will be essential (Figure 4). Recently, two first-in-human clinical studies 
are performed by our research groups using tumor-specific intra-operative 
imaging in PDAC, targeting CEA with SGM-101 [Hoogstins CE et al. under review] 
and EGFR with cetuximab-IRDye800.114 Hoogstins et al. performed a phase 1 
clinical trial targeting CEA, with a 700nm fluorescent agent [Hoogstins CE et al. 
under review]. Tummers et al. conducted a clinical trial using both NIR and PA 
imaging for the tumor-specific detection of PDAC with cetuximab-IRDye800.114 
In both trials successful PDAC imaging could be performed, however interfering 
autofluorescence was seen with the fluorescent agent at 700 nm. These trials 
show the first proof that this imaging technique is possible in PDAC, despite the 
idea that the dense stroma of PDAC will restrict targeted-imaging and therapy. 
Tummers et al. even show proof of drug penetration into the a single tumor 
duct.114
Molecular-targeted agents for fluorescent molecular imaging
As described above, until now only agents targeting the CEA and EGFR receptor 
are used in clinical trials for NIR fluorescent imaging of PDAC. With cetuximab-
IRDye800, it was even possible to establish a significantly different fluorescent 
signal in PDAC compared to peritumoral inflammation.114 Furthermore, only 
preclinical work is performed for the identification of intraoperative imaging 
agents and targets. As mentioned before, αvβ6 seems to be a reliable target 
for PDAC. Gao et al. synthesized an integrin αvβ6-targeted near-infrared 
phthalocyanine dye-labeled agent, termed Dye-SA-B-HK, and investigated it 
for possible targeted theranostics. Dye-SA-B-HK specifically bound to integrin 
αvβ6 in vitro and in vivo with high receptor binding affinity, and when used 
for surgical guidance, the tumors were successfully removed completely.93 The 
main advantage of this agent compared to nanoparticles is the size of this 
agent, which gives the ability to extravasate, and faster excretion. Zhang et 
al. recently developed an optical imaging agent, suitable for both fluorescent 
and photoacoustic imaging. This imaging agents consists of a cysteine knottin 
targeting αvβ6 conjugated to the dye Atto-740, A740-R01. The agent was able 
to successfully detect integrin αvβ6 both in vitro and in vivo by photoacoustic 
and fluorescence imaging.115
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Cathepsin E (Cath E) is a tumor-associated intracellular non-lysosomal aspartic 
proteolytic enzyme. In normal physiology Cath E is expressed in immune 
cells. In the pancreas, Cath E is present in PanIN lesions and PDAC, but not in 
normal pancreatic tissue.116 Targeting Cath E can be done by Cath E-activatable 
imaging probes. These agents are nonfluorescent or produce low-fluorescence 
in their unactivated state, but become fluorescent after activation as a result 
of binding to their molecular target such as a tumor-specific enzyme.35, 116, 117 
Using an activatable imaging probe has several advantages. First, in its native 
state the quenched probe is optically silent, thereby minimizing background 
fluorescence and enhancing tumor-to-background ratios. Second, protease 
recognition sites allow for specific activation of probes. Finally, probes can 
Figure 4. A. Schematic overview of the principle of fluorescent imaging, a suitable targeted imaging 
agent with a fluorescent dye will be administered into the subject (in this case a mouse). The agent 
is visualized using a fluorescence imaging system, with an adequate excitation laser and camera able 
to detect the emitted light. The targeted agents migrate to the cellular targets to visualize the tumor 
in a target-specific manner, the imaging agent can target the cancer at multiple locations depending 
on the size; e.g. intravascular, receptors on the cell membrane, or intracellular. B. Top: schematic 
overview showing the principle of fluorescent imaging. Bottom: Intraoperative image showing the 
use of tumor-targeted fluorescent guided imaging during pancreatic cancer surgery.
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be designed to be activated by different proteases, thus permitting specific 
detection of tumors with different protease expression profiles.118, 119 Recently, 
Whitley et al. published results of the first-in-human trial using a protease-
activated fluorescent imaging probe, LUM015, to detect soft tissue sarcoma or 
breast cancer. This study demonstrated the probe’s safety in humans and also 
its tumor-specific fluorescence.120 
Despite improved tissue penetration as compared to visible light, an essential 
limitation of the use of NIR fluorescence imaging intraoperatively is its inability 
to visualize structures deeper than approximately 5 – 8 mm below the surface.35, 
121 As a result of this limitation, the field has been shifting towards developing a 
combination of different forms of imaging modalities, such as PAI, as described 
in the clinical trial of Tummers et al.114 
Photoacoustic imaging
Photoacoustic imaging (PAI), also referred to as optoacoustic imaging, is a 
relatively new imaging technique with significant promise. PAI provides real-
time, noninvasive imaging of the optical absorption properties of tissues. PAI 
relies on the photoacoustic effect; a pulsed nanosecond-long red-shifted laser 
beam that is used to stimulate localized thermoplastic expansion of the tissues. 
This expansion generates pressure waves, synonymous with those produced in 
ultrasound, which can be detected by a transducer and converted into images.121 
The combined use of light and sound gives PAI an important advantage over 
other imaging modalities including CT, PET or ultrasound because it provides 
unique scalability of its spatial resolution. The penetration up to clinically 
relevant depths, namely from 6 mm to 5 cm, is an important factor for its 
potential intraoperative use during PDAC surgery (Figure 5).121-124
PAI can be performed based on two methods: by relying on the differences in 
the optical absorption properties of endogenous tissue or by using exogenous 
imaging agents targeting a specific molecular process of interest. Exogenous 
imaging agents have the ability to greatly enhance the contrast generated by 
PAI. The selection of an imaging agent will depend on the application for which 
it will be used. Design considerations and requirements for a PAI imaging agent 
include: (1) ease of synthesis, (2) overall size on the nano-scale or smaller in 
order to extravasate the vascular compartment, (3) a large absorption cross-
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section of light in the NIR wavelength region where light penetration into 
tissue is maximized, (4) a surface chemistry that allows simple bioconjugation of 
targeting moieties, (5) proven safety profile, and (6) a structural and molecular 
biostability in biological fluids.125 Photostability is also very important for these 
agents as they often suffer from loss of optical absorption (photobleaching) 
due to exposure to prolonged pulsed laser irradiation.126 Nanoparticles are 
the most commonly used types PAI agents, and especially gold nanoparticles, 
single-walled carbon nanotubes (SWNT), and quantum dots.121, 125, 127, 128 Gold 
nanoparticles have an advantage in that their optical properties are highly 
tunable over the NIR spectrum by varying their size and shape. However, they 
Figure 5. A. Schematic overview of photoacoustic imaging principle; after injection of a tumor-tar-
geting agent the imaging agent will target tumor cells and produces an enhanced photoacoustic 
signal, after excitation with a laser. The agent can target the cancer at multiple locations depending 
on the size; e.g. intravascular, receptors on the cell membrane, or intracellular. B. Top: Schematic 
overview showing the principle of photoacoustic imaging; the thermo-elastic expansion caused by 
heating of the tissue due to the laser will lead to acoustic waves that can be converted into both 
ultrasound and molecular images. Bottom: Tumor-targeted photoacoustic imaging. Mice bearing 
FTC133 tumors were photoacoustically imaged using 680 and 750 nm light before and after the 
injection of a MMP-targeting probe [From: Levi, et al. Clin Cancer Res. 2013 Mar 15;19(6):1494-502].
 Tumor-Specific Imaging for Pancreatic Cancer | 39
have major disadvantages since they consist of gold, which is not approved for 
human use, and they can become deformed after extended exposure to laser 
radiation.129 SWNTs absorb light over a broad spectrum, and targeting agents 
can easily be conjugated for molecular imaging. Quantum dots are strongly 
fluorescent and have been shown in multiple studies to be successful PAI agents 
in PDAC.130, 131 Other important disadvantages of gold nanoparticles, SWNTs, and 
quantum dots are their inability to sufficiently extravasate and the potential 
long term effects due to retention in the reticuloendothelial system which are 
not an issue for small particles.132, 133
As previously stated, the strengths of PAI include its clinically relevant depth 
penetration compared to fluorescence imaging and the potential to visualize 
extravascular molecular imaging targeted compared to molecular CEUS. 
The main disadvantages of PAI are its inability to image through bone or air-
filled structures, and the fact that no commercial intra-operative systems are 
available for now.55 Clinical applications for molecular photoacoustic imaging 
are still being explored. For diagnostics in PDAC, PAI could potentially be 
used during EUS in order to improve the sensitivity of the procedure. Studies 
investigating the intraoperative use of PAI are limited, and only described by 
Tummers et al.114 By targeting the EGFR receptor, a significant difference was 
shown in PA signal in the tumor and surrounding pancreatic tissue. This indicates 
that intraoperatively PAI could potentially help determining the extent of the 
tumor infiltration before removal, tumor delineation, and the completeness of 
removal following resection and also play an important role in the assessment 
of metastases and lymph node status.121 
Molecular-targeted agents for photoacoustic molecular imaging
In preclinical studies, the first use of targeted photoacoustic imaging using 
SWNT was described by De La Zerda et al. in 2008. Intravenous administration 
of SWNT conjugated to cyclic Arg-Gly-Asp (RGD) peptides in mice bearing 
tumors showed eight times greater photoacoustic signal compared to mice 
injected with non-targeted nanotubes.128 Levi et al. developed and validated 
both tumor-specific PAI agents for prostate cancer, against gastrin-releasing 
peptide receptor.134, and for follicular thyroid carcinoma, against MMP-9.135 Both 
agents showed increased PAI signal compared to a control agent. Conjugated 
polymers (CPs) are upcoming optical imaging agents that have unique chemical 
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and optical properties thus allowing them to be used as imaging agents for PAI 
among other technologies.136 Balasundaram et al. used folate-CP dots for the 
molecular imaging of breast cancer and showed a strong PA signal compared to 
non-specific CP dots.137 Promising PAI agents are activatable agents, as firstly 
described by Levi et al. targeting a proteolytic enzyme, e.g. MMP-2, which is 
photoacoustically silent before cleavage and leads to PAI signal after activation 
by the target.138 
To tackle the abovementioned limitation fluorescence guided surgery is facing 
with limited depth penetration, PAI could help determining the extent of tumor 
before removal, and the completeness of the resection intraoperatively. On the 
other hand, fluorescent imaging has a superior sensitivity for superficial lesions. 
By combining the two modalities, the strengths of both NIR fluorescence 
imaging and PAI have the potential to overcome the limitations of the individual 
techniques in a combinatorial fashion. 
Raman optical imaging
Raman optical imaging is based on the Raman effect, a process discovered by 
Chandrasekhara Venkata Raman in 1928 that is based on the inelastic scattering 
of light. Objects made of different molecular compositions will scatter light 
differently and produce unique spectra that are a function of the chemical bonds 
contained in the molecule of interest. Unfortunately, Raman scatter is very weak, 
with less than one in a million incident photons experiencing this effect.121, 139, 140 
When the scattering molecule is placed on a surface of a roughened plasmonic 
substrate, the signal is increased by many log orders and is known as surface-
enhanced Raman scattering (SERS).141, 142 A major advantage of Raman optical 
imaging is the potential to detect multiple SERS nanoparticles simultaneously 
(a process called multiplexing), by modifying the Raman active layer that is 
absorbed onto the metal surface.139 Raman spectroscopy is recently tested ex 
vivo on human colon tissue. Zavaleta et al developed a Raman spectroscope in 
combination with a multiplexed panel of tumor-targeting Raman nanoparticles, 
to rapidly distinguish between normal and precancerous tissues and to identify 
flat lesions in the colon.143 This technology could be used for helping endoscopists 
or surgeons to delineate tumors while performing procedures.144, 145 Additionally, 
Jermyn et al. developed a handheld contact Raman spectroscopy probe for the 
detection of cancer cells in the human brain. Intra-operatively, they were able to 
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differentiate normal brain from cancer and normal brain invaded by cancer with 
a cellular resolution with sensitivity of 93% and specificity of 91% in humans.146 
Kircher et al. described a MRI-PAI-Raman imaging nanoparticle to delineate the 
margins of brain tumors. This triple-modality-nanoparticle approach combines 
the strengths of the three modalities and leads to more accurate brain tumor 
imaging and resection in mouse models.147 A variation on Raman spectroscopy, 
transmission Raman spectroscopy, has enabled identification of calcifications at 
depths of up to 2.7 cm in breast tissue.148 This technique could potentially be 
used in the differentiation between PDAC and pancreatitis, since the latter is 
known for containing abundant calcifications. However, continued development 
of Raman spectroscopic instrumentation is needed in order to perform at the 
level necessary for intraoperative clinical use, including the design of a probe 
and the complete hardware which will need to be compact and easily integrated 
into the clinical OR.149
 
SUMMARY AND CHALLENGES FOR THE FUTURE
Despite great efforts to improve treatment for patients with PDAC in recent 
years, the disease still has the worst prognosis of all major solid cancers. 
Molecular imaging using tumor-targeting agents and various modalities has 
shown great potential, both clinically and preclinically, in order to bridge the 
gap between diagnostic and intraoperative imaging for PDAC treatment, and for 
monitoring response to perioperative chemo- and or radiotherapy. Multimodal 
imaging modalities also have significant potential when used as an integrated 
diagnostic and intraoperative technology, since this can overcome limitations 
of the individual modalities. At this point, feasibility of tumor-specific PET and 
fluorescence is shown in PDAC patients, and as soon as the other modalities are 
translated into the clinic the full potential of tumor-specific molecular can be 
assessed (Figure 6).
The discovery of the perfect target (Table 2) and translation of molecular-
targeted imaging to the clinic remains challenging due to the need for specific 
exogenous imaging agents in order to image the biochemical process of interest. 
The discovery and validation of such imaging targets is time-consuming and 
expensive, and rarely results in a clinically useful agent. Many of the imaging 
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probes reported in animal models have failed to reach the clinic and are still 
in the investigational stage. Unfortunately, the extensive approval process of 
the FDA makes it impossible to quickly test imaging probes in a clinical pilot 
study in order to determine effectiveness in humans and thus save resources 
and concentrate on more promising probes.150 In addition, the added value of 
molecularly-targeted imaging to patient benefit still needs to be proven before 
wide-spread use of this technique is expected. This needs to be accomplished 
by increasing the number of human trials using a standardized technique to 
demonstrate safety and effectiveness. Although this is still far from current 
reality, the bulk of preclinical studies and the first successful clinical studies 
outlined in this review, show that more wide-spread clinical use is on the 
horizon. 
Figure 6. A schematic overview of the principle of tumor-targeted imaging in pancreatic cancer, 
showing the most promising imaging modalities for early diagnosis and improved surgical treatment, 
and most promising targets for this purpose. Αvβ6; Integrin αvβ6, CEA; Carcinoembryonic Antigen, 
EGFR; Epidermal growth factor receptor, Thy1; Thy-1 cell surface antigen, uPAR; Urokinase receptor, 
VEGFR2; Vascular endothelial growth factor receptor 2, Plec1; Plectin 1, Cath E; Cathepsin E.
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Table 2. Summary of Potential Targets Molecular Imaging Purposes for PDAC with Main Advantag-
es and Disadvantages.
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Table 2. Summary of Potential Targets Molecular Imaging Purposes for PDAC with Main Advantag-
es and Disadvantages.
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Table 2. Summary of Potential Targets Molecular Imaging Purposes for PDAC with Main Advantag-
es and Disadvantages.
Target Type Localization Main advantage Main disadvan-
tage
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ABSTRACT
Background: The prognosis of patients with PDAC remains poor and selection 
of patients for potentially curative surgery is challenging. Here, we examined 
the impact of margin-positive (R1) resection on locoregional recurrence and 
overall survival (OS), tumor characteristics and/or surgical technical factors that 
determine R1 resection in PDAC surgery, and how these factors affect outcome. 
Methods: This retrospective study included 470 patients who underwent surgery 
for PDAC. The effect of tumor margin status, patient characteristics, and tumor 
characteristics on locoregional recurrence, distant recurrence, and OS were 
assessed. 
Results: R1 resection was associated with decreased OS (p<0.001) and reduced 
time until locoregional recurrence (p<0.005). In contrast, disease recurrence 
patterns were similar between R1 and R0 patients. The main risk factors for early 
recurrence were tumor stage, tumor-positive lymph nodes (N1), and perineural 
invasion. Among patients with tumor-negative lymph nodes (N0), those with R1 
resections had significantly reduced OS compared to patients who underwent 
R0 (radical) resection.
Conclusion: For pancreatic cancer surgery, R1 status is determined largely by the 
tumor characteristics. Although R1 resection is a major contributor to reduced 
survival and early recurrence, overall recurrence patterns are similar between 
R0 and R1 patients. Finally, in N0 patients, surgical factors affect R1 status.
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INTRODUCTION
The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing. Despite 
recent advances in cancer therapy, including improved chemotherapy regimens, 
overall survival (OS) among patients with PDAC remains poor.1 Currently, radical 
surgical resection, combined with (neo)adjuvant chemotherapy, is the only 
potentially curative treatment. Unfortunately, among patients who undergo 
surgical resection, margin-positive resections (R1) and rate of recurrence are 
high.2, 3 Several factors have been identified as potentially affecting outcome 
among patients who undergo surgical resection; these factors include resection 
margin status, tumor size, the presence of perineural and/or lymphangioinvasion, 
and lymph node status. Among these factors, margin status receives the most 
attention in literature, yet remains the most controversial and debatable factor.4 
More than two decades ago, Yeo et al. reported that patients who underwent a 
radical (R0) pancreatoduodenectomy had a 5-year survival rate of 26%, whereas 
patients who underwent an R1 resection had a 5-year survival rate of only 8%.5 
In addition, Ghaneh et al. recently reported the results of a large multicenter, 
randomized controlled trial in which they found a significant difference in 
median survival between R0 resection (24.9 months) and R1 direct positive 
margin resection (18.7 months).6
In contrast, a growing body of data has become available showing that 
resection margin status is not an independent risk factor for survival. 7-10 One 
reason suggested to explain this finding is the lack of a standard, international 
consensus for pathological evaluation and assessment, as well as the lack of a 
uniform definition of microscopic margin involvement.11, 12 In addition to this lack 
of a clear definition, geographical differences have been observed. For example, 
in the US, a resection margin is considered to be positive if the tumor cells 
have reached the inked margin;5, 13 in contrast, in Europe a resection is defined 
as R1 if the tumor is present within 1 mm of the resection margin.11, 14, 15 This 
discrepancy has led to a wide range of reported rates of microscopic resection 
margin involvement (R1) from less than 20% to more than 75% of cases.14, 16-20
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When using the R0 definition “absence of tumor tissue at the ink margin”, 
50-80% of these patients will develop local recurrence.21, 22 This finding indicates 
that this definition does not accurately represent clinically relevant outcomes 
such as disease-free survival (DFS). Recently, Osipov et al. reported an improved 
DFS when defining a R0 resection as tumor cells >2 mm from the margin; 
specifically, increasing the margin from 0.5 mm to 2 mm increased both OS and 
DFS, whereas further increasing the margin >2 mm did not significantly improve 
clinical outcome.23 These results support reports by Chang et al.24 and Gebauer 
et al.,25 who recommend a resection margin definition of 1.5 mm or 2 mm. An 
alternative hypothesis suggests that recurrence following R1 resection is not 
due to residual tumor cells, but rather a more aggressive biology of the original 
tumor.26, 27 This hypothesis is based on the finding that among patients with a 
recurrence, an isolated recurrence without distant metastases is relatively rare, 
occurring in only 10-25% of these patients.7, 28 
In addition to a high rate of R1 resections, another major problem is the 
significant prevalence of early recurrence, either locoregional or at distant 
site, within six months following surgery. Although these patients underwent 
an extensive surgical procedure with high morbidity and a high risk of reduced 
quality of life, they received no oncologic benefit.
Here, we investigated a relatively large cohort of pancreatic cancer patients 
at a tertiary referral center in order to correlate microscopic margin status to 
survival, local control, and distance metastasis. In addition, we performed a 
subset analysis in order to investigate the impact of tumor biology characteristics 
and surgical technical aspects.
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MATERIALS AND METHODS
Study design
This retrospective database study was approved by the Institutional Medical 
Ethics Committee at Leiden University Medical Center (LUMC) in Leiden, the 
Netherlands. Data were retrieved from the electronic patient records of all 
patients who underwent pancreatic cancer resection at LUMC from January 2006 
through December 2016, and follow-up data were collected through October 
2017. Patients were included in the study if the diagnosis of pancreaticobiliairy 
adenocarcinoma was confirmed by pathological examination; patients with any 
other histopathological diagnosis were excluded. The demographic information 
and patient characteristics collected in the database included the patient’s age at 
the time of surgery, sex, and type of surgery. The tumor characteristics included 
pTNM stage, grade, histopathological diagnosis, lymph node involvement, and 
lymphangio- and/or perineural invasion.
For detailed information on the indications for surgery, adjuant therapy and 
follow-up plan, please see supplementary methods. Recurrence was defined 
as evidence of disease on an imaging scan. Local recurrence was defined as 
the presence of disease in the surgical bed. Regional recurrence was defined 
as presence in the mesentery, periaortic soft tissue, the pancreatojejunal 
anastomosis, or in the intracaval, periceliac, and/or retroperitoneal lymph 
nodes. Distant metastases were defined as the presence of disease in the 
omentum, peritoneum, solid organs, and/or pelvic lymph nodes. We defined 
early recurrence as recurrence that occurred within six months following 
surgery, based on the published definition.29, 30
Pathological assessment
Macroscopic and microscopic examination of the pancreatoduodenectomy 
specimen was performed using standardized methods in accordance with the 
guidelines established by the Dutch Pancreatic Cancer Group (DPCG), which 
followed the recommendations reported by Verbeke and colleagues.11, 14 Before 
2010, examination was performed by bi-valving of the specimen in accordance 
to Rosai and Ackerman’s surgical pathology and Adsay et al. After the specimen 
is resected, the surgeon attaches colored beads to specific resection margins. 
Upon receiving the specimen, the pathologist then uses multicolor inking of the 
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specimen in order to clearly identify the margins. The following terms were used 
to define the margins: posterior margin, vascular margin (superior mesenteric 
vein or superior mesenteric artery), common bile duct margin, anterior margin, 
pancreatic neck margin, caudal margin, and circumferential margin.
Histological findings were reviewed to confirm the diagnosis, tumor 
characteristics, and R1 status of the margins. Staging was determined using 
the TNM cancer staging system, 7th edition (2010). For this study, we used the 
following definition for R1 resection in accordance with Dutch guidelines: a 
surgical margin with malignant cells identified ≤1 mm from the inked margin 
was considered positive, per the guidelines of the British Royal College of 
Pathology (RCPath).
Statistical analyses
Data were analyzed using SPSS Statistics for Windows, version 23.0 (IBM Corp., 
Armonk, NY). For a detailed statistical plan, please see supplementary methods. 
Kaplan-Meier analysis and the log-rank test were used to analyze differences 
in survival between groups. Characteristics that were found to be correlated 
with either recurrence status or survival were included in a Cox proportional 




From January 2006 through December 2016, a total of 470 patients underwent 
surgery for pancreaticobiliairy adenocarcinoma at our center. Among these 
470 patients, 322 patients underwent resection (68.5%); the remaining 148 
patients (31.5%) underwent exploratory surgery only, either with or without 
palliative bypass surgery due to distant metastases or non-resectable disease. 
Of the resected patients, 299 underwent Whipple surgery or pylorus-preserving 
pancreaticoduodenectomy (PPPD), 35 patients distal pancreatectomy, and 12 
total pancreatectomy. Among the 322 resected patients, 193 (59.9%) had an 
R0 resection, and 129 patients (40.1%) had an R1 resection; 161 of these 322 
patients were men, and 161 were women, the mean age was 65.4 years, and the 
median survival time following resection was 18.0 months. Compared to the 
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R0 group, more patients in the R1 group received adjuvant therapy (49.2% vs. 
59.7%, respectively; p=0.065). Prior to adopting the so-called Verbeke protocol 
for grossing of pancreas specimens (i.e., from 2006 through 2009), the R1 
resection rate was 32.4%; in 2010 and later, the R1 resection was 42.1%; these 
rates did not differ significantly (p=0.144). Compared to the patients in the R0 
group, the patients who underwent an R1 resection (Table 1) had significantly 
larger tumors (p<0.001), more tumor-positive lymph nodes (p=0.001), and a 
higher prevalence of perineural invasion (p<0.001).
Patients with R1 resection have increased risk of recurrence
Of all resected patients 60.9% of patients developed a form of recurrence at 
follow up after resection: 32.6% developed locoregional recurrence, 46.9% 
developed distant metastases. Time until locoregional recurrence was 
significantly shorter in the R1 resection group (median: 16 months; 95% CI: 
12.5–19.5) compared to the R0 group (median: 36 months; 95% CI: 5.3–66.7; 
p<0.005) (Figure 1A). Interestingly, in the first 6 months following resection, 
the prevalence of locoregional recurrence was similar between the R1 and R0 
groups (~8%) (Figure 1A). Time until distant metastases was also significantly 
shorter in the R1 group (median: 15 months; 95% CI: 10.6–19.4) compared to the 
R0 group (median: 20 months; 95% CI: 13.4–26.6; p<0.05) (Figure 1B). Among 
the patients who developed metastases, metastases developed more rapidly in 
the liver (median: 8 months; 95% CI: 6.8–9.2) compared to extrahepatic distant 
metastases (median: 13 months; 95% CI: 10.6–15.4; p<0.001) (Figure 1C). Finally, 
time until overall recurrence was significantly shorter in the R1 resection group 
(median: 13 months; 95% CI: 9.9–16.1) compared to the R0 resection group 
(median: 15 months; 95% CI: 12.2–17.9; p<0.001) (Figure 1D). Locoregional 
recurrence was significantly correlated with perineural invasion (HR: 1.62; 
p<0.04), and the only significant predictor of distant metastases was lymph 
node status (HR: 1.96; p<0.005) (Table S1).
R1 status of the vascular margin negatively influences outcome
Next, an in-depth analysis was performed of the technical aspects of pancreatic 
cancer surgery and found that among the various surgical margins, the vascular 
margin was affected in 46.5% of patients who underwent an R1 resection 
(Supplementary Table S2). The location of the R1 margin had little effect 
on surgical outcome. Among the various margins, only the vascular margin 
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Table 1. Patient characteristics categorized by R0 and R1 resection.
Variable R0 (N=193) R1 (N=129) p-value
Age in years, mean SD) 66 (10) 64 (9) 0.172
Sex, M/F 95/98 66/63 0.733
Death, N (%) 130 (67.4) 101 (78.3) 0.033
Median survival in months 
(95% CI)
22 (17.2-26.8) 15 (12.6-17.4) <0.001
Tumor size in mm, mean 
(SD)
26 (15) 33 (15) <0.001
Adjuvant therapy, N (%) 95 (49.2%) 77 (59.7%) 0.065
Tumor differentiation, N 
(%)
0.564
Well 40 (20.7) 23 (17.8)
Moderate 80 (41.5) 53 (41.1)
Poor 71 (36.8) 53 (41.1)
Undifferentiated 2 (1.0) 0 (0.0)
Lymph node status posi-
tive, N (%)
122 (63.2) 100 (77.5) 0.007
Median number of positive 
lymph nodes
 (IQR)
1 (0-3) 3 (1-5) 0.001
Tumor stage, N (%) <0.001
IA 23 (11.9) 4 (3.1)
IB 9 (4.7) 2 (1.6)
IIA 40 (20.7) 19 (14.7)
IIB 118 (60.6) 89 (69.0)
III 2 (1.0) 13 (10.1)
IV 1 (0.5) 2 (1.6)
Perineural invasion, N (%) 104 (53.9) 97 (75.2) <0.001
Lymphangioinvasion, N (%) 35 (18.1) 35 (27.1) 0.055
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appeared to affect the clinically relevant outcome measures. Although the 
vascular margin did not affect OS (Figure S1A), performing an R1 resection at 
this margin increased the risk of local recurrence compared to other R1 margins, 
with a shorter amount of time until recurrence (median: 16 months; 95% CI: 
14.5–17.5 vs. 28 months; 95% CI: 17.6–38.5; respectively; p=0.07) (Figure S1B). 
Other margins did not affect the time until local recurrence (Figure S1C). Lastly, 
distant metastases were not affected by the location of the R1 margin. 
Among the 196 patients who had a recurrence, 55 (28.1%) had a recurrence 
within 6 months following surgery. The patients with early recurrence had a 
higher tumor stage, more tumor-positive lymph nodes, and a higher prevalence 
of perineural invasion compared to all other patients without a recurrence 
within 6 months following their resection, however none of these differences 
were significant (Table 2). Finally, among the patients who developed distant 
metastases, liver metastases were significantly more common in the early 
recurrence group compared to the patients in the late recurrence group (70.9% 
vs 22.5%, respectively; p<0.001).
Figure 1. (A-B) Locoregional recurrence (A), and distant metastases (B) in patients who underwent R0 or 
R1 resection. (C) Time course of distant metastases in the liver or other locations. (D) Overall recurrence 
in patients who underwent R0 or R1 resection. 
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Table 2. Patient characteristics categorized by time until recurrence.
Variable <6 months recurrence 
(N=55)
All other patients 
(N=267)
p-value
Age in years, mean (SD) 64 (10) 66(10) 0.150
Sex, M/F 29/26 132/135 0.657
Death, N (%) 53 (96.4) 185 (64.5) <0.001
Median survival in 
months
8 23 <0.001
Tumor size in mm, mean 
(SD)
32 (14) 28 (16) 0.083




Well 6 (10.9) 57 (21.3)
Moderate 20 (36.4) 113 (42.3)
Poor 29 (52.7) 95 (35.6)
Undifferentiated 0 (0.0) 2 (0.7)
Lymph node status 
positive, N (%)
43 (78.2) 179 (67.0) 0.104
Median number of posi-
tive lymph nodes
(IQR)
2 (0-4) 2 (1-5) 0.125
Tumor stage, N (%) 0.192
IA 2 (3.6) 25 (9.4)
IB 1 (1.8) 10 (3.7)
IIA 9 (16.4) 50 (18.7)
IIB 38 (69.1) 169 (63.3)
III 3 (5.5) 12 (4.5)
IV 2 (3.6) 1 (0.4)
Perineural invasion, N 
(%)
40 (72.7) 161 (60.3) 0.083
Lymphangio invasion, 
N (%)
15 (27.3) 55 (20.6) 0.275
Resection margin, N (%) 0.071
R0 27 (49.1) 166 (62.2)
R1 28 (50.9) 101 (37.8)
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Margin status does not affect long term patterns of recurrence
Among the patients who developed metastases, the majority of these patients 
(n = 99) developed liver metastases as the first site of distant spread, compared 
to only 52 patients with other distant metastases (primarily lung metastases). 
However, we found no difference in the pattern of metastases between the 
R0 and R1 resection groups (Figure 2). Interestingly, among our entire patient 
cohort, 14% presented with distant metastases within 5 months, and of the 
Figure 2. Spatial distribution of local recurrence (purple) and distant metastases (blue) following re-
section, for all patients (left) and only the patients with distant metastases sorted by R0 and R1 status 
(right).
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patients who develop distant metastases, 26.3% of patients had liver metastases 
within 6 months after resection. 
R1 resection reflects poor tumor characteristics and leads to decreased overall 
survival 
The patients in the R1 resection group had significantly decreased OS time 
(p<0.001), with median survival of 15 months (95% CI: 12.6–17.4) compared 
to the patients in the R0 group (median OS: 22 months; 95% CI: 17.2–26.8) 
(Figure 3). Overall, the prognosis among the 55 patients with early recurrence 
was extremely poor, with overall survival similar to patients who underwent 
exploratory surgery without resection (p=0.408); the median survival time of 
these two groups was 8 and 5 months, respectively. Multivariable analyses 
revealed that perineural invasion, tumor-positive lymph node status (N1), and 
an R1 resection were significant predictors of OS, with hazard ratios (HR) of 1.44 
(p<0.02), 2.15 (p<0.001), and 1.37 (p<0.05), respectively. Adjuvant chemotherapy 
had a protective effect on OS, with HR of 0.70 (p<0.02) (Table S3).
In node-negative (N0) patients surgical factors play a major role
Locoregional recurrence occurred significant earlier in the patients with R1 N0 
(median: 17 months; 95% CI: 8.7–25.3) or R1 N1 status (median: 16 months; 95% 
CI: 12.3–19.8) compared to the patients with R0 N0 (median: 67 months) or R0 
N1 (median: 27 months; 95% CI: 14.7–39.3) (Figure 4A). Finally, the patients with 
R0 N0 status had significantly longer interval until the development of distant 
metastases (median: 67 months; 95% CI: 17.0–117.0) compared to the patients in 
the R0 N1 (median: 14 months; 95% CI: 10.6–17.4), R1 N0 (median: 13 months; 
95% CI: 6.1–19.9), and R1 N1 (median: 17 months; 95% CI: 12.7–21.3) groups 
(Figure 4B).
On average, the patients with R0 N0 status had significantly longer survival 
(median: 45 months; 95% CI: 0.00–95.3) compared to the patients with R0 N1 
(median: 17 months; 95% CI: 14.7–19.3; p<0.001), the patients with R1 N0 status 
(median: 17 months; 95% CI: 10.4–23.6; p<0.001), and the patients with R1 N1 
status (median: 14 months; 95% CI: 11.7–16.3; p<0.001). Moreover, the patients 
with R1 N1 status also had significantly longer survival than the patients who 
underwent exploratory surgery without resection (median: 5 months; 95% CI: 
3.9–6.1; p<0.001 vs. the R1 N1 group) (Figure 4C). As discussed above, in the 
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overall patient population tumor characteristics appears to affect outcome 
and local control more than performing an R1 resection. However, when 
we performed a subset analysis based on lymph node status, we found that 
survival was significantly worse in the N0 patients with an R1 resection, while 
tumor characteristics were similar (Table 3). Finally, we assessed the effect 
of adjuvant therapy on OS in node-negative and -positive patients (Figure 
4D and 4E). All patient groups with adjuvant therapy show an improved OS, 
especially node-negative patients with R0 resection (figure 4D). Thus, for the 
node-negative patients performing a radical surgical resection will make a 
difference and, primary treatment should focus on getting the patient in an 
optimal condition to received adjuvant chemotherapy, to improve outcome. 
Table 3. Effect of tumor biology.
Lymph node status 
Negative (N0)
Lymph node status 
Positive (N1)
R0 N0 R1 N0 p-value R0 N1 R1 N1 p-value
Perineural invasion, Y (%) 47.9% 55.2% 0.509 57.4% 81.0% <0.001
Lymphangioinvasion, Y (%) 11.3% 20.7% 0.218 22.1% 29.0% 0.241
Tumor differentiation, N (%) 0.802 0.741
Well 22.5% 20.7% 19.7% 17.0%
Moderate 35.2% 34.5% 45.1% 43.0%
Poor 39.4% 44.8% 35.2% 40.0%
Undifferentiated 2.8% 0% 0.0% 0%
Mean tumor size in mm 27 27 0.933 26 34 <0.001
Figure 3. Subset analysis of the effect on overall survival of margin status 03
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DISCUSSION
Patient stratification in order to determine the optimal primary treatment 
modality with respect to pancreatic cancer surgery is challenging. Our 
results show a clear difference between R0 and R1 resection with respect to 
the clinically relevant outcomes OS and DFS. Several studies have gone one 
step further when defining clear margins, using a resection margin of ≥2 mm 
rather than >1 mm.23-25 Potentially, the benefits associated with achieving an 
R0 resection in our study could have been even more robust if we had used a 
margin of ≥2 mm for R0 resections.
The posterior margin is often reported as the clinically relevant margin;22, 23 
however, this margin is the most challenging to clear.4 In their recent study, 
Osipov et al., included the posterior surface, vascular groove, and uncinate 
margins in the posterior margin,23 in accordance with criteria established by 
the American Joint Committee on Cancer. Their results are consistent with this 
study, in which the vascular margin was found to be the margin that has clinical 
consequences with respect to local recurrence. When we sorted the margins in a 
similar manner to that by Osipov et al., we found that 64.4% of R1 margins were 
posterior margins. In their recent study including 1151 patients, Ghaneh et al. 
found that an R1 direct posterior resection margin was associated with reduced 
overall survival and recurrence-free survival, whereas an R1 direct positive 
superior mesenteric margin was associated with local recurrence; for both of the 
margins, however, an R1 <1 mm did not affect clinically relevant outcomes.6 On 
the other hand, other groups found that the transection margin of the pancreatic 
neck and the SMA-facing margin were the only significant R1 sites of R1 with 
respect to prognosis.31 Although it is currently unclear why involvement of one 
margin would have higher prognostic value than another margin, the answer 
may lie in differences in the density of bloodvessels, nerves, and/or lymphatic 
vessels surrounding the pancreas. Another important factor to consider is that 
the resection commonly performed for pancreatic cancer is already quite an 
extensive procedure. Oftentimes, in order to resect more tumor the only option 
available to the surgeon is to perform a vascular resection. Therefore, a highly 
sensitive detection method for detecting the tumor’s boundaries is essential, 
as the surgeon can still make a difference in the extent of the resection at the 
vascular margin and, according to this study, patient outcome.
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70 | Chapter 3
A striking finding from our study is the relatively high recurrence rate within 6 
months after surgery in both the R0 and R1 groups. This finding indicates that 
several lesions were not detected by preoperative imaging, possibly due to the 
use of conventional imaging modalities (i.e., computed tomography and MRI), 
which are currently not sufficiently sensitive for identifying small lesions. This 
issue is clinically relevant as mean OS of these patients was only 8 months 
compared to 11 months of OS in patients who receive palliative chemotherapy 
due to non-resectable or metastatic disease with FOLFIRINOX (leucovorin and 
fluorouracil combined with irinotecan and oxaliplatin). Thus, the patients with 
early recurrence often have a poorer prognosis following surgery. 
We believe that focus should shift toward improving the detection of distant 
disease and determining the feasibility of local resection prior to performing 
pancreatic cancer surgery. For example, the development of detection methods 
with improved sensitivity will allow clinicians to select patients for the optimal 
primary treatment approach—i.e., direct surgery or neoadjuvant therapy—
thereby resulting in improved outcome following resection. New molecular 
imaging modalities, such as fluorescence or photoacoustic imaging, could be 
used to improve the detection of tumor-positive lymph nodes and the resection 
at difficult margins such as the posterior margin.32-34 These modalities provide 
both anatomical and molecular information. These imaging techniques, use 
an exogenous imaging agent directed against the tumor allowing the surgeon 
to image the tumor using a tumor-specific approach, providing important 
additional information during the resection. In addition, molecular imaging 
may be beneficial in terms of staging the disease. On the other hand contrast-
enhanced ultrasound and/or tumor-specific PET imaging could be useful for 
preoperative detection of distant metastases and local staging. These methods 
can be used to detect disseminated disease in a specific manner, thereby 
increasing sensitivity and potentially improving early detection; alternatively, 
the surgeon may choose to stop a resection that is likely to have little or no 
oncological benefit.
Previous reports noted that R1 status can not only be a reflection of surgical 
quality, but can also be a reflection of the tumor’s biological behavior.26, 27 In our 
study, we found a significant difference in perineural invasion, tumor-positive 
lymph nodes, and tumor stage in our R1 patient group. These results are similar 
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to those reported by Kimbrough et al., who found a significantly higher lymph 
node ratio and more microvascular invasion in their R1 group.35 This difference 
may also explain the difference in OS between our R1 and R0 patient groups. 
Since the introduction of FOLFIRINOX for treating pancreatic cancer, 
chemotherapy has become an additional treatment modality that appears to 
improve resection rates and the outcome of patients with pancreatic cancer. 
In support of this notion, a recent study found that patients who undergo R1 
resection followed by adjuvant therapy have similar OS compared to patients 
who undergo R0 resection.23 Thus, if R0 and R1 are determined primarily by 
tumor biological behavior—e.g., lymphangioinvasion and lymph node status—
then patients with tumors with aggressive biological behavior might reach the 
same improved prognosis as patients with tumors with less aggressive biological 
behavior after receiving (neo)adjuvant therapy.
Based on a subset analysis in our study, tumor biological behavior appears to 
have only a limited effect in N0 patients. Our results support the notion that the 
outcome of these patients is influenced primarily by margin status. Therefore, 
we suggest that in cases of suspected N0 disease based on preoperative—and 
possibly intraoperative—imaging, the surgeon should make every reasonable 
effort to achieve radical resection. Based on our results, involvement of the 
large vessels should be examined thoroughly during surgery, as the vascular 
margin is the margin at risk in nearly half of all R1 resections. Novel techniques 
such as fluorescence-guided surgery could aid the surgeon in these situations. 
In addition, these patients should receive adjuvant chemotherapy and/or local 
radiotherapy in order to improve an aggressive biological behaviour associated 
with potential R1 resection.
 
CONCLUSIONS
Here, we report the results of a large, single-hospital retrospective analysis of 
pancreatic cancer patients treated at a specialized pancreatic cancer center, 
in which we used a consistent R1 definition to examine the prognostic effect 
of specific positive margins. We found that patients with R0 resection have 
significantly longer survival, and a R1 vascular margin appears to be the most 
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clinically relevant margin. Furthermore, our data support the notion that R1 
status is likely associated with more aggressive tumor biological behavior, 
thus identifying patients with a high risk of recurrence and who may benefit 
the most from adjuvant or neoadjuvant chemotherapy. Moreover, we found that 
achieving radical resection can change the outcome in lymph node-negative 
patients; therefore, involvement of the large vessels should be thoroughly 
examined intraoperative in patients with suspected N0 disease in order to 
achieve maximum local control. 
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ABSTRACT
Discrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic 
pancreatitis (CP) or peritumoral inflammation is challenging, both at preoperative 
imaging and during surgery, but it is crucial for proper therapy selection. Tumor-
specific molecular imaging aims to enhance this discrimination and to help 
select and stratify patients for resection. We evaluated various biomarkers for 
the specific identification of PDAC and associated lymph node metastases. Using 
immunohistochemistry (IHC), expression levels and patterns were investigated 
of integrin αvβ6, carcinoembryonic antigen-related cell adhesion molecule 
5 (CEACAM5), Cathepsin E (Cath E), epithelial growth factor receptor (EGFR), 
hepatocyte growth factor receptor (c-MET), thymocyte differentiation antigen 
1 (Thy1), and urokinase-type plasminogen activator receptor (uPAR). In a first 
cohort, multiple types of pancreatic tissue were evaluated (n=62); normal 
pancreatic tissue (n=8), CP (n=7), PDAC (n=9), tumor associated lymph nodes 
(n=32), and PDAC after neoadjuvant radiochemotherapy (n=6). In a second 
cohort, tissues were investigated (n=55) with IHC and immunofluorescence (IF) 
for concordance of biomarker expression in all tissue types, obtained from an 
individual patient. Integrin αvβ6 and CEACAM5 showed significantly higher 
expression levels in PDAC versus normal pancreatic tissue (P=0.001 and P<0.001, 
respectively) and CP (P=0.003 and P<0.001, respectively). Avβ6 and CEACAM5 
expression identified tumor-positive lymph nodes correctly in 84% and 68%, 
respectively, and in 100% of tumor-negative nodes for both biomarkers. In 
conclusion, αvβ6 and CEACAM5 are excellent biomarkers to differentiate PDAC 
from surrounding tissue and to identify lymph node metastases. Individually or 
combined, these biomarkers are promising targets for tumor-specific molecular 
imaging of PDAC.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second 
cause of cancer-related death in 2030.1 Patients with PDAC have a dismal 
prognosis, with a five-year survival rate of less than 5%.2 At this point, complete 
surgical resection is the only potential curative treatment. However, at the time 
of primary diagnosis, 75% to 85% of patients has advanced unresectable disease 
due to locoregional spread and metastasis.3, 4 Therefore, accurate identification 
of potential candidates for resection is crucial to prevent unnecessary surgical 
risks and delay in systemic therapy.5 Another challenge during surgery, is that 
despite careful selection of resectable patients using CT, MRI and/or PET 
imaging, incomplete (R1) resection occurs in up to 70% of cases.6 Failure to 
identify tumor-positive margins during surgery is not surprising, and is due to 
the tumor’s characteristic to quickly spread beyond the pancreas via perineural 
and perivascular pathways7 and the inability of the surgeon to differentiate 
between tumor and (peritumoral) inflammatory pancreatic tissue.8, 9 This is also 
challenging in pre-operative imaging with conventional technique since both 
PDAC and chronic pancreatitis (CP) may present similar due to abundant stroma. 
To improve surgical outcomes, novel neoadjuvant treatment protocols, such 
as FOLFIRINOX, are being successfully implied in the treatment of PDAC. 
Unfortunately, a drawback of these neoadjuvant therapies is that current 
imaging modalities are unable to differentiate between vital tumor and 
radiochemotherapy-induced tumor necrosis and fibrosis.10-12 In addition, 
neoadjuvant treatment effects worsen the ability of the surgeon to differentiate 
(vital) tumor form fibrotic pancreatic tissue and often times, serial frozen section 
analysis is required to assess whether to continue a resection.
Tumor imaging using molecularly targeted probes has the potential to play 
an important role in improving patient management and treatment in these 
situations. This technique can be used for tumor detection, characterization, 
staging, and response assessment to neoadjuvant treatment. Moreover, it can 
facilitate image-guided therapy, and provide surgical guidance during tumor 
resection.13 Recently, a first-in-human study was conducted using intra-operative 
tumor-specific imaging. A targeting ligand combined with a fluorophore was 
80 | Chapter 4
used for the detection of tumor-specific biomarkers for diagnostic imaging and 
surgical decision-making in ovarium cancer [14]. 
For tumor-specific imaging, a biomarker is required to function as a target. In 
PDAC, a large number of biomarkers are known to be overexpressed. However, 
a limited number of these markers are eligible candidates for targeted 
imaging. Potential biomarkers for tumor-specific targeting must possess certain 
characteristics, such as homogeneous expression, upregulation of more than 
ten times compared to normal and surrounding tissue, and localization on 
the cellular membrane.15-17 A preliminary study from our own research group 
identified several potential targets which are overexpressed in pancreatic tumor 
compared to normal pancreatic tissues; integrin αvβ6, carcinoembryonic antigen 
(CEA), epidermal growth factor receptor (EGFR), and urokinase plasminogen 
activator receptor (uPAR).18 These biomarkers have also shown their potential 
for tumor-targeted imaging in pre-clinical studies.15, 19-31 However, a potential 
target for clinically relevant differentiation between PDAC and peritumoral 
inflammation or CP has yet to be identified. Next to the ability to discriminate 
PDAC from CP, the target also needs to be able to identify lymph node 
metastases and differentiate between vital tumor cells versus necrosis and 
fibrosis in patients that have received neoadjuvant therapy.
The primary aim of this study was to evaluate the ability of integrin αvβ6, 
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), 
Cathepsin E (Cath E), epithelial growth factor receptor (EGFR), hepatocyte 
growth factor receptor (c-MET), thymocyte differentiation antigen 1 (Thy1), and 
urokinase-type plasminogen activator receptor (uPAR) as targets to differentiate 
between PDAC, CP and normal pancreatic tissue for tumor-specific imaging and 
for the potential to develop clinically translatable imaging agents targeting 
these markers. The biomarkers were selected based on a literature search and 
our previous study using tissue microarrays (TMA) of 137 patients.18, 19, 32, 33
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MATERIALS AND METHODS
Patient and tissue selection
Medical records and tissue specimens were retrospectively reviewed from 
patients who underwent pancreatic resection at the Leiden University Medical 
Center (LUMC) and Erasmus Medical Center (EMC) in Rotterdam between 
January 2011 and September 2015. Patients were selected with the histological 
diagnosis PDAC (n=8) or CP (n=7). In addition, normal pancreatic tissue lying 
adjacent to a PDAC was obtained from nine patients (n=9). Locoregional lymph 
nodes (n=32; n=17 tumor-negative, n=15 tumor-positive) were included from the 
PDAC patients to identify biomarker expression in lymph node metastasis. For 
our second cohort, all tissues (n=55; normal pancreatic parenchyma, inflamed 
pancreatic tissue, and PDAC tissue) were obtained from individual patients 
(n=12). All tissue samples were reviewed by a specialized pathologist before 
inclusion in the study. Tumor differentiation grades according to guidelines 
established by the World Health Organization were included. Colonic (n=3) and 
duodenal tissues (n=3) (from Department of Pathology, LUMC) were included as 
controls to assess biomarker expression in the peripancreatic organs. Patterns 
of expression of tumor biomarkers on pancreatic surgical specimens following 
neoadjuvant therapy were assessed in a small cohort (n=6) of patients who 
received radiochemotherapy; three cycles of gemcitabine and 15 fractions of 36 
Gy radiotherapy during two cycles (PREOPANC trial). 
Antibodies and reagents
The antibodies used for immunohistochemical (IHC) staining are shown in 
supplementary table 2.
Immunohistochemistry on tissue sections
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were collected from the 
Pathology Department of the LUMC and EMC. Tissue sections of 5 µm thickness 
were obtained from two different types of tissue blocks, one type with standard 
measurement of 40 x 26 mm, and the other type of 75 x 50 mm. The second 
type was used to determine the expression pattern across the entire specimen. 
All tissue slides used in the study were immunohistochemically assessed. For 
the second cohort of slides, additional immunofluorescence was performed. 
For preparation of IHC staining, the slides were deparaffinized with xylene 
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and rehydrated in serially diluted ethanol solutions (100%-50%), followed by 
demineralized water according to standard protocols. Endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen peroxidase in phosphate 
buffered saline (PBS) for 20 min. Antigen retrieval for CEACAM5, Thy1, and 
uPAR was performed by heat induction at 95°C using PT Link (Dako) with 
low-pH Envision FLEX target retrieval solution (pH 6.0, citrate buffer, Dako). For 
c-MET and Cath E, the high-pH Envision FLEX target retrieval solution was used 
(pH 9.0, citrate buffer, Dako). For αvβ6 and EGFR staining, antigen retrieval was 
performed with 0.4% pepsin incubation (Dako) at 37°C for 10 min.
Following antigen retrieval, the tissue sections were incubated overnight 
with the primary antibodies in 100 µl for standard tissue sections and 500 µl 
for the large tissue sections at room temperature. A pre-determined optimal 
dilution was used for all antibodies; anti-αvβ6 antibodies 1:800, anti-CEACAM5 
antibodies 1:1000, anti-EGFR antibodies 1:100, anti-CD90/Thy1 antibodies 
1:800, anti-MET antibodies 1:8000, anti-Cath E antibodies 1:1000, and anti-
uPAR antibodies 1:800. The slides were washed with PBS, followed by 
incubation with secondary antibody for 30 minutes at room temperature. After 
additional washing, the staining was visualized with 3,3-diaminobenzidine 
tetrahydrochloride solution (DAKO, Glustrup, Denmark) at room temperature 
for 5 minutes and counterstained with hematoxylin for 20 seconds. Finally, the 
tissue sections were dehydrated and mounted in Pertex (Histolab, Rockville, 
MD, USA).
IHC analysis
All stained sections with standard measurements (40 x 26 mm) were scanned 
and viewed at 40x magnification using the Philips Ultra-Fast Scanner 1.6 RA 
(Philips, Eindhoven, Netherlands). The large tissue sections were viewed under 
the microscope. Evaluation of the immunohistochemical staining was performed 
blinded independently by two observers (W.S.F.J.T. and A.F.S.). The following 
scoring method was used; percentage specific staining (normal/PDAC/CP) was 
scored as percentage of total tissue 0=<10%, 1=10-25%, 2=26-50%, 3=51-75%, 
4=>75%. Staining intensity was scored as 0=none, 1=weak, 2=moderate, 3=strong 
(Figure S6). Undesired staining of structures other than investigated tissues 
(i.e., normal/tumor/inflammation/stroma) was scored as 0=none, 1=moderate, 
2=strong. In tumor tissue, a comparison was made between staining at invasive 
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border compared to core of the tumor. This was scored as tumor core vs invasive 
border: 0=lower, 1=similar, 2=stronger. 
Interim analysis to assess biomarker suitability
Primary analysis of all biomarker characteristics included expression pattern, 
expression in normal pancreatic parenchyma, pancreatitis, PDAC and expression 
in tumor-positive and tumor-negative lymph nodes. Next an interim analysis 
of the different biomarkers was performed to assess the suitability of these 
markers as targets for tumor-specific molecular imaging of PDAC. After this 
analysis the most suitable biomarkers (αvβ6 and CEACAM5) were chosen for 
further assessment to specifically identify their potential in clinically relevant 
situations, tailored to tumor-specific molecular imaging.” 
Immunofluorescence
Double immunofluorescent staining of αvβ6 and CEACAM5 was performed 
on FFPE tissue sections of normal pancreatic tissue, PDAC, and CP. The slides 
were treated similar as described above. Antigen retrieval for both targets was 
performed by heat induction at 95°C using PT Link with a low-pH Envision FLEX 
target retrieval solution. Sections were incubated with 5% Fetal Bovine Serum 
in PBS for 10 minutes at room temperature prior to incubation with primary 
antibodies. Both primary antibodies against αvβ6 and CEACAM5 were applied 
overnight at room temperature. These were detected using secondary antibodies 
mentioned before; anti-IgG1-AF488 for αvβ6 and anti-IgG2a-AF647 for CEACAM5. 
After washing three times in PBS, nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI, Prolong Gold, Life Technologies) and stored at 4°C. The 
slides were examined using a Leica DM5500B digital fluorescence microscope 
(Leica Microsystems B.V., Son, the Netherlands) equipped with a Leica DFC365FX 
camera using LAS X software for image acquisition and processing.
Statistical analysis
The statistical analysis was performed using SPSS version 20.0 software 
for Windows (SPSS, IBM Corporation, Somer NY, USA) and GraphPad Prism 6 
(GraphPad, Software, Inc, La Jolla CA, USA). Mean percentage staining and 
difference in staining between tissues was calculated with One-way ANOVA with 
post-hoc Bonferroni correction. In all tests, results were considered statistically 
significant at the level of P<0.05.















Figure 1. Expression patterns of investigated markers. Representative images of immunohistochemi-
cally staining patterns in PDAC of all molecular markers; αvβ6 (A-C), CEACAM5 (D-F), EGFR (G-I), Thy1 
(J-L), uPAR (M-O), CathE (P-R), cMET (S-U) showing respectively from left to right normal pancreatic 
tissue, CP, PDAC and graphical representation of mean percentage staining on all the tissue slides 
(*: p<0.05, **: p<0.01, ***: p<0.001).
86 | Chapter 4
RESULTS
In the first cohort, a total of 62 tissues (n=8 PDAC, n=7 CP, n=9 normal pancreatic 
tissue, n=32 lymph nodes, n=6 PDAC after neoadjuvant radiochemotherapy) were 
stained for all biomarkers to assess expression patterns. In the second cohort, 
a total of 55 tissue slides were stained with the two most suitable biomarkers 
(n=12 PDAC, n=12 CP, n=12 normal pancreatic tissue, n=19 lymph nodes). Patient 
and tumor characteristics are summarized in Supplementary table 1.
Avβ6, CEACAM5, CathE and uPAR are significantly higher expressed in PDAC 
versus CP.
All biomarkers were overexpressed in PDAC, except for c-MET (Fig 1S-U) 
and Thy 1 (Fig 1J-L), which showed equal or even higher staining in normal 
pancreatic tissue or CP compared to PDAC. Although there was abundant Thy1 
stromal staining in PDAC, it was also present in stroma of adjacent normal 
and inflamed pancreatic tissue. Therefore, both targets were excluded from 
further analysis. All other targets showed significant higher expression in PDAC 
compared to normal pancreatic tissue; αvβ6 (Fig 1A-C) (p <0.001), CEACAM5 
(Fig 1D-F) (p <0.001), EGFR (Fig 1G-I) (p <0.05), Cath E (Fig 1P-R) (p <0.001), 
and uPAR (Fig 1M-O) (p <0.001). Avβ6 was homogeneously expressed, uPAR, 
and Cath E were slightly heterogeneously expressed, and all other biomarkers 
showed a markedly heterogeneous expression pattern in PDAC tissue (Figure 
S1). Furthermore, only CEACAM5 expression in PDAC was slightly more intense 
in the invasive border compared to the tumor core. The following biomarkers 
were significantly overexpressed in PDAC versus CP; αvβ6 (Fig 1B-C) (p<0.001), 
CEACAM5 (Fig 1E-F) (p <0.001), Cath E (Fig 1Q-R) (p <0.001), and uPAR (Fig 
1N-O) (p <0.001). All targets, except for CEACAM5, showed expression in the 
duodenum especially at the luminal side (not shown). This was also the case 
in colonic tissue where there was luminal staining for most targets except for 
uPAR (not shown).
Interestingly, immunohistochemical staining for CEACAM5 (Figure S2) and 
uPAR showed complete absence of staining in normal pancreatic parenchyma. 
Avβ6 showed moderate staining in normal ductal structures, but there was a 
significantly higher expression in malignant ducti. The substantially higher 
ratio of ductal structures in malignant pancreas compared to normal pancreatic 
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Figure 2. Biomarker expression in tumor-positive lymph nodes. Biomarker expression in tumor-pos-
itive lymph nodes for the different biomarkers αvβ6 (A), CEACAM5 (B), EGFR (C), uPAR (D), CathE (E) 
(Objective 1x, insert 20x).
Figure 3. Biomarker expression after neoadjuvant therapy. In all neoadjuvant treated tissue a markedly 
higher αvβ6 expression was identified in vital tumor tissue (A) compared to surrounding fibrosis or 
necrosis (B) after neoadjuvant therapy. CEACAM5 biomarker expression showed increased hetero-
geneity after neoadjuvant therapy in the tumor (C), therefore clear distinction between vital tumor 
and fibrosis and necrosis is not possible (C and D) (Objective 10x).
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parenchyma adds to the significant increase total of marker expression per high 
power field. (Figure S3).
Avβ6 specifically differentiates tumor-positive and tumor-negative lymph 
nodes. 
Next, we investigated biomarker expression in tumor-positive and –negative 
lymph node. A total of 17 tumor-positive and 15 tumor-negative nodes were 
stained. The described biomarkers identified the investigated positive and 
negative lymph nodes correctly with, respectively, a sensitivity and specificity 
of; αvβ6 (84%; 100%), CEACAM5 (68%; 100%), EGFR (93%; 67%), Cath E (54%; 
83%), and uPAR (69%; 67%). Figure 2A shows CEACAM5 expression in both 
tumor-positive and tumor-negative lymph node, figure 2B shows αvβ6 in 
identical lymph nodes for comparison.
An interim analysis to assess the suitability of the biomarker panel as targets 
for tumor-specific molecular imaging of PDAC was performed, shown in table 
1. Biomarkers αvβ6 and CEACAM5 met most of the criteria of an optimal tumor-
specific biomarker and were selected for further evaluation.
Biomarker patterns change after neoadjuvant radiochemotherapy. 
Molecular targeted imaging could be useful tool for neoadjuvant therapy 
response monitoring. The consequence of neoadjuvant therapy on αvβ6 and 
CEACAM5 expression was assessed by staining tissues from patients who 
received radiochemotherapy. In all investigated neoadjuvantly treated tumors, 
there was a markedly higher αvβ6 expression seen in the remaining vital tumor 
cells compared to the surrounding fibrosis and necrosis, as shown in Figure 3A 
and 3B. This level of expression was comparable to the expression in PDAC 
without neoadjuvant therapy, as previously shown. CEACAM5 expression in 
vital tumor cells after neoadjuvant therapy was reduced, as shown in Figure 
3C, compared to PDAC not treated neoadjuvantly. As a result, no difference in 
expression of CEACAM5 between vital tumor cells and surrounding fibrosis and 
necrosis was seen (Figure 3C and 3D). In the samples of two out of six patients 
there was no expression of CEACAM5 in the remaining vital PDAC cells. Due to 
small sample size, we were not able to determine significance of results.
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Avβ6 and CEACAM5 expression is markedly different between normal 
pancreatic parenchyma, peritumoral inflammation, and PDAC of individual 
patients. 
In a second cohort, normal pancreatic parenchyma, peritumoral inflammation 
and PDAC of individual patients (n=12) were included in order to mimic the 
actual clinical situation. In 11 out of 12 patients, αvβ6 staining in PDAC was 
clearly higher compared to inflammation and to normal pancreatic parenchyma 
(4 and 2 times higher, respectively). CEACAM5 expression was only present 
in PDAC, and therefore, the staining pattern was markedly different between 
normal pancreatic parenchyma, peritumoral inflammation and PDAC in all 
patients except for two who did not express CEACAM5 in any of their tissue 
samples (Figure S4). In concordance with the first patient cohort, CEACAM5 
staining of PDAC was weaker and more heterogeneous compared to αvβ6. In 
Figure 4, expression of CEACAM5 (Figure 4B) and αvβ6 (Figure 4C) in PDAC, 
peritumoral inflammation, and normal pancreatic parenchym of one individual 
patient are presented next to the corresponding H&E stain (A), showing the 
difference in expression even in such close proximity.
Multiplexing for optimal discrimination between malignant and benign tissue. 
Double staining of CEACAM5 and αvβ6 using immunofluorescence showed that 
multiplexing by targeting both biomarkers leads to an improved discrimination 
between malignant and benign pancreatic tissue and identification of all PDAC 
tissue. Examples of using multiplexing to achieve improved detection are shown 
in figure 5, and figure S5. This improved detection is obtained by the different 
expression patterns of both targets, as also shown in figure 1, which are 
complementary to each other. Targeting αvβ6 will identify all PDAC as shown 
above, and CEACAM5 reduce the false positive staining by αvβ6 in normal 
pancreatic parenchyma and CP.
 
DISCUSSION
Imaging using tumor-specific molecular probes has the potential to solve some 
of the challenges regarding PDAC diagnosis, treatment response monitoring and 
surgery. For tumor-specific molecular imaging to be successful, it is essential to 
have suitable biomarkers that can be targeted by molecular probes and that are 
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able to distinguish primary PDAC and metastases from normal pancreatic tissue, 
CP or acute (peritumoral) inflammation. With the current imaging modalities, 
the differentiation between PDAC and CP remains a challenge as still 7-13% of 
pancreatectomies are performed for benign pathology.34 Molecular imaging can 
potentially also improve the outcome of PDAC patients by providing the ability 
to identify small tumor nodules in an early stage and therefore increasing the 
chance of cure and improving survival rates.35, 36 Another major problem for PDAC 
surgery is the high recurrence rate within 6-12 months, which suggests that 
local or distant micrometastases were already present at the time of surgery.37, 
38 This underscores that conventional imaging modalities (i.e., MRI, CT and PET) 
lack the sensitivity to detect small amounts of tumor leading to highly morbid 
surgical procedures for patients that do provide the desired oncologic benefit. 
A technique that improves the stratification of patients to ensure they receive 
the proper therapy could serve as a helpful tool for personalized treatment in 
Figure 4. Biomarker expression in different tissue types within one patient. Expression of CEACAM5 
(B) and αvβ6 (C) of one individual patient with the corresponding H&E slide (A) in PDAC (above red 
line), peritumoral inflammation (between red lines), and normal pancreatic parenchyma (below red 
lines), showing the difference in expression even in such a close proximity (Objective 2x).”
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PDAC. Examples of tumor-specific imaging modalities include: ultrasound, CT, 
PET, and fluorescent optical imaging. Fluorescent optical imaging has shown the 
ability to detect lesions <2mm as described by Warram, et al..39 Of course, this 
modality can only be used during surgery but will lead to better stratification 
intraoperatively. 
For PDAC, the greatest improvements in patient outcome would likely be the 
result of better selection of patients surgery, preoperative visualization of all 
tumor-positive lymph nodes and distant metastases, or the decision to abort 
surgery in a noncurative procedure. This study implies that molecular imaging 
using tumor-specific targets, such as αvβ6 and CEACAM5, can help to guide this 
process. The main advantage of the present study is the use of tissue sections 
that represent a cross section of the entire pancreas which is preferred above 
tissue microarray (TMA) cores, as we could assess exact staining patterns 
Figure 5. Value of multiplexing in PDAC. Immunofluorescent staining of αvβ6 and CEACAM5 simul-
taneously in PDAC. Showing the additional value of using two biomarkers to target all tumor tissue 
compared to one biomarker (Objective 40x).
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more thoroughly in a larger surface and can recognize heterogeneity more 
reliably. This change in technique potentially explains why substantially higher 
expression rates are found in normal ductal pancreatic tissue compared to the 
literature.18, 32, 40 To assess clinical relevance of the technique and represent 
the clinical situation during imaging and surgery of PDAC, lymph nodes, CP 
and peritumoral inflammation as well as unremarkable pancreatic parenchyma 
were included from the same unique patients. To our knowledge, this is the 
first report comparing the expression of biomarkers not only in different tissue 
types but also in benign and malignant lesions within the same organ from a 
single patient leading to the identification of ideal biomarkers for preoperative 
and intraoperative imaging.27, 28, 30, 41 The results of CEACAM5 and αvβ6 in PDAC 
tissues are in line with most previous reports.21, 27, 30, 31 However in contrast, 
Allum et al. and Jewkes et al. both reported CEA staining in CP.28, 42 For their 
study, they used the monoclonal anti-CEA antibodies, 11-285-14 and 11-359-6, 
but it is unknown if their antibodies were directed against CEACAM5 or another 
subtype of CEA.
The fact that CEACAM5 could be a potential biomarker for the tumor-specific 
identification of PDAC would lead to other advantages. CEA is known to be 
present in soluble form in the serum for multiple cancer types. Recent studies 
have reported a positive relation between CEA levels in cancer tissue and serum 
CEA levels,43, 44 while other studies did not show this relation.45-48 For now, this 
phenomena is mainly studied in colorectal cancer and the correlation between 
serum CEA and tissue CEA in PDAC is unclear, but is subject of investigation in 
our group.
As shown in this study as well as in literature, no individual biomarker is 
perfect. For most tumor types, one unique biomarker is not sufficient for exact 
tumor-specific identification, as shown, and therefore the potential to perform 
multiplexing is crucial. In this study, we showed the advantage of using probes 
with different fluorescent labels for multiplexing purposes, An example of a 
technique which is optimal for multiplexing is Raman imaging. Several different 
nanoparticles can be produced by modifying the Raman surface and therefore 
generating unique spectral signatures.49 Unfortunately, this technique is still far 
from wide clinical use. To target multiple biomarkers with fluorescence imaging, 
diabodies are the ligand of choice now. However, if a diabody was used with 
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one fluorescent label to target CEACAM5 and αvβ6, exact differentiation would 
not have been possible between normal pancreatic tissue, CP and inflammation, 
and PDAC since both targets have their own strengths in this differentiation. 
Targeting both biomarkers with different fluorescently-labeled ligands might 
thus be beneficial for imaging purposes. 
Since the successful introduction of novel neoadjuvant regimens for PDAC, like 
FOLFIRINOX, resectability rates have increased up to 51%.50 However, a major 
drawback of this success is that after neoadjuvant treatment conventional 
imaging modalities are not able to differentiate between vital tumor cells and 
radiochemotherapy-induced tumor necrosis and fibrosis, and are therefore no 
longer able to predict resectability.10 A potential role for targeted imaging, would 
require that the parts of the tumor that have remained vital unless neoadjuvant 
therapy would have to retain their expression levels. Avβ6 was shown to possess 
that capacity. CEACAM5 expression, on the other hand, was reduced compared 
to in PDAC tissue without neoadjuvant treatment. Two potential explanations 
for this effect could be: (i) there is tumor heterogeneity where the subtype with 
CEACAM5 expression is selectively killed by the (radio)chemotherapy,51-53 or (ii) 
the neoadjuvant therapy has a selective effect on the cell genome.54 However, 
before final conclusions can be drawn in neoadjuvant treated tissues, these 
results need to be validated in a larger series of patients. Another limitation 
of our approach in this series is that the biomarker expression before (radio)
chemotherapy is unknown. However, based on the available literature and our 
presented results, we feel confident that biomarker expression of these tumors 
prior to therapy is comparable to expression in tumors that are not treated with 
neoadjuvant therapy. 
A potential hurdle for the clinical translation of tumor-targeted imaging could 
be need for agents directed against different targets in the various cancer types, 
which is costly and a regulatory burden. For example, the role of c-MET as a 
biomarker in fluorescence imaging seems to be cancer type-specific. Burggraaf 
et al. showed the potential of c-MET as biomarker in colon cancer,55 whereas in 
PDAC, its role is less clear. In this study, as with others, c-MET shows relevant 
overexpression in normal pancreatic tissue, excluding it as target for tumor-
specific molecular imaging applications.56 Also biomarkers targeting stromal 
components and microenvironment such as uPAR and Thy1 are suggested for 
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molecular imaging of cancer.19, 57 However, as shown, biomarkers targeting the 
microenvironment of PDAC, are less useful when extravasation occurs because 
abundant stroma exists not only in PDAC, but also in normal pancreatic tissue 
and especially in chronic and acute pancreatitis. Another main disadvantage 
of uPAR was the expression in negative lymph nodes, potentially due to its 
natural expression on macrophages. This is in line with a recently published 
review paper from Petrushnko et al..58 Since lymph node identification was one 
of our main criteria, uPAR was not included in the second cohort for evaluation 
although it performed similar to CEACAM5 on several other characteristics. 
In conclusion, both CEACAM5 and αvβ6 are promising candidates for tumor-
specific molecular imaging for PDAC. Especially when used in combination, 
these biomarkers can discriminate between normal pancreatic tissue, CP and 
peritumoral inflammation, and PDAC. Also, αvβ6 can help identify vital tumor 
after neoadjuvant radiochemotherapy and identify lymph nodes metastases. 
Therefore, agents recognizing both biomarkers, combined with a different label 
or two separate agents, would have the potential to create a huge impact in 
PDAC diagnostics, therapy and patient outcome.
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ABSTRACT
Purpose: Intraoperative near-infrared fluorescence (NIRF) imaging could help 
stratification for the proper primary treatment for patients with pancreatic 
ductal adenocarcinoma (PDAC), and achieve complete resection since it allows 
visualization of cancer in real time. Integrin αvβ6, a target specific for PDAC, is 
present in >90% of patients, and is able to differentiate between pancreatitis 
and PDAC. A clinically translatable αvβ6-targeting NIRF agent was developed, 
based on a previously developed cysteine knottin peptide for PET imaging, R01-
MG, and validated in preclinical mouse models. 
Experimental Design: The applicability of the agent was tested for cell and 
tissue binding characteristics using cell-based plate assays, subcutaneous 
and orthotopic pancreatic models, and a transgenic mouse model of PDAC 
development (Pdx1-Cretg/+;KRas LSL G12D/+;Ink4a/Arf−/−). IRDye800CW was 
conjugated to R01-MG in a 1:1 ratio. R01-MG-IRDye800, was compared to a 
control peptide and IRDye800 alone. 
Results: In subcutaneous tumor models a significantly higher tumor-to-
background ratio (TBR) was seen in BxPC-3 tumors (2.5±0.1) compared to 
MiaPaCa-2 (1.2±0.1) (p<0.001), and to the control peptide (1.6±0.4) (p<0.005). 
In an orthotopic tumor model tumor-specific uptake of R01-MG-IRDye800 was 
shown compared to IRDye800 alone (TBR 2.7 versus 0.86). The fluorescent signal 
in tumors of transgenic mice was significantly higher, TBR of 3.6±0.94, compared 
to the normal pancreas of wild type controls, TBR of 1.0±0.17 (p<0.001). 
Conclusion: R01-MG-IRDye800 shows specific targeting to αvβ6, and holds 
promise as a diagnostic and therapeutic tool to recognize PDAC for fluorescence-
guided surgery. This agent can help improve the stratification of patients for a 
potentially curative, margin-negative resection.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis.1, 2 In fact, it is 
the fourth leading cause of cancer-related deaths in the western world; 43,090 
patients are estimated to die of PDAC in 2017 in the Unites States. The median 
size of a PDAC at the time of diagnosis is ~3.1cm, and this has not changed 
in the past three decades despite major advances in both anatomical and 
molecular imaging technologies as well as in vitro diagnostics.3, 4 Early detection 
of pancreatic cancer is difficult because patients are often asymptomatic or 
present with non-specific symptoms until late stage disease.4, 5 After diagnosis 
the patient selection for surgical resection is challenging. A potential curative 
resection can only be achieved in a minority of patients, and is dependent 
on tumor stage and grade. Two major predictors of long-term survival after 
resection are the achievement of tumor free resection margins and the absence 
of systemic metastases. Unfortunately, margin-positive resections (R1) are a 
frequent phenomenon (up to 70%) as is the emergence of distant metastases 
soon after surgery, which were likely present at the time of surgery in the form 
of visually occult micrometastases.6-8 Failure to identify tumor-positive margins 
during surgery is not surprising, due to the tumor characteristics to quickly 
spread beyond the pancreas via perineural and perivascular pathways9 and 
the inability of the surgeon to differentiate between tumor and (peritumoral) 
inflammatory tissue, such as associated chronic pancreatitis.10, 11
The integration of innovative molecular imaging techniques into the operating 
room can lead to the transformation of current gold standard intraoperative 
imaging modalities, such as intra-operative ultrasound and the surgeon’s eyes, 
into pancreatic cancer-specific molecular imaging tools. Optical imaging in 
real-time, using a novel near-infrared fluorescent pancreatic cancer-targeting 
imaging agent, could add relevant information to the surgeon, by enhancing 
tumor margins and improving the detection of visually occult lesions. This would 
improve the selection of patients for the most suitable primary treatment.
In previous studies, out of a panel of different biomarkers, we selected integrin 
avβ6 as the most promising target for pancreatic cancer detection, based on 
its potential to discriminate tumor and inflammation, to identify lymph node 
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metastases, to differentiate between viable tumor cells and necrosis in patients 
who received neoadjuvant therapy.12, 13
We previously developed a cysteine knottin that binds to integrin αvβ6 with 
subnanomolar affinity (Kd~1nM).14 At this point, this peptide is tested in a Phase I 
trial in humans as a targeted PET tracer, [18F]FP-R01-MG-F2, without any safety 
concerns (eIND #126379). Zhang et al. recently published data showing the 
development and preclinical validation of R01 conjugated to the photoacoustic 
dye Atto-740.15 Zhang showed selective binding of the imaging agent to αvβ6-
positive tumors. However, this agent exhibited hepatobiliary clearance marked 
by high uptake in the liver, spleen, and intestine. For a pancreatic cancer 
imaging agent, a renal clearance pathway is preferred for a due to the close 
proximity of the liver, and therefore potential interference of signal. Since the 
PET tracer show renal clearance the fluorescent dye was changed to achieve 
Figure 1. Schematic overview of imaging agent concept. Agent is injected intravenously, and migrates 
via the vessel to the target of interest (αvβ6). Resection of the pancreatic cancer can be performed 
guided by fluorescent signal, and fluorescent signal at microscopic level is conformed with tumor status 
on histopathology. The agent preferably has renal clearance, since fluorescent signal from the liver in 
case of a hepatic route could interfere with signal from the tumor.
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these favorable pharmacokinetics. The NIR fluorescent dye IRDye800 is known 
to clear via the kidneys, and has a high extinction coefficient.16 In addition, 
IRDye800 is already tested extensively in humans and shown safe in clinical 
studies.11, 17 Therefore, IRDye800 was the NIR fluorescent dye of choice in the 
current study. The preferred imaging concept is shown in figure 1, highlighting 
the preference of an intravenously injected agent. This agent needs to bind 
selectively to the tumor receptors, facilitating fluorescence-guided resection, 
and excretion by the kidney’s is favorable in pancreatic cancer surgery. Lastly, 
the fluorescent signal needs to be correlated to tumor status on H&E to ensure 
specific binding.
Here, we show the development and validation of a novel αvβ6-targeting 
probe for intraoperative tumor-specific fluorescent imaging of PDAC, with high 




All Fmoc amino acids and Rink Amide resin were purchased from CS Bio Co. 
(Menlo Park, CA). Peptide synthesis were carried out following the standard 
solid phase Fmoc synthesis. Analysis and purification of the peptides was 
performed using the Dionex Summit high-performance liquid chromatography 
(HPLC) system (Dionex Corporation, Sunnyvale, CA) and reverse phase HPLC 
column Higins Analytical (Higins Analytical, Mountain View, CA) (C18, 4.6 mm × 
250 mm). The mobile phase was 0.1% trifluoroacetic acid (TFA; Thermo Fisher 
Scientific, Pittsburgh, PA)) in water (solvent A) and 0.1% TFA in 90 % acetonitrile 
(CH3CN; Thermo Fisher Scientific, Pittsburgh, PA) in water (solvent B). Matrix 
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS) was performed by the Canary Center proteomics facility on AB Sciex 
5800 TOF/TOF System (Foster City, CA).
Development of tumor-specific fluorescent probe
Knottin peptide R01-MG targeted integrin αvβ6 were synthesized using the 
described standard solid phase Fmoc synthesis, and folded and purified as 
previously described.18 For labeling of the knottin peptide R01-MG, IRDye800 
05
108 | Chapter 5
N-hydroxysuccinimide (NHS) ester (LI-COR Biosciences, Lincoln, Nebraska) was 
dissolved in anhydrous, amine-free dimethylformamide (DMF; Sigma Aldrich, 
St Louis, MO) to a 0.5 mg/ml solution. Knottin peptide R01-MG was dissolved 
in Dulbecco’s Phosphate-Buffered Saline (DPBS; Life technologies, Foster City, 
CA) to a 1.5 mg/ml solution. IRDye800 NHS solution was mixed with knottin 
peptide R01 solution in 1:1 molar ratio. The reaction mixture was incubated 
and protected from light for up to 1 hour at room temperature. The reaction 
mixture was injected directly onto the HPLC column, and the separation of the 
product mixture followed using absorbance at 780 nm. The imaging agent had 
a retention time of 16.89 minutes and m/z of 4817. The lyophilized IRDye800-
peptide was dissolved in 100uL dimethyl sulfoxide (DMSO; Thermo Fisher 
Scientific, Pittsburgh, PA) and 100uL DPBS. Maximum absorption wavelength of 
R01-MG-IRDye800 agent was performed using Cary50 (Varian).
Development of control cysteine knottin
The tumor-specific probe is based on the trypsin inhibitor, momordica 
cochinchinensis trypsin inhibitor (MCoTI-II). For the control cysteine knottin the 
binding sequence of R01-MG to αvβ6 was replaced with the MCoTI-II sequence at 
these positions, to develop a control knottin most similar to the original R01-MG. 
This resulted in the following sequence; N’-GCPRILMRCRRDSDCPGACICRGNGYCG. 
Synthesis, folding and purification was performed as described. The control 
cysteine knottin had a retention time of 20.60 minutes and m/z of 3033. The 
control peptide was labeled with IRDye800 N-hydroxysuccinimide (NHS) ester 
(LI-COR Biosciences, Lincoln, Nebraska, USA) in a similar fashion as R01-MG-
IRDye800. The reaction mixture was injected directly onto the HPLC column, 
and the separation of the product mixture followed using absorbance at 780 
nm. The imaging agent had a retention time of 16.53 minutes.
Photostability
100 µL of R01-MG-IRDye800 (0.5x10-6 M) was placed in a 96-well plate in the 
SpectraMax Gemini EM microplate reader (Molecular Devices, Ramsey, MN, USA) 
in triplicate and scanned with laser light using maximum absorption wavelength 
(750 nm) and emission wavelength (800nm) for 30 min. Photobleaching was 
determined by the change in fluorescent intensity over time.
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Human cancer cell lines
A total of six cancer cell lines were used for the cell-based experiments, 
including four pancreatic cancer cell lines (BxPC-3, BxPC-3-luc2, MiaPaCa-2, 
and AsPC-1), one colorectal cancer cell line (HCT-116), and one epidermoid 
carcinoma (A431). All cell lines, except for BxPC-3-luc2, were purchased from 
American Type Culture Collection (ATCC, Manassas, VA) and expression was 
authenticated within 6 months before the in vitro experiments. The BxPC-3-luc2 
cell line was purchased from PerkinElmer (MA). BxPC-3 (CRL-1687TM), provided 
by ATCC, was used as source for the parental cell line. BxPC-3 and BxPC-3-luc2 
cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum, 1 
% penicillin and streptomycin. MiaPaCa-2, HCT-116 and A431 cells were cultured 
in DMEM containing 10% fetal bovine serum, 1 % penicillin and streptomycin. 
For MiaPaCa-2 cells, also 2.5% horse serum was added according to ATCC 
guidelines.
Mouse cancer cell lines
The binding of R01-MG-IRDye800 to mouse αvβ6 was assessed to determine 
the in vivo specific binding to mouse αvβ6. The following two cell lines were 
used; a mouse breast cancer cell line (4T1), and mouse colon carcinoma cell line 
(CT-26). All cell lines were purchased from American Type Culture Collection 
(ATCC, Manassas, VA) and expression was authenticated within 6 months before 
the in vitro experiments. A maximum of ten passages was performed for all 
cells, between thawing and use in the described experiments. CT-26 cells were 
cultured in DMEM medium containing 10% fetal bovine serum, 1 % penicillin 
and streptomycin. 4T1 cells were cultured in RPMI-1640 medium containing 
10% fetal bovine serum, 1 % penicillin and streptomycin.
Flow cytometry
All cells were tested for αvβ6 expression using flow cytometry. The cells were 
grown to 90% confluence and detached with trypsin/EDTA. After evaluation of 
cell viability using trypan blue, cells were adjusted to 1 x 106 per tube in ice-
cold PBS with 4% formaldehyde for fixation and incubated in a binding buffer 
containing DMEM, 0.1% BDA and 0.1% NaN3 with 100ul of anti-αvβ6 mouse 
monoclonal antibody (10D5, ab77906, Abcam, Cambridge, United Kingdom) 
for 1h at room temperature. After incubation, cells were washed thrice and 
incubated with the secondary antibody anti-mouse IgG F(ab)2 fragment 
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conjugated to Alexa Fluor® 647 (#4410, Cell Signaling Technology, Danvers, 
MA, United States, 1/800) for 30 min. After three washing steps with the 
washing buffer, cells were resuspended in 500ul PBS. Samples were measured 
on the Scanford flow cytometer (Custom Stanford and Cytek upgraded FACScan 
Analyzer) and 1x105 cells were counted.
Cell binding study
Human cancer cell lines BxPC-3 (αvβ6 positive) and MiaPaCa-2 (αvβ6-negative), 
and murine cancer cell lines 4T1 (αvβ6 positive) and CT-26 (αvβ6-negative) 
were placed in a 8 well chamberslide (0.7 cm2, NuncTM Lab-TekTM II Chamber 
SlideTM System; ThermoFisher Scientific, Waltham, MA, USA) and grown to ~85% 
confluence. Cells were fixed for 20 min at 4 °C with 1% formaldehyde. R01-MG-
IRDye800 was diluted in integrin-binding buffer (IBB). The IBB was similar as 
previously described [19], and added to the chamberslide with concentration 
of 0.1 µM, 0.2 µM or 0.5 µM and incubated at room temperature for 2 h. After 
being washed with DPBS three times, the chamber was removed and the 
nuclei were counter stained with ProLong® Gold Antifade Mountant with DAPI 
(ThermoFisher Scientific, MA, Waltham, USA). The cellular binding of R01-MG-
IRDye800 was assessed by co-staining of cells with DAPI and fluorescence with 
the EVOS Cell Imaging Systems (EVOS FL Cell Imaging System, ThermoFisher 
Scientific, MA, USA) with EVOS light cube Cy7, excitation 710-740 and emission: 
775-746, and EVOS light cube DAPI, excitation: 357-344 and emission: 447-
460. For quantitative analysis, mean fluorescent intensity (MFI), defined as 
total counts/region of interest (ROI) pixel area, was calculated using custom 
ROI generated for each specimen using the imaging software ImageJ version 
1.50i and bundled with 64-bit Java for Windows (National Institutes of Health, 
Bethesda, MD; http://rsb.info.nih.gov/nih-image). Specificity of the binding was 
determined by a blocking experiment with incubation of BxPC-3-luc2 cells with 
0.5 µM of R01-MG-IRDye800 and varying amounts of R01-MG (50x (25 µM) – 
150x (75 µM) – 200x (100 µM) excess), and by incubation of BxPC-3-luc2 cells 
with IRDye800 0.5 µM alone. All samples were done in triplicates. For IRDye800 
alone, IRDye800-NHS ester was used which is equal to the dye used in the 
agent. The NHS ester was reacted with water before injection, to ensure no 
reaction with amine groups could take place. A linear regression analysis was 
performed to determine if there was a linear correlation between concentration 
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and fluorescent signal; for BxPC-3 (Y = 118171*X + 11944) and for MiaPaCa-2 (Y 
= 23296*X + 9738). 
To identify fluorescence intensity with increasing amount of αvβ6 receptors, 
an experiment was designed with both BxPC-3 and MiaPaCa-2 cells, in varying 
percentages; with the lowest amount of receptors in 100% MiaPaCa-2, and 
increasing amounts onwards; 20% BxPC-3 - 80% MiaPaCa-2, 40% BxPC-3 - 60% 
MiaPaCa-2, 60% BxPC-3 - 40% MiaPaCa-2, 80% BxPC-3 - 20% MiaPaCa-2, and 
100% BxPC-3. The cells were incubated with 0.5 µM of R01-MG-IRDye800 for 
2 h. Additional cell experiments were performed comparing R01-MG-IRDye800 
to the newly synthesized control peptide. BxPC-3 cells were placed on a 8-well 
chamberslide, and after fixation incubated with both agents separately at 
concentration of 0.1 µM, 0.2 µM or 0.5 µM.
Fluorescent imaging of αvβ6 in Small Animal Models
Subcutaneous mouse model of human pancreatic cancer
The Administrative Panel on Laboratory Animal Care of Stanford University 
approved all procedures using laboratory animals. Eight week old nude female 
mice (n=20) (Charles River) were injected with 1 million BxPC-3-luc2, A431, or 
MiaPaCa-2-luc cells into the right shoulder. Mice bearing 0.4-0.8 cm tumors 
(n=8 BxPC-3-luc2, n=3 A431, n=4 MiaPaCa-2) for R01-MG-IRDye800, and n=5 
for control cysteine knottin) were fluorescently imaged at 800 nm using a 
commercially fluorescent imaging system (The Pearl Impulse imaging platform 
(LI–COR Biosciences, Lincoln, NE). For each animal we first obtained pre-
injection images at 800 nm. R01-MG-IRDye800 (30 µM), the control cysteine 
knottin (30 µM), or IRDye800 alone (30uM) was dissolved in 200 µL PBS (pH 7.4) 
and administered to mice via tail-vein injection. The data was acquired from 30 
min up to 24h after the injection of the imaging agent.
Xenograft mouse model of human pancreatic cancer
Human AsPC1 pancreatic ductal adenocarcinoma cells (αvβ6 positive) (ATCC, 
Manassas, VA) were cultured to 70%−80% confluency. AsPC-1 cells were 
cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin 
and streptomycin. AsPC1 cells were suspended in culture medium and mixed 
1:1 with Matrigel® (BD Biosciences, San Jose, CA) for orthotopic implantation. 
Sterile insulin syringes were loaded with the mixture and kept on ice until 
05
112 | Chapter 5
orthotopic implantation. After midline laparotomy, the pancreas of nu/nu mice 
was exposed, and AsPC1 cells (total of 6 × 106 cells, dissolved in 25 µL Matrigel 
containing epidermal growth factor [0.7 ng/mL], insulin-like growth factor [16 
ng/mL], and transforming growth factor−β [2.3 ng/mL]; BD Biosciences, San 
Jose, CA) were co-injected into the body or tail of the pancreas in 8 female nude 
mice (6−8 weeks old; Charles River, Wilmington, MA). The abdomen was then 
closed by layers. Orthotopic xenografts were allowed to grow for 21 days. R01-
MG-IRDye800 (30 µM) or IRDye800 (30 µM) was dissolved in 200 µL PBS (pH 
7.4) and administered to mice via tail-vein injection. The data was acquired from 
30 min up to 24h after the injection of the imaging agent.
Transgenic Mouse Model of PDAC
The transgenic pancreatic cancer mouse model (Pdx1-Cretg/+; KRasLSL G12D/+; 
Ink4a/Arf−/−) was used (n = 10), which spontaneously develops foci of pancreatic 
cancer within 4−7 weeks of age.20 Tumor diameters ranged between 3.0 and 4.8 
mm. Age-matched littermates without KRasG12D mutation were used as normal 
wildtype control (n = 10). R01-MG-IRDye800 (30 µM) was dissolved in 200 
µL PBS (pH 7.4) and administered to mice via tail-vein injection, in both the 
wildtype controls and tumor-bearing mice.
Toxicity of R01-MG-IRDye800 in mice
The toxicity of R01-MG-IRDye800 in living mice was determined in Nu/Nu mice 
(n=3). After injection of R01-MG-IRDye800 (30 µM) the mice were followed 
for three weeks and weight and overall appearance was assessed. In addition, 
blood draws were done to assess effect on red and white blood cells, aspartate 
transaminase (ASAT), alanine transaminase (ALAT) and creatinine. 
Ex vivo imaging and biodistribution
All the mice were sacrificed between 6 or 24 h postinjection of the imaging 
agent as described above. Optical imaging of the excised organs was carried out 
using The Pearl Impulse imaging platform at 800 nm for biodistribution studies.
NIR-fluorescent animal imaging analysis
The Pearl Impulse small animal imaging system (LI-COR) was used for NIR-
fluorescence measurements to measure NIR-fluorescent signals of the tumor, 
biodistribution analysis and to calculate TBR (tumor-to-background ratios). 
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The specific and control images were normalized and regions of interest were 
marked. The background signals were extracted from the surrounding tissue 
that was defined as the (normal) tissue/organ that lies around the tumor. After 
measuring the signal intensity from the macroscopic images they were divided 
by each other using the following formula: TBR = mean signal tumor/ mean 
signal surrounding tissue.
Histology
Formalin-fixed paraffin-embedded tumor tissues were sectioned at 5 µm 
thickness and fluorescence imaging was performed using the Odyssey NIR 
scanner (LI-COR Biosciences). All histologic sections were stained with standard 
hematoxylin-eosin immunohistochemical staining (H&E). To confirm the 
presence of αvβ6, additional sections were stained with immunohistochemistry 
(IHC) for anti-human αvβ6 (1/80, 6.2A1, Biogen Idec, Cambridge, MA). For 
preparation of IHC staining, the slides were deparaffinized with xylene and 
rehydrated in serially diluted ethanol solutions (100%-50%), followed by 
demineralized water according to standard protocols. Endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen peroxidase in phosphate 
buffered saline (PBS) for 20 min. Antigen retrieval for αvβ6 was performed with 
0.4% pepsin incubation (Dako) at 37°C for 10 min. Following antigen retrieval, 
the tissue sections were incubated overnight with the primary antibodies 
in 100 µl for standard tissue sections at room temperature. The slides were 
washed with PBS, followed by incubation with secondary antibody at room 
temperature according to the Vectastain ABC HRP kit (Peroxidase, Mouse IgG, 
Vector Laboratories Inc., Burlingame, CA). After additional washing, the staining 
was visualized with 3,3-diaminobenzidine tetrahydrochloride solution (DAKO, 
Glustrup, Denmark) at room temperature for 5 minutes and counterstained with 
hematoxylin for 20 seconds. Finally, the tissue sections were dehydrated and 
mounted in Pertex (Histolab, Rockville, MD, USA).
Statistical Analysis
Analyses were performed in SPSS 22.0 (IBM technologies). All data were 
presented as the mean ± standard deviations. Means were compared using 
Independent-Samples T test, or with One-way ANOVA with post-hoc Bonferroni 
correction. A P-value of less than .05 was considered to indicate a significant 
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difference. Graphs and linear regression were performed in GraphPad Prism 7.0 
(version 7.02, IBM Corp.)
 
RESULTS
IRDye800 (NIRF dye) conjugation of the cysteine knottins
R01-MG was synthesized, and labeled with IRDye800CW at 1:1 ratio (Figure 
S1A). In addition the control cysteine knottin was synthesized (Figure S1B), 
and conjugated following the same protocol. R01-MG-IRDye800 showed high 
stability without clear decrease in fluorescent signal after laser exposure at 
750nm for 30 minutes (Figure S1C). This correlates to the stability of IRDye800 
alone.21
avβ6 expression on cancer cell lines
The expression of αvβ6 in the cancer cell lines (listed above) was evaluated 
by flow cytometry using the monoclonal antibody, 10D5, and shown in the 
supplementary figures (Figure S2). Four of the cancer cell lines showed high 
αvβ6 expression; BxPC-3-luc2, A431, AsPC-1 and 4T1. Three cancer cell lines 
showed none or low αvβ6 expression; MiaPaCa-2, HCT-116, CT-26. Based on 
these experiments, we selected BxPC-3 and A431 as positive and MiaPaCa-2 as 
negative controls respectively for further studies.
R01-MG-IRDye800 specificity
The retained αvβ6-specificity of R01-MG-IRDye800 was confirmed using 
chamberslide assays. An increase in agent concentration resulted in an almost 
linear increase in signal intensity in the αvβ6 positive cell line (BxPC-3), while 
the αvβ6 negative cell line (MiaPaCa-2) showed limited signal intensity (Figure 
2A). The difference between the cell lines was observed for all the different 
concentration tested, however staining at the lowest concentration [0.1uM] 
was also weak in BxPC-3 cells (Figure 2A). Competition of R01-MG-IRDye800 
with unlabeled R01-MG resulted in a 77.2% reduction in NIR signal intensity, 
suggesting that the αvβ6-specific binding capacity of R01-MG after conjugation 
to IRDye800 remained. In addition, in a cell assay with different concentration 
of αvβ6 receptors, simulated by different percentages of BxPC-3 and MiaPaca-2 
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cells together, an increase in receptors led to a linear increase in fluorescent 
signal (R2 = 0.80) (Figure 2A).
A significant difference in fluorescent (figure 2B, C) signal between BxPC-3 
and MiaPaCa-2 cells was detected (p<0.001), and after 2h of incubation the 
fluorescent signal in BxPC-3 cells was 3.1 fold higher compared to the MiaPaca-2 
cells. To control for non-specific staining of the fluorescent dye, incubation with 
the fluorescent dye alone, [0.5uM] IRDye800, was performed. The fluorescence 
intensity was 2.7 times lower compared to the incubation of [0.5uM] R01-MG-
IRDye800 in BxPC-3 cells (p<0.001) and equal to the intensity in MiaPaCa-2 
(p=1.000), indicating the specific binding of R01-MG-IRDye800 to αvβ6 (Figure 
Figure 2. Cell binding study of R01-MG-IRDye800. (A) Graphic representation of fluorescent signal 
in BxPC-3 (αvβ6-positive), MiaPaCa-2 (αvβ6-negative) cells with regression line, after blocking with 
R01-MG, and with different concentrations of αvβ6-receptors. (B) Comparison of fluorescent signal in 
αvβ6-positive, and –negative cells after incubation with R01-MG-IRDye800, and after incubation with 
IRDye800 alone. (C) Representative fluorescence microscopy images of BxPC-3 cells with fluorescent 
signal at 800nm (green) and in overlay with DAPI signal (blue) to co-stain cell nuclei, and MiaPaCa-2 
cells without any fluorescent signal at 800nm, but with DAPI-signal (blue). (D) Comparison between 
R01-MG-IRDye800 and newly synthesized fluorescent control knottin in BxPC-3 cells. ***; p<0.001, 
graphs are mean ± SD.
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2B). A significant (p<0.001) lower fluorescent signal was observed after 
incubation with the control cysteine knottin, compared to R01-MG-IRDye800 as 
shown in Figure 2D. There was no fluorescent signal observed in both cell lines 
after incubation with PBS.
Mouse models
Specificity of R01-MG-IRDye800 in subcutaneous mouse models
To validate the performance of R01-MG-IRDye800 in living subjects, three 
different mouse models were used: (1) a subcutaneous model with different 
cell lines, (2)an orthotopic, intrapancreatic xenograftmodel using different cell 
lines, and (3) a spontaneous transgenic pancreatic cancer model. Subcutaneous 
tumor models were used to compare the binding of R01-MG-IRDye800 in αvβ6-
positive and –negative tumors, and to determine the TBR over time (Figure 
3A). The highest TBR for BxPC-3 mice was measured 20h post injection (4.08 
± 0.95) (Figure 3B). There was a difference in TBR between BxPC-3 tumors (2.5 
± 0.1), MiaPaCa-2 tumors (1.2 ± 0.1), and A431 tumors (1.8 ± 0.5), with a linear 
increase in TBR for both the BxPC-3 tumors and A431 tumors over time. The 
TBR of MiaPaCa-2 tumors remained stable at~1.0 during the investigated period 
of 5 hours (Figure 3C). BxPC-3 tumors had a significantly higher TBR compared 
to MiaPaCa-2 tumors (p<0.001) (Figure 3D). As controls R01-MG-IRDye800 
was compared to a control peptide and fluorescent dye alone. The TBR of the 
mice injected with R01-MG-IRDye800 after 24h (3.5 ± 0.95) was significantly 
(p<0.005) higher compared to control peptide (1.6 ± 0.36), and dye alone (1.4 
± 0.2) (p<0.005) suggesting specific targeting of αvβ6 by R01-MG-IRDye800 
(Figure 3E). In addition, compared to IRDye800 alone, a clear increase in mean 
TBR was seen over time for R01-MG-IRDye800, compared to an approximately 
constant mean TBR for IRDye800. This difference was significant from T=4h 
after injection (T=0h p=0.95, T=1h p=0.16, T=3h p=0.05, T=4h p<0.001, T=6h 
p<0.001, T=24h p<0.005) (Figure 3F).
αvβ6 binding and biodistribution in orthotopic mouse models
The efficacy of R01-MG-IRDye800 to bind and detect αvβ6 in vivo was evaluated 
in pancreatic cancer orthotopic xenografts implanted in nude mice. A mean TBR 
of 2.7 ± 1.22 at 24 hours post-injection was measured, compared to a mean 
TBR of 0.86 ± 0.13 for IRDye800 alone (Figure 4A). Ex vivo NIR-fluorescence 
measurements showed tumor specificity of the tracer with a mean TBR of 6.96 ± 
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Figure 3. Preclinical validation R01-MG-IRDye800 in subcutaneous tumor models at 800nm. (A) Repre-
sentative image of mouse with BxPC-3 and MiaPaCa-2 tumor 4h post-injection of R01-MG-IRDye800, and 
clear excretion via de kidneys. The tumor is indicated with a red arrow, the kidneys with white arrow. 
(B) Tumor-to-background ratio over time in BxPC-3 tumors with nonlinear fit curve, and (C) in tumors 
with different levels of αvβ6. (D) Comparison of maximum TBR in BxPC-3 and MiaPaCa-2 tumors, 5h 
post injection. (E) Validation of αvβ6-specific binding with R01-MG-IRDye800 compared to a control 
cysteine knottin and the fluorescent dye alone at maximum TBR, and (F) over time. Scale bar represent 
1 cm. Graphs are mean ± SD.
Figure 4. Validation in pancreatic cancer orthotopic xenografts at 800nm. (A) Representative images 
of tumor visualization using R01-MG-IRDye800, both in vivo and ex vivo. Ex vivo the pancreas with 
tumor is shown (left), the bowel (middle), and the kidney’s (right). TBR in vivo over time, and comparison 
of maximum TBR between R01-MG-IRDye800 and IRDye800 alone. (B). Biodistribution of R01-MG-
IRDye800, with highest uptake in the kidneys. (C) Correlation between tumor on H&E (outlined in red), 
and increased fluorescent signal. Scale bar represent 1 cm, unless indicated differently. P = pancreas, 
B = bladder, LV = liver. Graphs are mean ± SD.
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2.2. Biodistribution assays showed high fluorescence in the kidneys (MFI 1.12 AU) 
and urine (MFI 0.22 AU) compared to the liver (MFI 0.007 AU) indicating a renal 
clearance route, and some fluorescence in the bowel (MFI 0.03 AU) and skin (MFI 
0.02 AU) (Figure 4B). Fluorescence in the bowel can be explained by mild αvβ6 
expression in gastro-intestinal tract mucosa.22, 23 At the microscopic level, high 
fluorescence matched well with location of the tumor on H&E (Figure 4C). 
Validation in transgenic mouse models
In the spontaneous transgenic tumor mouse model, the tumor could be 
visualized, even with the skin intact, and fluorescence localized at tumor regions 
was clearly visible ex vivo (Figure 5A). Even a subcentimeter metastasic lesion 
on the bowel (0.7 x 0.5 cm) could be visualized with fluorescence, corresponding 
to tumor-positive H&E (Figure 5B). In mice with the tumor genotype, the TBR 
Figure 5. Fluorescent imaging and validation of R01-MG-IRDye800 in transgenic mice model at 800nm. 
(A) In vivo fluorescent imaging of mouse with pancreatic cancer, showing agent excretion via the kid-
neys in mouse with skin and without skin. In addition, ex vivo fluorescent imaging of resected pancreas 
with localized fluorescence and corresponding H&E section of entire pancreas with tumor localizations 
(outlined in red). (B) Ex vivo fluorescent imaging of primary tumor with subcentimeter metastasis on 
the bowel (white arrow), and corresponding fluorescence intensity scan with Odyssey Imaging System 
(LI-COR) showing high fluorescence in tumor areas, with corresponding H&E section of PDAC (black 
box). In addition, a graphic representation of mean TBR in transgenic mice of tumor versus normal 
pancreas (p<0.001). (C) Immunohistochemical correlation between fluorescent signal, tumor status 
and αvβ6 expression. Scale bar represent 1 cm, unless indicated differently. P = pancreas, B = bladder, 
LV = liver. Graphs are mean ± SD.
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obtained with R01-MG-IRDye800 (3.6 ± 0.94) was significantly higher compared 
to the TBR in the normal pancreas of the WT controls after R01-MG-IRDye800 
infusion (1.0 ± 0.17) (p<0.001) (Figure 5B). Fluorescent signal, and tumor status 
corresponded well to αvβ6 expression as assessed by immunohistochemistry 
(Figure 5C). To resemble the human situation, fluorescent signal provided by 
R01-MG-IRDye800 showed successful distinction between PDAC and peritumoral 
inflammation when in close proximity, even on microscopic level (Figure S3).
Toxicity of R01-MG-IRDye800
Pilot toxicity of the agent was determined in nude mice (N=3) by measurement 
of weight and hematology and chemistry blood panels. There was no significant 
difference observed in weight of mice pre-injection of R01-MG-IRDye800, 
directly after injection (p=0.054) and after the observation period of 3 weeks 
(p=0.732). The liver panel slightly increased after agent injection, and red blood 
cells count decreased, but all returned to baseline levels after follow-up. A slight 
increase in white blood cell count and creatinine was also seen, but these levels 
remained within normal limits for the entire observation period (Figure S4). 
 
DISCUSSION
To improve the dismal prognosis of patients with PDAC, focus should be on 
early detection, improved patient selection for treatment and better surgical 
outcomes. A significant number of patients with PDAC present while the disease 
has already spread and will therefore not benefit from surgery as primary 
treatment. A limitation of conventional imaging techniques, such as CT and 
MRI, is the low sensitivity for detection of subcentimeter lesions and therefore 
metastatic spread is not always detected prior to surgery.24 To overcome this 
limitation, optical imaging could be an additional tool to be applied during a 
diagnostic laparoscopy, prior to resection, to screen the abdomen for potential 
metastatic spread, such as liver or peritoneal metastases. For superficial 
lesions, fluorescent imaging is superior. Adjacent to that, for a more thorough 
screening of the liver, optoacoustic imaging could be added to provide sufficient 
depth penetration.10, 25 If no spread is found in this initial stage, the surgery 
can proceed using the same optical imaging techniques to guide the resection. 
During resection, use of optical imaging can improve radical resection rates 
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by enhancing tumor margins and increase detection of tumor-positive lymph 
nodes.26 
Previously, Hutteman et al. showed the use of the non-targeted optical imaging 
agent, Indocyanine Green (ICG), for the detection of PDAC. It was concluded 
that no useful tumor demarcation could be visualized after intravenous injection 
of ICG. However, the common bile duct and biliary anastomoses were clearly 
visualized.27 Clinical trials performed in other malignancies, such as ovarian 
cancer, using tumor-specific imaging agents, showed successful use of this 
technique for the specific identification of cancer during surgery.11, 28-30 
Integrin αvβ6 has been shown to be a promising target for identification of 
PDAC, and differentiation with pancreatitis and normal pancreatic tissue, with 
retained expression in vital tumor cells after neoadjuvant therapy.12, 13, 15, 31, 32 
Nowadays, the majority of patients will receive neoadjuvant therapy prior to 
surgery due to late onset of symptoms and therefore, presentation with locally 
advanced disease, or borderline resectable tumors. Currently, the distinction 
after neoadjuvant therapy between necrosis, fibrosis and vital tumor is 
impossible using conventional imaging techniques, and tumor-specific imaging 
could potentially fill this gap and be of added value in the diagnostic process.
Cysteine knottin peptides are relatively small (3-4 kDa), and have been 
extensively validated as alternative molecular imaging agents to antibodies.31, 33, 
34 We showed that the previously engineered cysteine knottin peptide R01-MG18 
demonstrated high and specific tumor uptake and high tumor-to-normal tissue 
ratios in mouse models of integrin αvβ6-positive PDAC, after conjugation to the 
near-infrared fluorescent dye, IRDye800. Moreover, the agent did not accumulate 
in integrin αvβ6-negative tumors. Due to the well-defined secondary structure, 
cysteine knottin peptides possess improved in vivo stability, and resist both 
chemical and physical insult compared to linear peptides, such as “A20”.18, 35-37 
R01-MG-IRDye800 targets integrin αvβ6 with high affinity binding (Kd = 1.2 nM) 
and in a highly specific manner,18 compared to for example cyclic-RGD, which 
mainly targets αvβ3, but also αvβ5, α5β1, α6β4, α4β1, and αvβ6.38
To prove that R01-MG-IRDye800 specifically targets αvβ6, and fluorescent 
signal in the tumor is not due to enhanced permeability and retention (EPR) 
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effect, especially seen in subcutaneous tumor models,39 we have chosen to use 
a humanized transgenic mouse model. In addition, we performed several control 
studies using IRDye800 alone, and a newly synthesized control peptide with 
similar characteristics as the targeting peptide. Furthermore, to minimize non-
specific leakage of the agent to the tumor, subcutaneous tumors with BxPC-3 
cells were used which are known to be poorly leaky tumors, and therefore 
minimize EPR effect.40 Our studies showed that the fluorescent signal of R01-
MG-IRDye800 was significantly higher compared to both controls, indicating 
specific binding of R01-MG-IRDye800 to αvβ6.
A limitation of using optical imaging as described here, is the use of one 
target to image the tissue of interest compared to multiplexing, targeting of 
multiple markers, to increase the detection sensitivity and potentially assess 
aggressiveness of the tumor.41 Ideally, you would be able to deliver a cocktail of 
imaging agents to patients, each targeting a specific biomarker that is known to 
be overexpressed in PDAC and supplement each other for improved detection.13 
However, at this point none of the newly developed NIR tumor-specific optical 
imaging agents is approved by the U.S. Food and Drug Administration (FDA), 
which is partly due to the comprehensive process and costs associated with 
getting regulatory approval for an optical imaging agent, and the current 
lack of proven patient benefit.42 Therefore, the possibility to deliver multiple 
agents at once, can probably not be realized in the near future. A benefit of the 
investigated target is that αvβ6 is overexpressed in > 95% of PDAC patients, 
and significantly higher expressed in PDAC versus pancreatitis and normal 
pancreatic tissue.13 Therefore, it is expected that multiplexing will not cause 
significant benefits over the use of R01-MG-IRDye800 as a single agent. As 
reported above, the differentiation between chronic pancreatitis and PDAC is 
one of the aspects where tumor-specific molecular imaging can be of additional 
benefit to the patient. A limitation of this study is that the agent is not tested in 
chronic pancreatitis mouse models. However, we know from previous performed 
research that αvβ6 expression is significantly lower in pancreatitis compared 
to PDAC.12, 13 In addition, we did address the difference in fluorescent signal 
between PDAC and peritumoral inflammation, because if the technique is 
able to do this, it would fill a clinically relevant gap in conventional imaging 
techniques. Based on our results, and due to high specific binding of the agent, 
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no limitations are expected for the clinical use of this agent for tumor-specific 
detection.
Our developed agent has high potential for clinical translation into patients, 
since it consists of two parts that are already successfully translated into 
humans. The cysteine knot peptide, R01-MG, is currently used in the clinic 
as an αvβ6-targeting PET tracer for the detection of pancreatic cancer (eIND 
#126379, NCT02683824) and the NIR fluorescent dye, IRDye800CW, has already 
been used for fluorescence-guided surgery in multiple clinical trials.11, 30 We 
performed a pilot toxicology study that showed that the newly developed agent 
was well tolerated. However, some changes in hematology and chemistry blood 
panels were seen immediately after injection, which could potentially be due 
to the agent. These levels returned within the normal range after observation, 
but before final conclusions can be drawn, larger toxicology studies need to be 
performed to determine the meaning of these changes. 
In conclusion, the developed optical imaging agent R01-MG-IRDye800 binds 
selectively to αvβ6. In cell studies, R01-MG-IRDye800 outperformed all controls, 
and a clear correlation between levels of receptor expression and fluorescence 
signal was found. In multiple preclinical mouse models, tumor-specific targeting 
was achieved, with favorable renal clearance. The agent exhibited high tumor-
to-background ratios, and clear correlation between fluorescence signal and 
histopathologic evidence of PDAC. Thanks to the fact that this agent contains 
two elements, R01-MG and IRDye800 that were already proven to be safe for 
use in humans, we do not expect major hurdles for the clinical translation of 
this optical imaging agent.
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A cost-effective strategy for early-stage cancer detection would be based on 
a two-step paradigm1. First, a sensitive and specific blood test screens for 
individuals in the general or high-risk population who display cancer-specific 
biomarkers released from tumour cells. Patients with abnormal blood biomarkers 
then undergo follow-up tests, in which sensitive molecularimaging techniques 
targeting multiple cancer markers assess the location, size and aggressive state 
of the putative tumour. Yet such a screening paradigm is not a reality. For tumour 
detection, current blood biomarkers and imaging probes require high sensitivity 
to accurately identify small early-stage lesions, as well as high specificity to 
accurately distinguish benign tissues from malignant transformations 1–3. 
However, blood biomarkers such as cancer antigen 125 (CA125) and prostate-
specific antigen (PSA) have had limited success in clinical practice because they 
are also frequently shed by healthy cells in physiological conditions. Even in 
the pursuit of other types of tumour-specific biomarker, such as patient-specific 
circulating tumour DNA, more sensitive methodologies and validation are 
required to provide substantial evidence that these methods can be effective 
in early cancer screening. On the molecular-imaging front, in which probes are 
engineered to non-invasively target and visualize a molecular marker indicative 
of disease in real time, the level of marker expression in cancer cells is often 
low or heterogeneous, leading to difficulties in distinguishing signals from the 
tumour and its healthy surrounding tissue, which in turn results in low detection 
sensitivity. For early cancer detection to succeed using blood-based and imaging 
approaches, better tumour-to-normal tissue ratios (TNRs) are needed, either by 
increasing the tumour signal, decreasing the background signal, or both. Two 
complementary developments reported in Nature Biomedical Engineering now 
demonstrate how higher TNRs can be achieved with nanoscale probes that are 
only activated within the tumour microenvironment.
On the one hand, Sangeeta Bhatia and colleagues show that intravenously 
delivered activity-based nanosensors (ABNs) decorated with tumour-targeting 
ligands and with peptides cleavable by specific proteases (proteolytic enzymes) 
overexpressed in the tumour microenvironment can overcome the blood-
based detection problems plaguing endogenous secreted biomarkers for early 
cancer detection 4. On interaction with specific tumour proteases, the peptide 
substrates, which are fluorescence-quenched,
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are cleaved and secreted in the urine, where they can be detected by a 
fluorescence assay (Fig. 1). On the other hand, Xiqun Jiang and colleagues 
describe the design of a molecular probe, a poly(ethylene glycol)-conjugated 
iridium (iii) complex (Ir-Im-PEG) that, when activated by two tumour-specific 
stimuli, results in imaging-signal amplification and thus improved detection 
sensitivity5. The probe responds progressively to subtle differences in 
extracellular pH and oxygen levels, and distinguishes healthy tissue (which is 
usually alkaline and normoxic) from tumour tissue (which is acidic and hypoxic).
Bhatia and co-authors, who have championed similar diagnostic nanosystems6,7, 
have now optimized the presentation of the nanoparticle-coating substrates on 
the basis of mathematical modelling of the pharmacokinetics of the ABNs (ref. 6) 
to increase the TNR. The authors focused on targeting matrix metalloproteinase 
9 (MMP9), as MMP9 mRNA is shown to be upregulated in many human cancers 
at varying stages of disease4. Having previously predicted that a 100-fold 
improvement in tumour signal was needed to detect sub-5-mm sized tumours, 
the authors now report the detection of intraperitoneal ovarian tumours as 
small as 36 mm3 in mice, outperforming by 2.4-fold the endogenous ovarian 
Figure 1. Optimized tumour-activated nanoparticle-based sensors, consisting of a nanoparticle (NP) core 
decorated with a protease-cleavable substrate and tumour-targeting ligands. Following intravenous (i.v.) 
injection of the nanoparticles (1), the quenched substrates are cleaved by highly expressed proteases 
in the tumour microenvironment, which subsequently emit a fluorescence signal (2). The dequenched 
urinary reporter enters the urine (3) and is detectable via a fluorescence assay (4). Figure adapted from 
ref. 4, Macmillan Publishers Ltd. 06
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cancer biomarker human epididymis secretory protein 4 (HE4). The authors also 
show with mouse xenograft models of epithelial cancer and colorectal liver 
metastasis that the optimized ABNs markedly increase the enzyme-generated 
diagnostic signal with respect to the signal expected on the basis of ABN 
accumulation in tumour alone. This suggests that exogenous biomarkers can 
be optimized to produce urine-based assays with increased sensitivity for the 
earlier detection of tumours. 
Protease-based cancer-imaging probes are making their way from mouse 
xenograft models to human clinical trials8. One question to be answered is 
how accurately the preclinical results reported by Bhatia and collaborators will 
translate into early cancer screening in patients. MMP9 is highly expressed in the 
tumour microenvironment but is also expressed in normal tissue, so activation 
of ABNs at non-tumour sites may decrease the TNR. Assuming successful 
nanoparticle delivery and safety, Bhatia and colleagues predict that the ABNs 
could detect a human serous ovarian cancer 5 months earlier than the clinically 
relevant biomarker HE4. In reality, extrapolating the behaviour of the ABNs 
from mice to patients involves the consideration of allometric scaling between 
species, as well as taking into account biomarker pharmacokinetics, body weight 
or surface area, tumour vascularity, and possibly other cancerspecific properties. 
Ultimately, whether ABNs would be sufficiently sensitive and specific for early 
cancer detection in humans will have to be tested. 
Nevertheless, there is a need for better tumour-specific blood-based biomarkers 
for cancer detection, be them endogenous factors or markers generated from 
exogenously administered nanoparticles or genetic constructs 9. Beyond the 
binary distinction between presence and absence of disease, it is important to 
identify biomarkers that inform about the state of the malignant tumour. In this 
context, ABNs or other exogenous biomarkers could be designed to specifically 
target aggressive and lethal tumours (and to not be activated in benign 
tumours). Exogenously delivered ABNs, if multiplexed with appropriate enzyme-
cleavable substrates and tumour-targeting ligands, may well be a valid strategy 
to increase the sensitivities and specificities of tumour diagnoses. 
Following biomarker-based screening, imaging probes activated at the tumour 
site provide the possibility to image tissue at high TNRs and therefore validate 
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the potential presence and location of the disease. Jiang and colleagues 
exploited events occurring in the tumour microenvironment to trigger signal 
amplification, in contrast to conventional amplification techniques based on 
chemical or physical modifications of the probe itself. In the acidic tumour 
environment (pH 6.5–6.9), hydrolysis of the aciditysensitive imine bond in the 
Ir-Im-PEG complex leads to the conversion of the precursor form of the probe 
(which emits light at 610 nm) to its reporter form (with emission at 705 nm). 
If the second stimulus (hypoxia) is also present in the microenvironment, 
the 705-nm signal is amplified5 (Fig. 2) The increased sensitivity of this dual-
activation approach enabled the detection of tumour nodules as small as 1 mm 
in diameter. However, one disadvantage of this approach is that optical imaging 
assays, although useful for localized and intraoperative imaging, may not be 
ideal for whole-body screening.
Figure 2. Tumour-activated imaging probe with signal amplification, driven by the conversion of thep-
robe’s precursor form into the reporter form. The intravenously injected precursor probe emits at610 nm. 
In the acidic tumour microenvironment, the precursor form converts to the reporter form,which emits 
at 705 nm. At the hypoxic conditions of the tumour microenvironment, the optical signalis amplified. 
Emission spectra are shown at increasing-pH and decreasing-oxygen conditions. Figure adapted from 
ref. 5, Macmillan Publishers Ltd.
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In contrast to the behaviour of other microenvironment-responsive probes 
10–12, the cleavable Ir-Im-PEG reports coupled events (acidity and hypoxia), 
and by doing so enhances the detection signal. Indeed, when compared with 
a previously reported hypoxia-activated iridium macromolecule 13, Ir-Im-PEG 
achieved roughly a fourfold enhancement in TNR, and improved the detection 
of small tumour lesions in the liver. The higher TNR of the improved probe was 
generated by reducing the background signal rather than by increasing the 
optical signal, so it is possible that the brightness of the probe might not be 
sufficient for clinical use, for example during real-time surgical resections. 
Jiang and co-authors used patient-derived tumour xenograft models and 
histological analyses of the human tumour microenvironment to validate 
the Ir-Im-PEG probe. Yet before this imaging approach can be translated to 
patients, efficacy and dose studies need to be carried out. Nevertheless, the 
improved sensitivity of Ir-Im-PEG highlights the advantages of enabling signal 
amplification and of focusing on multiplexing strategies rather than targeting 
individual markers. The authors’ imaging approach could become widely used for 
the detection of solid tumours, in which subtle changes in acidity and hypoxia 
are generally present 14,15. They also showed that such context-sensitive probes 
might have other applications, for example in wound healing, and that they 
could pave the way for monitoring the metabolic activity of cells to determine 
treatment response. 
Synthetic nanoparticle systems and optical imaging probes are rarely approved 
for human use by the US Food and Drug Administration, mainly owing to safety 
issues, a complex regulatory system, scalability and manufacturing challenges, 
and a lack of proven benefit in humans. To improve and expedite the clinical 
translation of new probes for eventual clinical diagnostics, their development 
should plan for rigorous proof-of-safety and proof-of-benefit studies. These are 
critical steps in making earlier cancer detection with biomarkers and imaging 
probes feasible. Although the safety of the probes reported by Bhatia, Jiang 
and their respective co-authors remains unclear because high dosages might be 
needed to establish desired effects, it is not too early to state that the detection 
sensitivity benefits of tumour-activatable probes are promising.
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ABSTRACT
Considerable advances in cancer-specific optical imaging have improved the 
precision of tumor resection. In comparison to traditional imaging modalities, 
this technology is unique in its ability to provide real-time feedback to the 
operating surgeon. Given the significant clinical implications of optical 
imaging, there is an urgent need to standardize surgical navigation tools and 
contrast agents to facilitate swift regulatory approval. Because fluorescence-
enhanced surgery requires a combination of both device and drug, each may 
be developed in conjunction, or separately, which are important considerations 
in the approval process. This report is the result of a one-day meeting held 
on May 4, 2016 with officials from the National Cancer Institute (NCI), The 
Food and Drug Administration (FDA), members of ASIGS (American Society of 
Image-Guided Surgery) and members of the World Molecular Imaging Society 
(WMIS), which discussed consensus methods for FDA-directed human testing 
and approval of investigational optical imaging devices as well as contrast 
agents for surgical applications. The goal of this workshop was to discuss FDA 
approval requirements and the expectations for approval of these novel drugs 
and devices, packaged separately or in combination, within the context of 
optical surgical navigation. Additionally, the workshop acted to provide clarity 
to the research community on data collection and trial design. Reported here 
are the specific discussion items and recommendations from this critical and 
timely meeting.
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INTRODUCTION
Surgery with negative margins is the foundation for curative treatment in 
many solid cancers.1 While conventional imaging modalities such as magnetic 
resonance imaging (MRI), computed tomography (CT), positron emission 
tomography (PET), and ultrasound (US) facilitate surgical planning, they are 
generally difficult to integrate into the surgical environment. Most importantly, 
however, these traditional modalities do not reliably communicate real-time 
feedback to the surgeon except for ultrasound. Therefore, surgeons must depend 
on subjective palpation and subtle visual changes for achieving complete tumor 
clearance. Although intraoperative frozen tissue sectioning, staining, and 
microscopic visualization are routinely used for achieving negative margins, this 
is time-consuming, costly, and samples only a small proportion of the wound 
bed, which may lead to sampling error with false-negative results. Positive 
or close margins directly correlate with poorer outcomes, often necessitating 
post-operative adjuvant therapy and, in some instances, a second operation.2 
Conversely, aggressive radical resections can remove normal tissue, leading 
to excessive morbidity and/or disfigurement. Thus, real-time surgical guidance 
for differentiating tumor and healthy tissue is crucial to both improved overall 
survival in addition to preservation of tissue function and appearance. 
The recent advances in optical contrast imaging have brought forth a myriad of 
cancer-specific agents that have the ability to expand the information required 
for the surgeon to make informed clinical decisions. These optical imaging 
techniques are highly variable with a wide range of imaging wavelenghts and 
spatial scales.3 Together, these developments offer tremendous advantages to 
the field of surgical guidance, with an unparalleled ability to transform surgical 
oncology. In fact, due to their potential for high signal to noise ratios (SNR) and 
sensitivity to a broad range of spatial resolution, optical fluorescence imaging 
has the potential to impact patient care in multiple arenas. For example, in 
comparison to shorter wavelengths, the penetrating deep tissue properties of 
near-infrared (NIR) fluorescence has led to a focus on similar long-emitting 
fluorophores for this and many other optical imaging applications (see NIH 
Research Portfolio Online Reporting Tools (RePORT) for details).4 Nevertheless, 
there are a number of variables that impact the success of intraoperative optical 
imaging that are intrinsic to the imaging hardware or the molecular probe itself. 
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Perhaps the greatest variable, however, is inter- and intratumor heterogeneity. 
Despite three decades of research to identify tissue-specific targets and develop 
effective imaging agents, 5-aminolevulinic acid (5-ALA) is the only real-time, 
cancer-specific agent available in the clinic today. Administered orally or 
topically, 5-ALA is converted intratumorally to fluorescent protoporphyrin IX. 
Currently, 5-ALA is approved for oral administration in Europe, Canada, and 
Japan to highlight brain tumors during cytoreductive surgery. The 5-ALA ester 
derivative hexaminolevulinate (HAL) is approved for topical use for bladder 
cancer detection in both the United States and Europe.5, 6 The use of 5-ALA was 
shown to be successful during intracranial tumor resection5 by achieving more 
complete resection and improving progression-free survival in patients with 
malignant glioma, which suggests that it carries the potential for use in other 
cancer types with similar favorable outcomes.7-9
There are a number of additional tumor-specific molecular probes that are 
widely applicable to several cancer types that have been described,10 and an 
increasing amount of clinical trials are being conducted to evaluate both their 
safety and efficacy. Favorable safety data from non-human primates allows 
antibody-based optical imaging to build on the advances in immunotherapy 
and immunoPET imaging.11 For example, cetuximab conjugated to IRDye800 
(cetuximab-IRDye800) has been studied in phase 1 clinical trials and has 
demonstrated the ability to identify subclinical tumor in patients with head 
and neck cancer.12 However, successful regulatory approval for the widespread 
use of this technology requires additional clinical trials. These trials must be 
designed and performed according to the standards of the FDA Investigational 
New Drug Application (IND) recommendations to demonstrate safety and patient 
benefit as well as the Centers for Medicare & Medicaid Services (CMS) for cost-
effectiveness. Over the past few years, the number of FDA submissions for 
IND or Investigational Device Exemptions (IDE) related to optical imaging has 
doubled annually, with 26 clinical trials currently planned or already underway.
A unique feature of fluorescent optical imaging is that it facilitates real-time 
decision-making by guiding surgeons to potential areas of microscopic disease 
in a macroscopic setting. From a regulatory standpoint this deserves special 
considerations since real-time feedback not only fosters dynamic decision 
Regulatory requirements for fluorescence guided surgery | 141
making but also permits adjustments to the treatment plan, which is not 
possible with current pre-operative imaging modalities. 
In February 2015, the American Society of Image Guided Surgery (ASIGS) held 
a meeting with surgeons and scientists in the field of Image Guided Surgery to 
critically evaluate imaging platform technologies and optical imaging agents. 
The goal of this meeting was to provide recommendations regarding trial 
development and the regulatory approval process, and come to an agreement 
on how this technology could be used to meet the needs of cancer patients.13 
Since then, several new clinical trials have incorporated major elements 
from the resulting ASIGS consensus report. However, the appropriate clinical 
trial endpoints that meet FDA requirements for successful device and/or 
drug approval remain ill-defined due to a lack of precedence and diagnostic/
therapeutic crossover inherent to this technology. As such, these potential 
setbacks formed the basis of the one-day workshop on May 4, 2016, which 
included representatives from the National Cancer Institute (NCI), the FDA, 
members of ASIGS and members of the World Molecular Imaging Society 
(WMIS). The primary aim was to define consensus methods and endpoints for 
FDA-regulated human testing and approval of investigational optical imaging 
devices and contrast agents (drugs) in surgery. The first step was to report 
FDA considerations for evaluation of any new device or drug, and obtain their 
guidance on how devices, drugs, or their combination, would most effectively 
obtain market approval. Recognizing that there is significant controversy 
regarding this topic, we have summarized to the best of our ability the findings 
and recommendations from this meeting. This report can critically assist in the 
development of optical imaging products, and the regulatory pathways for their 




When approving imaging devices and agents for clinical use, the FDA relies on 
data supplied by marketing applications and regulatory bodies. Taking this into 
consideration, the field should identify clinically meaningful endpoints as well as 
surrogates of clinical benefit to aid the approval pathways of any new promising 
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technologies, including optical imaging. However, this task is confounded by the 
paucity of clinical data on contrast-enhanced oncologic imaging agents, which 
consequently results in limited or lack of regulatory precedents. Therefore, it 
is critical to identify clinical developmental pathways for optical imaging in 
oncological surgery using similar yet appropriate modalities and companion 
agents that can be used for FDA’s consideration. For instance, the use of MRI-
guided surgery in brain cancer is analogous to fluorescence-guided surgery, 
where enhancement is used to influence surgical decisions and has previously 
shown benefit in patient outcome.14 However, MRI procedures do not use 
products that have been specifically approved by FDA for surgical intervention; 
hence, FDA does not consider MRI-guided surgery an established predicate for 
fluorescence-guided surgery. Until these approaches have been thoroughly 
evaluated by the FDA, we will not have any certain guidance documents to 
clearly define the principles of study design and appropriate outcome measures 
based on safety and benefit to the patient.
 
IMAGING DEVICES
A wide range of intraoperative fluorescence imaging devices have been 
developed by academic and commercial institutions that use similar illumination 
strategies, light sources, detectors, device architectures and collection 
geometries. Systems for use in open surgery, laparoscopic, thoracoscopic, 
and robot-assisted procedures have all been described, and likely represent 
a broad range of sensitivities to a given set of fluorophores, and differences 
inherent to their background noise levels. Because they have been developed 
with a specific usage in mind, they differ significantly in their fields-of-view, 
resolution, and wavelengths. Although the concept of these devices is relatively 
straightforward in that they simply require a light source, filters, detector(s), 
and display, there are specific chal lenges intrinsic to the system design. These 
include having appropriate light sources with a variety of wavelengths but 
within the prescribed safety standards for illumination,15 adequate filter design 
to eliminate excitation and ambient light for use with one or more fluorophores, 
detectors with the appropriate spectral range and sensitivity with good SNR, 
real-time readout superimposed on a reference image, and ultimately, a user-
friendly and ergonomic design. The ideal optical imaging system for the OR 
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should have additional characteristics, such as seamless operation with room 
lights, quantitative pattern recognition, and favorable ergonomic characteristics 
for use in a demanding environment. For a more detailed overview of the 
different characteristics imaging systems should possess and the challenges for 
development we would to refer to the review paper by DSouza et al.3 While many 
of the current systems include these features, there is considerable variation 
among these devices, and industry standards are only just emerging. Most of 
these instruments possess a broad range of wavelength imaging capabilities, 
which translates to a potential for imaging several distinct fluorophores. This 
imaging potential is further compounded by the fact that any fluorophore can be 
conjugated to a number of targeting moieties. For these reasons, many different 
molecular formulations could be used with the same instrument. The FDA will 
review an application for a new drug intended for use in combination with a 
specific instrument or intended for use with multiple instruments as designated 
by the applicant drug manufacturers who need to carefully consider instrument 
design and capabilities before undertaking clinical development of a new drug.
FDA regulatory pathways for Device approval 
For imaging devices, the FDA regulatory process is directed by the Center for 
Devices & Radiological Health (CDRH). This process begins with an optional pre-
submission meeting with the FDA after a “Q-submission” request to the Agency 
has been requested. This meeting serves as a forum for individual sponsors 
and the FDA to discuss the planned Investigational Device Exemption (IDE) or 
marketing application/clearance submission. The subsequent route to regulatory 
clearance or approval for devices depends primarily upon the level of risk 
associated with the clinical application of the device. When the goal is simply 
anatomical, such as locating lymph nodes or blood vessels, the FDA typically 
views optical imaging systems as relatively low risk. Optical imaging systems 
used to visualize anatomy in clinical investigations could be considered “non-
significant risk” (NSR) devices, and an IDE is not required. Upon establishing 
safety and efficacy through the completion of such a clinical investigation, a 
sponsor can subsequently submit a traditional 510(k) application for market 
clearance if “substantial equivalence” to a predicate device is claimed.16 
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Optical imaging systems used in the diagnosis, prognosis, and/or treatment 
of diseases, however, are by default designated significant risk devices (SR) 
by the FDA regardless of disease severity. If the study sponsor intends to use 
such devices during an investigational human study, the FDA requires the study 
sponsor to file an IDE application.17 For combination drug and device products, 
an Investigational New Drug (IND) application for the associated molecular 
agent being used may be filed in place of an IDE, if the Center for Drug 
Evaluation Research (CDER) is assigned as the lead review center.
Depending on the intended use of the imaging system, the sponsor presents the 
appropriate NSR or SR designation to the local Institutional Review Board (IRB) 
for review. Once IRB and IDE (for significant risk devices) are granted, the sponsor 
is free to proceed with the investigation. The issue of NSR/SR designation has 
been discussed and documented in detail previously.18 The required elements 
for an IDE application can be found on the FDA website and are summarized 
in Table 1.19 Ultimately, a pre-market approval (PMA) application is filed for 
market approval of Class III medical devices. The information requested by the 
FDA for PMA approval depends upon its intended use and any specific claims 
about the device that have been made by the sponsor. Evidence must support 
the intended use claim. For device approval under a PMA, information on device 
labeling, performance specifications, valid scientific evidence, tissue effects 
of the product, mechanism-of-action, and clinical outcomes will be required.20 
Guidance documents for PMA submissions can also be found on the FDA website.
Currently approved devices
Currently, there are several optical imaging devices that have been cleared 
by the FDA mainly for non-cancer indications. All 510(k) cleared devices can 
be found in the FDA database.21 A recent review by dSouza et al. compares 
the existing fluorescent imaging devices and provides basic criteria for the 
comparison of different images for specific applications.3 To summarize these 
devices, a tabular overview detailing currently cleared devices are shown 
in table 2 along with more detailed information included in supplemental 
materials. For the main advantages and disadvantages of these devices we refer 
to the following reviews.3, 22, 23
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Table 1. Different types and characteristics of Investigational Device Exemption (IDE) studies
Early feasibility study Feasibility study Pivotal study
Sample size • Small number of patients, 
< 15 (approximate).
• More patients than 
EFS.




Criteria • Fundamental questions 
about device performance 
& safety exist
• Expected changes to 
design of prototype 
device.
• Limited nonclinical data 
available.
• Sufficient infor-
mation is known 
about the design, 
procedure or 
indication to justify 
clinical studies 
with more patients 
than EFS.
• Device is the final 
design and there 
is significant in-
formation known 
about the design, 
procedure and 
indication.
Purpose • To demonstrate a proof of 
concept.
• Early look at safety/ef-
ficacy.
• Examine human factors 
and work flow.
• Determine what design or 
procedure changes could 
optimize the therapy.
• Determine patient charac-
teristics that may impact 
device performance.
• Capture prelim-
inary safety and 
effectiveness.





port a marketing 
application.
 
Standardization of Devices and Device Performance 
Best practices for evaluating safety and performance of medical imaging devices 
are regularly published in the form of standards documents. While performance 
standards are commonly used in established medical imaging fields, such as 
the FDA-recognized PET imaging standards published by NEMA,24 only safety 
standards currently exist for optical imaging. Standards that address performance 
typically recommend phantom-based test methods. Specifically, these 
documents identify relevant characteristics (e.g., spatial resolution, uniformity, 
sensitivity, dynamic range), provide guidelines for testing (e.g., phantom material 
property range/geometry, methods for calculating metrics), and describe viable 
test methods for a performance characteristic. Standardization improves FDA’s 
ability to understand device working mechanisms and overall effectiveness, 
for benefit-risk assessments and substantial equivalence determinations. They 
also help to facilitate device development, standardize clinical trials and ensure 
product quality. 
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2005 K042961 The Philips Integra Series 2 Sys-
tems (K984545)








2012 K110480 Novadaq Technologies Inc.’s SPY 
Imaging System SP2000 (K063345)





Fluoptics 2014 K132475 Hamamatsu Photonics K.K., PDE 







2014 K141077 da Vinci Xi Surgical System device 
(K131861)







2015 K143474 PDE of Hamamatsu (K110480)














2016 K161792 PINPOINT Endoscopic Fluorescence 
Imaging System (K150956)
The use of a phantom or physical standard to ensure device performance is well 
accepted, yet the idea of requiring device developers or manufacturers to adhere 
to an equivalent standard remains somewhat controversial. This is largely due to 
the fact that optical imaging and fluorescent probes represent innovative, rapidly 
changing areas. Therefore, in addition to adhering to basic principles of image 
quality assessment, methods should be applicable to a wide range of devices 
and contrast agents. Furthermore, testing should be as “minimally burdensome” 
as possible, which includes factors such as complexity of preparation/execution 
and ability to assess multiple image quality characteristics simultaneously, or in 
relatively rapid succession.
Establishment of performance standards begins with research on phantom-
based test methods. While much progress has been made in this area, more 
work is needed to optimize methods addressing key characteristics. Professional 
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societies can use this research as the basis for generating publications that 
outline scientific consensus on best practices. Finally, authorship of a standard 
is performed by a standards organization (e.g., IEC, NEMA) committee that can 
draw on published consensus documents. Therefore, members of academia 
and industry are strongly encouraged to participate in optical safety and 
performance testing research, scientific consensus building and standards 
development that will inform and impact the regulatory process. 
Unlike PET, which relies upon annihilation events to produce photons at a 
specific energy (all emissions lead to 511 keV gamma rays), optical imaging must 
consider its interactive properties with regards to the wavelength or frequency 
of the tissue being imaged. In many respects, each of the 16 regions of the 
optical imaging spectrum falling between 500 and 1300nm is unique. However, 
the specific parameters to be used to define these tools and the community 
designated to regulate these optical instruments has yet to be determined. 
The onus may lie on both the FDA and device manufacturers to determine such 
characteristics and whether they are better suited for regulation at the industry 
or federal level. For other imaging modalities, there are established testing 
parameters like spatial resolution, uniformity, distortion, sensitivity, linearity, 
and field of view, all of which may be applicable to optical imaging but with 
additional considerations for optics.24 These may include dynamic range, spatial 
resolution, background collection, and sensitivity. To date, no accepted standard 
phantom for optical imaging or minimum requirements for device performance 
exist. 
Preclinical Safety Testing
Light safety standards typically used to ensure optical device safety do not 
address the increased potential for injury when light interacts with an exogenous 
agent present in tissue.15 Many fluorescence contrast agents (e.g., protoporphyrin 
IX, IR700DX, Cy5) are known to produce photochemical damage in DNA and other 
cellular components due to light-induced generation of reactive oxygen species. 
While beneficial for photodynamic therapy and photoimmunotherapy,25 this 
behavior presents a potential safety risk for imaging products. Contrast agents 
exhibiting strong absorption may intensify local energy absorption, increasing 
the risk of photothermal or mechanical (cavitation) damage.26 Furthermore, novel 
nanoparticles may introduce unique hazards – such as highly localized fluence 
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“hot spots” due to plasmon resonance effects. While no guidance documents 
have been developed to address testing of optical imaging contrast agents, a 
recent guidance published by FDA/CDER provides general recommendations for 
preclinical testing of medications’ photochemical safety27 through the use of 
chemical assays for evaluating production of reactive oxygen species as well 
as in vitro and in vivo assays for assessing damage to cells and tissues. In the 
absence of standards or even well-validated best practices to clarify potential 
issues with novel contrast-enhanced optical products, preclinical testing, which 
may include in vitro cellular, phantom or tissue testing, or in vivo animal studies, 
is often warranted on a case by case basis to ensure patient safety. 
 
IMAGING AGENTS
The challenge for cancer imaging agents is the detection of small lesions 
while maintaining a high tumor-to-background ratio (TBR). There are two major 
classes of optical agents: targeted and non-targeted probes. The targeted 
probes consist of a signaling moiety, a vehicle, and a targeting ligand. These can 
be further divided into “always-on” and “activatable” probes.28 Probe diversity 
further adds to the complexity of the approval process. Pharmacokinetics plays 
an important role in regulatory issues; for example, the longer an agent stays 
in the body the more significant the safety issues. Properties like molecule size, 
composition, and relative mass of signaling and targeting moieties result in 
different biodistribution and clearance rates. Not only toxicity should be taken 
into account when developing targeted contrast agents, but also other design 
considerations such as stability in human serum, specificity and sensitivity 
for the target.29 Additionally, the route of administration will influence safety 
issues, such that topical application may be more favorable from a safety 
standpoint due to low systemic absorption as compared to intravenous (IV) 
administration. However, there are practical considerations when using topical 
formulations not encountered with IV administration, such as an inability to 
wash off unbound probe, non-uniformity of delivery, local tissue toxicity and 
barrier effects of the tissue surface (e.g. the stratum corneum of the skin). 
These different elements affect data collection and interpretation, and must 
be considered in pursuit of regulatory approval and subsequent clinical studies. 
Therefore, a more standardized process for imaging agents could help improve 
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development and approval. This would improve the FDA’s ability to understand 
safety, working mechanism and overall effectiveness. However, the field also 
points out concerns regarding standardization in agent development, since this 
can slow down the rapidly changing chemistry in this field. A full review of 
these issues for imaging agents can be found elsewhere.30
Currently only the non-specific NIR imaging agent indocyanine green (ICG) is 
approved by the FDA for imaging purposes. However, at this point novel NIR 
fluorophores are developed with a substantially higher fluorescent yield 
compared to ICG and in contrast to ICG, these molecules can be conjugated to 
a targeting ligand, leading to targeted imaging agents.3 An example of such 
a fluorophore that is already tested extensively and shown safe in humans is 
IRDye 800CW (LI-COR Biosciences, Lincoln, NE). Additionally, ZW800 (Curadel, 
Marlborough, MA) is another advanced NIR fluorophore that is nearing clinical 
testing.31
Due to unique physiological and mechanical characteristics of these agents, 
all will require distinct safety and toxicity studies. The range of wavelengths 
combined with the range of agent types makes this area of imaging different 
than PET, MRI, or single-photon emission computed tomography (SPECT). Using 
an approved drug as an imaging vehicle that can be coupled to a fluorescent 
molecule, analogous to incorporating a radionuclide into a drug for PET imaging, 
might seem like a way to improve the efficiency of the clinical translation 
process due to known biodistribution, targeting and safety profiles. However, 
since fluorophores are often large in comparison to the approved pharmaceutical 
agent, the new entity may confer significant differences from the approved drug, 
and the FDA considers this a New Molecular Entity (NME), which limits many of 
the predicate drug advantages.32 The NME will be reviewed as a novel compound 
and require NME-specific safety and efficacy data. In diagnostic imaging, there 
is an option to perform a traditional dose-ranging Phase I clinical trial, or if 
the agent is likely to be visualized at very low doses, an exploratory IND can 
be initiated when the intended dose is limited to a microdose level (≤ 100 µg 
and 1/100 of the therapeutic dose or ≤ 30 nanomoles of a protein). Using this 
pathway, the early safety testing should demonstrate that the safety profile of 
the NME is similar to the previously approved parent compound. This approach 
will provide early information on biodistribution and streamline the testing and 
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approval process. For radioactively labeled agents, the FDA has developed a 
specific mechanism to facilitate early data acquisition through the Radioactive 
Drugs Research Committee (RDRC) mechanism, whereby radioactively labeled 
agents can be used to perform certain clinical research without IND approval. 
Information regarding metabolism, pathophysiology, or biochemistry can thus be 
obtained through early phase studies. The most important difference between 
an eIND and the studies conducted via the RDRC mechanism is that the RDRC 
can only review basic science research proposals for the use of radioactive drugs 
in humans, but is not intended for therapeutic or diagnostic purposes, nor for 
determining safety and efficacy.33
Nonclinical safety and toxicity studies
The potential toxicity for investigational agents needs to be balanced by 
potential benefits. For traditional diagnostic imaging agents undergoing early 
clinical testing serious or clinically important adverse reactions are generally 
not acceptable. Nonclinical safety and toxicity studies should be designed to 
establish a wide safety margin. However, because many new agents are being 
proposed for surgical resection of malignancies, which inherently involve major 
procedures for life-threatening diseases, higher levels of risk may be justified 
by the nature of the procedure’s anticipated benefits. When diagnostic imaging 
agents are evaluated for use to guide therapeutic decisions, there may be 
some flexibility (see below in Early Phase Clinical Trials). At this point current 
studies, both in humans and in preclinical setting, have not raised any specific 
safety issues for human use of NIR fluorophores since they have shown low or 
completely absent toxicity.
Nonclinical drug studies require identification of drug-target organs, 
characterization of pharmacology and toxicology, starting dose determination 
with dose escalation scheme, and study-tailored drug usage information. For 
NME, there are specific studies typically required prior to the onset of a Phase I 
trial (Table 3).34 However, it is important to note that with appropriate scientific 
justification, the FDA may allow trials to proceed without some of the required 
studies after thorough discussion in a pre-IND meeting. The criteria mentioned 
are for targeted contrast agent and focus specifically on the physiochemical 
properties of the agent, biodistribution, and clearance pathway. It is the opinion 
of the field that it is crucial to analyze these properties at this point of the 
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approval process. For modified existing agents, the requirements are variable 
and, in some instances, no new preclinical studies are required. Bridging toxicity 
studies may be required. When a change is made to the route of administration, 
dose, or population of an already approved agent, the FDA encourages early 
discussion since they will individually evaluate the need for any additional 
preclinical studies. Moreover, for certain nonclinical studies (e.g. reproductive 
toxicology), the sponsor may submit a waiver request to the FDA.35 For certain 
agents like nanoparticles, which are known to accumulate in off-target organs, 
the FDA might request chronic toxicology studies.
Table 3. Non-clinical studies needed for New Molecular Entity (NME) before Phase I trial can be con-
ducted for optical imaging agents
Study Explanation
Proof-of-concept Studies showing proof-of-concept of the NME.
Safety Pharmacology To measure functional indices of potential 
toxicity. The aim of the safety pharmacology 
studies should be to reveal any functional 
effects on major physiological systems.
Pharmacokinetics and Toxicokinetics Single and multiple dose pharmacokinetics, 
toxicokinetics, and tissue distribution studies. 
Information on absorption, disposition, and 
clearance in relevant animal models should be 
collected.
Expanded single dose toxicity study (can be 
combined with repeat dose toxicity study)
Single dose studies should generate useful 
data to describe the relationship of dose to 
systemic and/or local toxicity. 
Repeated dose toxicity must be done when 
there is a chance for a secondary dose.
Special toxicology e.g. phototoxicity, route irritancy, blood com-
patibility.
In vitro genotoxicity study The use of standard genotoxicity studies for 
assessing the genotoxic potential of biotech-
nology-derived pharmaceuticals is not consid-
ered appropriate.
*Note that FDA may permit delaying or omitting some of these studies during a pre-IND meeting
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FDA regulatory pathways for drug approval 
When a sponsor considers development of a broad-range optical imaging agent 
with use for multiple cancer types and subsequent FDA approval, a study 
can be conducted to demonstrate generalization of efficacy across a number 
of cancers, by extrapolating data when similar methods are applicable for 
the proposed cancer types. In this setting, the trial design typically does not 
address a therapeutic indication and instead seeks approval as a contrast agent. 
Lymphoseek,36 which is widely used for sentinel lymph node biopsy, followed 
a similar process for approval. These studies additionally serve to establish 
differences in pharmacokinetics and biodistribution among a range of tumor 
types and disease states. However, early phase trials should continue to focus 
on safety followed by efficacy. As such, it may be preferential to begin studies 
in a well-defined population, as this better facilitates successful completion of 
desired trial endpoints and further minimizes variability in results. Conversely, 
one benefit of feasibility testing in a variety of tumor types is the ability to 
confirm the proposed mechanism of visualization. For example, if the feasibility 
of an imaging agent has been demonstrated in the imaging of diseased blood-
brain-barrier (BBB), which is typical of brain cancer, there is no additional need 
to show efficacy in subsequent brain cancer histologies. Another example is 
2-deoxy-2-(18F)fluoro-D-glucose (FDG), an agent approved for imaging glucose 
metabolism upregulation, which is known to occur in multiple cancers; therefore, 
FDG is amendable to imaging multiple types of cancer. To be successful in drug 
development, the FDA encourages early interaction to optimize the efficiency 
of clinical data development and, therefore, optimize data usefulness, enhance 
communications with regulators, and expedite the drug development process. 
The intended indication of the product must be clear in the strategic plan and 
well-known at the onset of development. Therefore, this “target” indication 
should be a leading consideration in the trial design.
Case-by-case evaluation by the FDA
The FDA believes that open discussion of the scientific and clinical considerations 
regarding optical imaging agents and devices will successfully advance this field. 
The agency further recognizes that each case requires individual assessment 
and that strict regulatory guidelines do not uniformly fit all products due to 
the complex nature of optical imaging. Additionally, the FDA has regulatory 
flexibility to meet the needs of any specific product when necessary. If the 
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science and rationale of an investigational optical product are sound, the FDA 
will perform an individual analysis of the studies that should be conducted to 
collect safety and efficacy data for approval.34
 
COMBINATION DRUG AND DEVICE PRODUCTS
Optical imaging technologies for intraoperative imaging tend to be device 
and drug combinations,37 which may be beneficial for commercialization. 
The decision of whether or not to submit a combined application is entirely 
dependent upon the sponsor, not the FDA. Nevertheless, the FDA will examine 
each device and/or drug submission to determine the appropriate product 
designation (combination or individual) based on desired labeling. 
When a specific medical device is to be used with certain drug products, labeling 
for either product may be accomplished in a number of ways. For example, it 
may fall under general labeling, whereby the medical device (or drug) has a 
broad indication and without restrictions for use with a specific drug (or device). 
Additionally, one-way labeling may be applicable when a drug (or device) is for 
use with a specific device (or drug), but the device (or drug) can be used with 
multiple drugs (or devices). Lastly, two-way labeling or cross-labeling where the 
drug and device are tied together and seen as a combination product. 
By definition, a combination product refers to 2 or more different regulated 
components (such as a drug with device).38 Optical imaging usually includes 
two products that are sold separately but labeled for use together.38 An e(3) 
product is one that is developed for use with another already approved product, 
which according to the investigational plan, are both necessary for its intended 
use. If used with a device, labeling of a previously approved product will be 
seen as a combination product. An e(4) product has both an investigational drug 
and an investigational device component and specifies that both are required 
for their intended use. The assignment of the combination product to a lead 
FDA center (e.g. CDER, CBER, or CDRH) is based on the primary mode of action 
(PMOA) of the product. The PMOA is defined as the single mode of action of a 
combination product that provides the most important therapeutic action.38 The 
assignment algorithm considers precedence (i.e. where has similar technology 
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been assigned) in assigning a lead center. The lead center will become the 
point of contact for the sponsor and will communicate with other centers for 
the purposes of regulatory review. Consequently, there is a need for only one 
marketing application for most combination products, either an NDA or PMA. 
However, a sponsor can choose to submit two marketing applications.
If the sponsor wishes for a drug to be indicated for use with multiple devices, 
it does not automatically imply that it will be a combination product. This is 
especially true when said devices are already approved. Regardless, there must 
be technical and clinical data available to support the use of multiple devices in 
addition to one-way or general labeling.
The best examples of this approach are PET agents, which can be used on a range 
of PET imaging devices. When a PET scanner is cleared for human use, it is not 
indicated for a specific PET agent but rather for positron-emitting radionuclides, 
which is a broad label. The reason for this is that the FDA has evidence that PET 
devices operate with sufficient similarity. For optical imaging, however, this is 
not yet the case. As such, the FDA must continue to develop a similar level of 
experience when using an optical imaging agent with multiple devices. When 
comparing optical imaging devices to PET or MRI, there are several aspects to 
consider. First, there are orders of magnitude variations in signal levels, which 
makes it difficult to draw a parallel with the other techniques. Secondly, there 
is a wide variety of devices, large dynamic range differences (causing as much 
as 6 orders of magnitude variation in sensitivity), wavelength variation, and 
varying performance with room lights that will change background sensitivity, 
and intensity variation due to distance.
 
CLINICAL TRIAL TYPES AND IMPORTANCE OF 
DESIGN
Early feasibility studies - Devices
For the development of medical devices, it can be valuable to use the Early 
Feasibility Study (EFS) program as a regulatory tool, which is similar to a phase I 
study for drug development.39 The goal of the EFS program is to enhance patient 
access to beneficial technology and supporting innovation in the clinical sector. 
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A sponsor can conduct an EFS IDE trial when there are significant unknowns 
regarding device performance, because the device is early in development or 
is intended for a new use. Therefore, a small number of subjects are permitted 
for clinical investigation. The differences between the different types of IDE 
trials are shown in Table 1. Also part of the EFS guidance are recommendations 
on the optimal path for filing a pre-submission for an IDE.40 Early discussion 
with the FDA can be very helpful to agree on a test plan that will support the 
IDE and can help avoid unnecessary testing, which can be time consuming and 
expensive.19 Additionally, it may be possible, in some instances, to use novel 
devices for certain preliminary clinical studies without formal FDA approval, 
which would only require local Institutional Review Board (IRB) approval.
Pharmacology in clinical trials - Drugs
The pharmacology requirements during the clinical drug development process 
are primarily divided into safety and efficacy considerations (Table 4). Safety 
issues are based on what is being delivered to the patient (manufacturing), 
dosing, and appropriate monitoring during the trial. Recommendations on 
trial design, which are made by the FDA, can aid in making the process 
successful. The primary goal for efficacy trials is to determine a “near-optimal” 
dose, a process that is often finalized in Phase II. For the FDA, the definition 
of near-optimal is a dose regimen and imaging condition that are superior to 
alternatives, which have been studied for safety and pilot efficacy. This will 
require the investigation of a dose escalation scheme with 3 imaging windows, 
and the ability to conclude whether or not more will be better or fewer will be 
just as good. Early on, pharmacokinetic assessment can assist in the selection of 
optimal imaging window, timing of repeat dosing, and amount of repeat dosing. 
The goal should be to correlate concentrations to clinical outcome, which is 
typically performed in Phase III studies.
Phase I and II trials for Imaging Agents and Combination Products
As stated previously, potential risk vs. potential benefit considerations for 
investigational diagnostic tests require that the test products (drug and 
associated cameras/devices) have relatively low safety risks. However, when 
agents are developed to have an effect on therapeutic decisions, are supported 
by proof of concept data, and trials are designed to show improvement in 
clinically important outcomes it may be justifiable to adjust the safety threshold 
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in order to match potential benefits. For those agents or product combinations 
that claim improvement on patient survival, the safety requirements may be less 
Table 4. Safety and Efficacy requirements at all different phases of drug development
Study Requirements
First-in-human Minimum requirements for conducting study to establish safety 
data.
Safety:
• Collect early dosing information.
• Determine entry criteria; e.g. renal impairment.
• Monitoring cardiac safety; at baseline and after imaging.
• Adverse event collection during imaging and follow-up.
Important data set to obtain 
• Sufficient PK sampling.
• Drug interactions on concentration.
• Imaging characteristics at various doses and time points
Phase-II trial Controlled clinical study to collect early effectiveness data and 
generate hypotheses.
Safety:
• Same as Phase I, but supported by evidence obtained previ-
ously.
• Gain early understanding of the expected adverse event 
profile.
Efficacy:
• Refine dosing to determine “near optimal” dose.
• PK sampling for assessment of PK linearity. 
• Develop imaging interpretation standards.
End-of-Phase II meeting Generally considered the most important meeting between sponsor 
and FDA.
• Near optimal dose is determined, both in safety and efficacy 
manner.
• Determine what needs to be measured in future studies.
• Acquire input from FDA on how specific populations will be 
addressed in the label.
Phase III trial Safety:
• Same as Phase II, but supported by evidence obtained previ-
ously. 
• Sufficiently powered for statistical determinants.
Efficacy:
• Clinically meaningful primary endpoint success.
• Sufficient PK sampling to inform dose adjustment during or at 
end of trial for a typical patient and specific populations.
Pre-NDA/BLA meeting • Review data to fulfill recommendations made at end-of phase 
2.
• Review organization of future application: study reports and 
datasets.
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stringent than those agents that claim a lesser benefit. The main focus of trial 
design for phase I and II trials should be to collect sufficient safety data and 
information to define achievable endpoints for clinical benefit and also collect 
data that supports the intended clinical use and indication statement (Table 
4). When conducting Phase I and early Phase II studies, it is important that the 
standard of care be maintained to protect patients from imaging products that 
have not yet been provided preliminary evidence of effectiveness.
Efficacy endpoints in clinical trials
During design of clinical trials, endpoints need to align with the proposed drug/
device labeling indication and, therefore, high standard clinical claims will 
require more clinically meaningful evidence. The FDA works with a risk-benefit 
approach such that any risks must be outweighed by increased benefits. The 
variety of potential efficacy endpoints is demonstrated in Table 5 and includes 
clinical therapeutic outcomes as well as measures of diagnostic performance.
Table 5. Types of efficacy endpoints
Endpoint Explanation
Exploratory Used for development of hypotheses, pharmacodynamics 
measurements.
Primary Used to demonstrate efficacy.
Secondary Support efficacy, provide information on safety and efficacy in 
specific subpopulations.
 
To gain FDA approval for new drug applications (NDA),41 the study needs to 
show benefit to the patient. Endpoints that simply correlate fluorescence 
with the location of a known tumor are not considered sufficient for approval; 
rather evidence must be shown that imaging will have a positive benefit for 
the patient. An example discussed was the identification of positive tumor 
margins in a defined clinical setting. For example, if after standard surgical 
resection additional malignant lesions are identified, then this would indicate 
the potential benefit of the imaging, assuming that a more complete removal 
of malignant tissue for this type of cancer is directly correlated with survival or 
other clinical benefit such as reduced need for reoperation. This means the FDA 
does not specifically require direct measurement of survival endpoints for this 
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indication. It can be sufficient to show improved detection of positive margins 
when the new technology is used, since the correlation between clear margins 
and survival is already well established for many types of cancer. The same may 
be true for debulking surgeries. For example, if prior evidence indicates that 
debulking correlates to better outcomes, it may be sufficient to show that the 
optical technique improves the surgical safety and effectiveness of debulking 
procedures.
One of the important considerations for the conduct of imaging studies what 
procedures will be used to minimize bias. There was little consensus to better 
understand which clinical trial methodologies would be most efficient, cost 
effective and scientifically reproducible. Trial randomization increases the 
number of patients required for studies in several cancer types. Additionally, 
it is impossible to effectively blind the operating surgeon, who would most 
certainly realize when optical imaging was being utilized. An intra-patient 
controlled study can be adequately designed to test the hypothesis that the 
optical technique provides additional information that contributes to the tactile 
or visual information provided by standard of care. To tackle these problems 
the FDA established a recommendation panel. An example of a clinical setting 
where an intra-patient control study can be used successfully is a study of 
primary breast cancer resection. A pre-specification of optical agent diagnostic 
performance and definition of the meaningful improvement to be achieved by 
the investigational product in the clinical trials need to be defined in the clinical 
protocol before study initiation.
FUNDING AND RESOURCES AT NCI FOR MOLECULAR 
IMAGING AGENTS
The NIH and NCI have resources available to support molecular imaging 
research. Only funding specifically for imaging will be discussed here. Some 
grant opportunities for early phase clinical trials are available for image-
guided drug delivery, for combination of pre-clinical and clinical studies, and 
for collaborations between academia and industry to translate imaging systems 
for cancer imaging. Additionally, there are the SBIRs and STTRs for industry 
support. More extensive information can be found at the NIH website42 and 
special imaging grant opportunities are listed at: http://imaging.cancer.gov/
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researchfunding/fundingopportunities/currentcip. The NCI also has the NExT 
program for alleviating the substantial resource strain required to translate 
experimental therapeutics into the clinic. This program provides access to NCI 
recourses and expertise.43 
For late Phase II and Phase III trials, the NCI has the NCI National Clinical 
Trial Network (NTCN) to conduct large-scale clinical trials. The ECOG-ACRIN 
group is specialized in imaging.44 Lastly the NCI can provide help in regulatory 
issues and provide resources during pre-submission phases. It is also important 
to note that the nanocharacterization lab (NCL) can be a useful resource for 
nanoparticle based agents and is an important resource within the NIH.45
 
CONSIDERATIONS
Reimbursement by the CMS for optical imaging is an important consideration 
for industry investment. Traditionally, this is initiated after FDA approval has 
been granted. The goal of CMS is to assess whether new technologies are 
reasonable and necessary. Therefore, they may require patient and cost-
effectiveness outcome data. In contrast, the FDA has a different responsibility 
when evaluating new technologies, namely assessing safety and effectiveness. 
However, the FDA can assist in designing trials in collaboration with CMS to 
additionally assess those outcomes.
There was consensus that target-specific imaging agents are the most likely to 
have a long-term benefit when compared to non-specific agents like indocyanine 
green. However, the general opinion was that the field should first focus on more 
generalizable agents so as to expand the technique using fluorescent guidance 
beyond purely surgical applications. Clinical translation must be efficient, but 
it is rather unlikely that multiple agents will be approved in a timely manner. 
It is important to note that continued education of the CMS is likely necessary 
in considering molecular imaging agents, which has been the case for many 
years with the FDA regarding such agents. Lack of CMS reimbursement will be 
a key factor in hindering the widespread use of molecular imaging agents for 
intraoperative imaging. Thus, a consortium that includes professional societies, 
industry, NIH, and private foundations will be important to better educate 
07
160 | Chapter 7
the CMS and ultimately obtain reimbursement for specific molecular imaging 
agents.
When considering improvement of the approval process for devices and agents, 
regulatory and commercial incentives must be taken into account. While 
decoupling agents and devices would certainly aid in the advancement of 
optical imaging, this may not be in the economic interests of the manufacturers. 
The reason for this may not be solely financial, but also safety driven. When 
devices and drugs are coupled, a rigorous safety profile must be established, 
which is further associated with a higher regulatory burden.
 
CONCLUSION
The ultimate goal of NIR-fluorescent contrast-enhanced oncologic surgery 
is to provide information to the surgeon that lies beyond that of the visible 
light spectrum and amplify contrast enhancement in different tissue types. By 
improving visual detection of tumors, the surgeon gains critical information that 
can translate to improved overall outcomes for the patient. Since optical imaging 
techniques lead to real-time feedback, there is a direct and instantaneous effect 
on patient care and decision-making. While this is one of the main advantages 
of contrast-enhanced oncologic resection, it nonetheless requires proof of 
benefit to the patient. Thus, the field must clearly demonstrate the benefit in 
clinical trials and thoroughly assess relevant outcomes. The investigational 
imaging agent/device’s proposed “indication for use” will direct all future 
studies needed for approval and, therefore, should be chosen carefully. Lastly, 
the use of predicate devices and agents, when available, should help accelerate 
the eventual approval of new optical imaging technology.
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Summary statements
1. Contrast-enhanced surgery should be considered a complementary technique for the surgeon 
rather than a diagnostic tool. This technique is used to provide additional information to assist 
the surgeon in making clinical decisions to improve procedural outcomes.
2. Proving performance equality in different imaging devices (as in PET imaging) is critical to 
demonstrate so that imaging agents may be used on multiple devices.
3. Identifying a predicate device can help guide the approval pathway for a new or equivalent 
device.
4. If an optical imaging system is intended for the diagnosis, prognosis, or treatment of cancer 
during an investigational human study, such use is determined to be “significant risk” and FDA 
requires the study sponsor to file an Investigational Device Exemption (IDE) application.
5. Optical imaging products are traditionally viewed as combination products by the FDA.
6. Additional toxicity of imaging agents should be well justified by the benefit since the 
invasiveness of procedure does not factor into the FDA classification considerations. 
7. Clinical trials must be designed to obtain safety and efficacy data for the intended indication of 
use.
8. If the sponsor wants a drug to be indicated for use with multiple devices, there must be 
technical and clinical data available to support the use of multiple devices.
9. Clinical trials must prove patient benefit before FDA approval can be obtained since optical 
imaging inevitably influences patient care and decision making in real-time.
10. The FDA does not specifically require direct measurement of survival endpoints to show 
benefit for the contrast-enhanced surgery indication. It can be sufficient to show improved 
detection of positive margins when the new technology is used, since the correlation between 
clear margins and survival is already well established for many types of cancer.
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ABSTRACT
Optical molecular imaging with the use of tumor-specific molecular imaging 
agents (MI agent) has the potential to provide a personalized approach to both 
medical therapy and surgical procedures. This technique can improve patient 
stratification, increase margin-negative resections, detect metastatic spread, 
monitor therapy, and potentially improve overall patient care. To reach these 
goals, U.S. Food and Drug Administration (FDA)-approval is the first and very 
crucial step for successful and widespread clinical translation, which is often 
followed by acquisition of value data to receive insurance reimbursement. Data 
requirements for FDA approval vary considerably, but there are some constants: 
there is a need to demonstrate safety and efficacy of the novel MI agent and 
technique, and for the sponsor it is necessary to achieve this with the lowest 
cost and in shortest amount of time. Success or failure of optical MI agents 
will critically depend on the design of clinical trials and the chosen endpoints. 
Here we will provide some insights into the process of engaging the FDA in the 
evaluation of tumor-specific MI agents, and guide the way for designing optimal 
optical imaging clinical trials.
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INTRODUCTION
Molecular imaging allows non-invasive visualization of biological processes at 
cellular and subcellular levels in a living subject by integrating both disease- 
and patient-specific information and it is often fused with traditional anatomical 
images.1 Molecular imaging serves as a tool to acquire sequential and consistent 
information on the subject of interest enabling a precise understanding of the 
biological process and design studies with better statistical power and even 
reduce the number of subjects involved, following the Replacement, Reduction, 
Refinement (3 R’s) principle.2 There are high expectations of this personalized 
approach to therapy, since it could result in improved stratification of patients 
and will ensure that patients receive the most appropriate treatment. Ultimately, 
this approach can improve patient care. Molecular imaging can be applied to a 
wide range of indications, such as treatment, diagnostics, drug development, 
and monitoring of drug action.3,4 Molecular imaging could identify early failures 
in development of therapeutic agents (in phase I or II trials), which would result 
in reduction in time and cost for getting an agent to market. An example of an 
MI agent used for multiple indications is FDG-PET, which has proved useful not 
only in diagnostics but also in obtaining information on drug efficacy far earlier 
compared to the availability of survival data, thereby, identifying if a clinical 
trial is worth continuing.5-8
Recent maturation in optical imaging technology with targeted MI agents to 
visualize cancer is of high interest in the field, and since 2007 the number of 
publications increased with eightfold and 38 clinical trials have been done in 
this field.9-10 When using tumor-specific molecular imaging to image a tissue 
of interest, certain criteria need to be met: a tissue-specific target, a way to 
reach the target of interest, and highly sensitive, efficient imaging techniques.11 
To leverage the potential of molecular imaging in cancer treatment, U.S. Food 
and Drug Administration (FDA)-approved MI agents are needed. Countless 
preclinical studies have been published in recent years on identifying tissue-
specific targets and developing optical MI agents suggesting its great potential. 
However, until now only the non-specific (not targeted to a specific biomarker) 
optical MI agents indocyanine green (ICG) and methylene blue (MB), and the 
specific MI agent 5-ALA are approved for clinical use. Reasons for the failure of 
clinical translation of novel optical MI agents include high costs, both for GMP 
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manufacturing and toxicology studies, lack of reimbursement, and the high bar 
for demonstrating clinical value established by the FDA. Obtaining FDA approval 
not only allows use in the clinic but also the right to commercially market the 
application, and the ability to apply for reimbursement from the Centers for 
Medicare & Medicaid Services (CMS).
The translation of therapeutic drugs from bench to bedside is around $0.8-1.7 
billion with an estimated timeline of about 10-17 years.12-14 Of all initiated new 
therapeutics only 10% will reach it past the FDA’s Investigational New Drug 
(IND) stage, with up to 45% agents are found to lack clinical efficacy in phase 
III trials.13-17 Failure in phase III studies is often considered to be a result of 
inappropriate data collection in Phase I or II and poor Phase III study design. In 
2006, Nunn reported that the costs of bringing a new MI agent to the market 
are reduced compared to therapeutic drugs, around $100-150 million,18 however 
a hurdle of these MI agents is that they serve a smaller market, are used less 
frequently, and therefore generate less per patient revenue. A long investment 
cycle, the narrow patient population, the single use per patient, and 90% chance 
of failure make MI agents a complex investment (Figure 1). 
Figure 1. Schematic overview of the clinical translation of optical imaging agents, from MI agent 
discovery till the approval of one MI agent. This figure provides an overview of the expensive and 
time-consuming process of the development of a novel MI agent. The timeline gives an indication of 
the required time per phase but is dependent on the chosen agent. In case of an existing compound, 
both the costs and the time will decrease. Adapted for optical imaging agents. Original source: PhRMA
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United States health spending continues to shift from traditional to specialty 
medicines (accounting for $384 of the $895 per person per year spent on 
medicines) and new brands accounted for 13 billion dollars of growth in 2016.19, 
20 To address the overwhelming number and complexity of medical product 
development, the FDA launched the “Critical Path Initiative”. Since 2004, the 
number of approved new molecular entities (NME) or new biologics license 
applications (BLA) has increased, and the median total time to approval has 
decreased indicating the effectiveness of the new FDA regulations. To address 
these same issues for the optical imaging world, there has been several 
collaborative meetings between the optical imaging field, the FDA and National 
Cancer Institute (NCI).21, 22
The aim of this review is to provide a detailed overview of the required steps 
for successful clinical translation of optical MI agents for intra-operative use in 
oncologic surgery and suggestions for trial design to show clinical benefit and 
successful targeting for this specific class of MI agents.
 
POSITRON EMISSION TOMOGRAPHY (PET) TRACERS 
AS PRECEDENCE FOR OPTICAL IMAGING AGENTS
New technologic developments have resulted in a growing interest in optical 
imaging over the last 10-20 years, as a result there is corresponding development 
in the regulatory strategies by the FDA. Although the first optical agent was 
approved in the early 1950’s, PET radiopharmaceuticals have been consistently 
developed for clinical application and evaluated for new indications. In 2012, 
the FDA released the guidelines titled “Investigational New Drug Applications 
for Positron Emission Tomography (PET) Drugs” to improve understanding of the 
development path for novel PET tracers.23 Specific mechanisms were developed 
to facilitate early data acquisition, the Radioactive Drugs Research Committee 
(RDRC) mechanism, where radioactive labeled agents can be used to perform 
early-stage research without FDA IND approval through a local committee. 
Information regarding metabolism, pathophysiology, or biochemistry can 
therefore be obtained in early development of the agent. The RDRC is created 
by the FDA to review research proposals for the use of radioactive drugs in 
humans but not for therapeutic, diagnostic purposes, or for safety and efficacy. 
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The RDRC is designed to review first-in-human studies (such as an exploratory 
IND (eIND)) which are designed to identify the safety and/or efficacy of an MI 
agent for a potential clinical application.
From a regulatory standpoint, there is a significant difference between PET and 
optical MI agents. When a PET agent is approved, it will be approved with a 
general label, and therefore can be used in conjunction with a range of PET 
devices. Moreover, when a PET scanner is approved for human use, it is not 
linked as a combination product to a specific PET agent, but for any positron-
emitting radionuclide. This broad approval is granted because the FDA has a 
high level of confidence that PET devices operate sufficiently similar. This is not 
yet the case for optical MI agents and imaging systems since the similarity of 
performance is yet unproven. An important consideration to take into account 
when comparing optical imaging to PET agents that optical MI agents have 
key differences: 1) tissue penetration is less than or equal to 5-8 mm, 2) it has 
orders of magnitude lower signal intensity, 3) there is broad device variation 
(large dynamic range differences, wavelength variation, and performance can 
depend on ambient light).24, 25
 
REGULATORY VIEW ON OPTICAL MOLECULAR 
IMAGING AGENTS
The regulatory process for MI agents is handled by the Center for Drug 
Evaluation Research (CDER) within the US FDA. There are certain milestones 
and requirements that need to be met during the development process. The 
process will start with an Investigational New Drug application (IND), for which 
a pre-submission (Pre-IND) meeting with the FDA is encouraged. Successful 
demonstration of safety and efficacy in early phase trials can lead to Phase III 
trials which are necessary for demonstration of clinical utility and safety for a 
New Drug Application (NDA) or Biologics License Application (BLA). During the 
pre-IND meeting the FDA will comment on the proposed methods both for GMP 
manufacturing and clinical testing. Optical MI agents tend not to be treated as 
a drug for regulatory purposes, but instead as a combination products since MI 
agents require a complementary imaging instrument to facilitate visualization. 
It is unclear if the optical MI agent will require a marriage to an individual 
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imaging instrument26 or if two products can be sold separately but labeled for 
use together.27 This remains an evolving regulatory area and a more extensive 
elaboration on combination products in optical imaging is reviewed elsewhere.22
For regulatory bodies such as the FDA and European Medicines Agency (EMA), 
optical MI agents add another complexity into field, because they are used in 
real-time during procedures to expand the visual information of the clinician, 
thereby enabling them to make informed decisions based on unique data 
provided by the device and MI agent combination. From a regulatory point of 
view, the fact that intra-operative optical imaging occurs during the procedure 
gives the clinician the opportunity to alter their treatment plan based on 
real-time imaging information. As a result, these MI agents deserve unique 
consideration relative to other imaging modalities that are most frequently used 
exclusively in the diagnostics arena or the surgical planning process. 
 
DIFFERENCES BETWEEN REGULATORY PATHWAYS 
IN UNITED STATES AND EUROPE
In the United States, the FDA is responsible for protecting the public health by 
assuring the safety, efficacy and security drugs, and medical devices.28 In Europe, 
the European Medicines Agency (EMA) has the mandate to centrally approve new 
drugs for the European Union (EU). The mission of the EMA is to make science-
based decisions and to regulate medicines. One of the main differences between 
the FDA and EMA is that the EMA itself is a collaborative effort, opposed to a 
government organization. The agency has members from all EU countries, and 
with expansion of the EU, the structure gets increasingly complex compared 
to the review group of the FDA.29 An important similarity is that both agencies 
are participants in The International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) guidance. This project 
started in 1990 involving the regulators and research-based industries from 
the US, EU and Japan.30 Details regarding the review process by the different 
agencies world-wide is reviewed elsewhere.31
When an MI agent is approved by the EMA in Europe, it doesn’t mean that the 
same MI agent is also approved in the United States. Despite submission of 
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identical requests for drugs, with the same supporting data, both regulatory 
bodies can end up with a different decision regarding approval. Trotta, et al. 
looked at 100 indications for 42 cancer drugs evaluated by both the EMA and 
FDA between 1995 and 2008 and found that 19 indications were not approved 
by one of the two agencies.32 Important to note is that most of the differences 
in authorization are not in drugs where there is a clear risk-benefit profile. An 
example of different approval decisions in the field of optical MI agents is 
5-aminolevulinic acid (5-ALA). This MI agent is administered orally or topically, 
and converted intratumorally to fluorescent protoporphyrin IX. 5-ALA is 
approved for oral administration to highlight brain tumors for a long time in 
Europe, Canada, and Japan, but not till recently in the United States.33 
Another difference between the FDA and EMA is that the EMA is not responsible 
for clinical testing. The FDA on the other hand stringently regulates clinical 
trials. An IND needs to be submitted to the FDA along with all the preclinical 
data to seek permission for clinical testing, where the EMA most often only 
becomes involved when a company seeks authorization for a new drug after the 
development process. Another important difference is that the FDA carries out 
its own analysis of patient data to assess the reproducibility of the results, where 
the EMA requests more detailed information from the sponsor if something 
needs to be explored further. Lastly, a crucial difference is found when looking 
at marketing approval. The EMA does not grant marketing approval and will 
only give scientific opinions. In the US, one of the main reasons for a sponsor to 
get an NDA or BLA is to be able to market the application. This also gives the 
FDA the power to cancel a marketing approval if the product no longer meets 
the FDA specifications of safety and efficacy.38, 34
Despite the discussed differences, there is significant collaboration between 
the two regulatory agencies. There are collaborations on specific topics, 
called clusters, which focus on topic areas that have been identified as 
requiring intensified exchange of information and collaboration; for example, 
pharmacovigilance, medicines for cancer, and orphan medicines.
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CLINICAL TRANSLATION PATHWAY
The path from an idea for an novel MI agent all the way to an approved agent 
the is routinely use in patient care is a time consuming and costly path. In this 
paper we aim to provide insight in this comprehensive process. Figure 2 provides 
a schematic representation.
Figure 2. Translational path for a novel MI agent from bench-to-bedside. The development of a novel 
MI agent consists of several essential steps to ensure successful clinical translation and FDA approval. 
Here, an overview is given of these steps, from the clinical need, to development of a novel agent all 
the way to routine intra-operative use and the order in which these steps need to be taken.
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Target and agent discovery
The discovery process of a new MI agent often begins with the identification of 
a certain biological process unique to the tumor (such as a receptor or enzyme) 
that can function as a tumor-specific target. One of the main pitfalls prior to 
clinical translation is a non-functioning target or agent; thereby making this step 
one of the most important steps in developing a MI agent.35 Biomarkers suitable 
for tumor-specific targeting must possess certain characteristics such as diffuse 
expression throughout tumor tissue (intra-tumor homogeneity), consistent 
expression within a given tumor type (inter-tumor homogeneity), and significant 
up-regulation compared to normal or surrounding tissues.36 There are several 
potential approaches for a probe to interact with the target of interest. In 2008, 
Willmann et al.3 discussed the direct approach where the probe directly binds 
to the target for assessing target expression. This is a sensitive and specific 
method, but if the target is not consistently expressed in multiple tumor types it 
would require development and regulatory approval for probes directed at each 
different target, which is a costly and time-consuming method. Alternatively, 
an enzyme could be targeted that is overexpressed in multiple cancer types by 
administration of an activatable MI agent.3 From a regulatory point of view, MI 
agents applicable to a broad range of cancer types are likely to have a higher 
success rate in this phase of development since clinical translation needs to 
be as efficient as possible, and it is unlikely that tens-hundreds of different MI 
agents will be approved in a timely manner.
For tumor-specific optical imaging, the MI agent needs to consist of at least 
two entities; the targeting ligand and an optical signaling component.1 There 
are numerous categories of available ligands that can be designed to target the 
marker of interest including small molecules, peptides, aptamers, antibodies, 
engineered protein fragments, and nanoparticles. All these MI agents have 
different toxicities, biodistribution, tumor interactions, and pharmacokinetic 
properties, but it is beyond the scope of this review to describe all of these 
molecules. Details are reviewed elsewhere.1, 37 The signaling component 
consists of a fluorescent dye in case of optical imaging. Mostly used dyes are 
near-infrared (NIR) dyes due to increased depth penetration and the inability of 
the human eye to detect this signal. A good MI agent must possess high binding 
affinity, high selectivity for the target, excellent stability, lack of toxicity, 
emission in NIR window, and when possible, multiplexing capabilities. In the 
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ideal situation, you would have a MI agent that has rapid binding to the target 
and uptake by the tumor, urinary excretion compared to hepatic clearance, and 
persistent accumulation at the target site. Besides that, relatively simple and 
cost effective synthesis would enhance the clinical translation capacity. The 
use of approved drugs as MI agents, when combined to a signaling moiety, 
reduces the cost and risk of the early phase translation process due to known 
biodistribution, toxicity and targeting profile. However, when an existing 
approved agent is bioconjugated, (e.g., to a fluorescent dye), the FDA considers 
this agent to be a new entity, but may require less extensive non-clinical safety 
and toxicity studies compared to an entirely new compound.38 
Currently, most clinical trials are performed using a MI agent that is injected 
intravenously into the patient. These agents reach all organs and therefore, 
toxicity and excretion are crucial elements. Now, topical agents become more 
of interest since both toxicity and clearance are negligible and reduced amounts 
are needed. However, these agents have not been introduced into clinical trials 
and therefore, focus of this paper will mainly be on intravenous MI agents.
Non-clinical phase of development
Although imaging research remains dependent on preclinical animal models for 
initial testing, promising results in those models do not always translate well 
to human studies. However, until there is a more suitable model, preclinical 
imaging, and safety and toxicity data from animal studies are crucial to facilitate 
human testing. The goal of the nonclinical safety and toxicity testing is to assess 
toxicity in target organs, characterization of pharmacology, determination of a 
start dose and dose escalation scheme, and toxicity in relation to dose. Using 
body surface area or PK/PD modeling, the dose administered to animals can be 
used to calculate the starting dose in clinical trials.39 Since MI agents are seen 
by the FDA as diagnostic tools toxicity should be mild, not to exceed a grade 
1 reaction. Thus, nonclinical safety and toxicity studies should be designed to 
establish a wide safety margin. However, in this case were the clinical intended 
use is to guide invasive procedures, e.g. intra-operative oncologic resections, it 
is possible that the FDA would consider higher levels of allowable toxicity, if 
appropriately justified. 
08
178 | Chapter 8
In this review paper we will describe the clinical translation pathway of a novel 
MI agent, targeting αvβ6, to clarify the entire process. This MI agent, R01-MG-
IRDye800, will be used to detect pancreatic cancer and consists of a peptide 
and a fluorescent agent.40, 41 R01-MG-IRDye800 counts as a New Molecular 
Entities (NME), and for these agents there are certain studies required before 
a Phase I trial can be started. Nonclinical studies help to facilitate the timely 
conduct of clinical trials and therefore timing of those studies is crucial (Table 
1).42 In this phase the ICH guidance requires analysis of systemic exposure 
achieved in animals and its relationship to dose level and the time course. The 
route of administration, extent of exposure, and metabolites must be taken 
into account.43 For modification of an existing MI agent, such as fluorescently-
labeled antibodies, the requirements for non-clinical safety and toxicity 
studies are variable, and in certain circumstances, very limited additional 
studies are required. When a change is made in the route of administration, 
dose or population of an already approved agent, the FDA will also do a 
case by case evaluation for the required nonclinical studies that are needed, 
therefore researches should search for early consultation with the FDA, to avoid 
performing unnecessary tests wasting time and resources.44 
Product development plan
When initiating a new product, the FDA encourages researchers and sponsors 
to provide a Target Product Profile (TPP) which outlines a comprehensive 
approval process and defines the clinical indication, to ensure focus during the 
approval process. A TPP is a development tool with a statement of the overall 
intended use of the MI agent, and provides information at a particular time 
in development while documenting the specific studies intended to support 
development. Ideally it can minimize late-stage drug development failure, 
increase the probability that safety and efficacy data are adequate, improve 
labeling content, and possibly decrease the total time to approval. Therefore, 
a TPP enables the sponsor to pursue the desired outcome in the most efficient 
manner.45
eIND and IND submission
After obtaining the required non-clinical data, the next step is to apply for an 
IND. There are four types of INDs: exploratory IND (eIND), investigator IND, 
emergency use IND, and treatment IND. The IND application must contain 
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information regarding (i) animal pharmacology and toxicology, (ii) manufacturing 
information, and (iii) clinical protocol and investigator information. On the FDA 
website detailed information can be found on the complete IND application 
and the information required for submission. It goes beyond the scope of this 
article to describe all the specific information needed for an IND submission.46 
An overview of the FDA process after IND submission is provided in Figure 2. 
Once the IND is submitted, the investigator must wait 30 days before initiating 
the proposed clinical trial. The FDA will typically request additional information 
before the close of 30 days or issue a ‘Study May Proceed Letter’ to indicate 
their approval of the study. Subsequent changes or additions to the protocol 
(using the same agent) must be submitted to the FDA, but a 30-day waiting 
period is not necessary.
For most imaging studies early human data is desirable due to expected 
discrepancies between preclinical and clinical results. For that reason the FDA 
has developed the exploratory IND (eIND). This process makes it possible to test 
agents in clinical trials that involves a very limited human exposure (microdose 
administration), and has no diagnostic or therapeutic intent. This approach uses 
the concept that “the best model for man is man.” An eIND study is intended 
to provide information on pharmacokinetics, -dynamics, and metabolism in 
humans and these studies are conducted before the dose escalation, safety and 
tolerance studies. Because eIND studies present fewer potential risks compared 
to traditional phase I studies, an eIND study in humans can be initiated with less 
preclinical support.47, 48 After consultation of the FDA, a microdose study can 
even be conducted when the later intended dose is higher than a microdose, as 
is the case for optical imaging agents. It has been estimated that the time for 
drug development can be reduced by 12-18 months when using the microdosing 
technique compared to the traditional first-in-human studies.49, 50 This can 
lead to a significant cost reduction, taking into account that a reduction of 
development time by 25% would lead to 16% cost savings.51, 52 Time savings are 
not always realized without proper planning since after the eIND trial closes, 
the investigator will still need to submit a conventional IND for dose escalation 
studies. In case of our agent, an eIND was submitted for use of the peptide, 
R01-MG, as a radiolabeled PET-tracer. For the MI agent, R01-MG-IRDye800, an 
IND will be submitted with support of the data obtained from the eIND.
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Table 1. Recommended nonclinical data needed for New Molecular Entities (NME) before the sponsor 
can proceed to the various phases of clinical translation.
Study type Before Phase 1 Before Phase 2 Before Phase 3 Before NDA
Safety pharma-
cology
Major organs, and 
organ systems the 




Based on ICH 
guidance. 
The exposure in 
the animals should 
ideally equal or 
just exceed the 
maximum expected 
exposure (or known 





single dose (can 
potentially be com-
bined with repeat 
dose toxicity)
Short-term (2 to 













not required for 
microdose












are needed or 
waiver can be 
obtained
Drug interaction As needed
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Compared to clinical studies using higher doses, non-clinical toxicity studies 
for microdose applications can be done with a single mammalian species 
to showcase safety instead of one rodent and one non-rodent species (Table 
2). Obviating the need to test the agent in large animals or higher dosages 
significantly reduces costs and required time. There are also some potential 
weaknesses associated with the approach of microdosing, since there is still 
limited experience with this type of study, and it has not yet shown its real 
advantage with a sufficiently large number of MI agents. Secondly, a microdose 
may not predict the actual behavior of the dose that will be used in later clinical 
trials, giving a false sense of bioavailability and safety.
Table 2. Comparison of required preclinical studies for micro-dose initiated studies compared to tradi-
tional single dose preclinical studies.
Clinical Non-clinical




Pharmacology General toxicity 
study
Genotoxicity
Micro-dose Can be the same, 
but not allowed 
to exceed 100 µg
In vitro; target/recep-
tor profiling.
Mode of action and/
or effects character-
ization in PD model, 




study (in one spe-
cies, by intended 
route of adminis-
tration) and max 
of 1000-fold the 





studies at sub- 
therapeutic 




based on toxicity 
observed in most 
sensitive species.
Maximum dose: 









Mode of action and/
or effects character-
ization in PD model, 
to support human 
dose selection.

















(NOAEL = no observed adverse effect level) (PD = pharmacodynamics) (CVS = central nervous system)
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Clinical translation
In contrast to clinical studies with the non-specific fluorescent dyes ICG and MB 
there are a limited number of clinical studies done with tumor-specific optical 
imaging agents.53-59 Looking at these current clinical trials done for MI agents, 
most of these do not follow appropriate methodology for the different phases 
of clinical trials. Only five of 53 listed clinical trials for optical imaging in cancer 
done in the US and Europe, are done with the proper controls in a randomized 
controlled fashion (see overview Table S1).9, 10 Optical imaging agents are 
mostly tested using open label single group assignment, which introduces 
Figure 3. To conduct a well-designed clinical trial for intra-operative imaging, several elements need 
to be addressed. Here a graphic representation is given of the most important aspects that should be 
addressed, and need to be taken into account when designing a clinical trial for optical intra-operative 
imaging.
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investigator bias since the investigational method is applied to all investigated 
subjects, without randomization, blinding or controls. Because the clinical 
utility in surgical optical imaging studies is often vague (surgeon’s judgment) 
and has substantial variability between surgeons and by the same surgeon, it 
is difficult to objectively prove the benefit of optical imaging in clinical trials 
for regulatory approval. This emphasizes the need for creative study designs 
that will show patient benefit necessary to attain regulatory approval without 
being cost-prohibitive. Ultimately, the studies need to address that the imaging 
information will affect clinical care immediately since the information is 
available in real time. 
The use of 5-aminolevulinic acid (5-ALA) in the surgery of malignant glioma was 
one of the first “proof-of-principle” explorations to confirm that intra-operative 
optical imaging could be used to improve surgical resections.60 Stummer et 
al. showed in a randomized clinical trial from 17 centers in Germany with 322 
patients that the use of 5-ALA enables more complete resections of contrast-
enhancing tumors, leading to improved progression-free survival in patients 
with malignant glioma compared to the standard of care white light resections.33 
The primary endpoints of this study were the number of patients without 
contrast-enhancing tumor on early MRI (i.e., that obtained within 72 h after 
surgery) and 6-month progression-free survival as assessed by MRI. Secondary 
endpoints were volume of residual tumor on postoperative MRI, overall survival, 
neurological deficit, and toxic effects.33 Clinically relevant endpoints that show 
benefit are necessary for FDA approval, and subsequently to payers who will 
want to see added value.
Elements of an optical imaging trial
Clinical trials for intra-operative imaging are unique is a sense that certain 
elements are only applicable for these kind of trials. Below, several crucial 
elements of a clinical trial for intra-operative imaging are discussed (see figure 
3). In addition, it is important to recognize that surgeons typically operate using 
pattern recognition and experience. Therefore, MI agents should be considered 
as adjunct to clinical judgement as an additional source of information – just 
as abnormalities on an anatomical image are placed into the context of the 
disease and the patient.
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Endpoints
During the design of clinical trials, endpoints need to align with the proposed 
labeling indication which is the desired marketing application. The FDA works 
with a risk-benefit approach so when the MI agent contains more risk, more 
benefit needs to be shown. To gain FDA approval for a NDA, the study needs 
to show direct benefit to the patient or intermediate clinical endpoints that 
have been shown to predict clinical benefit. For example, if the use of R01-MG-
IRDye800 can reduce positive surgical margins, and since positive margins are 
known to correlate with poor clinical outcome, that would likely be sufficient 
to demonstrate clinical benefit.22 The same is true for decreased re-operation 
rate to re-excise breast cancer, or reduced local recurrence in pancreatic cancer. 
Clinical endpoints in phase II trials should be chosen to mirror the anticipated 
phase III study so that appropriate power calculations can be established. 
Furthermore, showing clinical patient benefit at an early stage helps to fund 
more expensive phase III trials, where the more comprehensive and clinically 
relevant endpoints are needed.61
Statistical design
For early phase trials sample size justification could range from a formal 
powered sample size based on clinical outcomes to a sample size with the 
main justification that the sample size is based on feasibility. The sample size 
will increase with smaller α and increase for a larger power.60 When the main 
aim of the study is to determine feasibility, determining the actual sample 
size is difficult. However, for situations where the intention is that later, more 
definitive, studies may be carried out, the proper sample size to start with is 12 
per group.62 The ICH states that the number of subjects in a clinical trial should 
always be large enough to provide a reliable answer to the questions addressed. 
This number is usually determined by the primary objective of the trial. If the 
sample size is determined on some other basis, as in this case for feasibility 
studies, this should be made clear and justified.63 For an extensive elaboration 
on statistical principles for clinical trials, please also see the FDA guidelines.63 
Role of histology
In studies in which MI agents are used to identify cancer, histology is 
crucial to determine the successful targeting of the cancer by the MI agent. 
Pathohistological assessment is the gold standard to determine whether 
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resected tissue is indeed tumor tissue and these results are correlated to the 
fluorescent signal. The optimal method for doing this correlation is to compare 
histologically confirmed tumor and fluorescence on the same microscopy slide.64 
Unfortunately, in this case the gold standard is not perfect, since pathologic 
examination is prone to sampling error. If the tissue sectioning process does 
not successfully capture the tumor (in a 5 um slice) on a glass slide, the tumor 
can be missed. In a study by Rosenthal et al, using cetuximab-IRDye800 in head 
and neck cancer, it was seen that 8% of lymph nodes were called negative by 
histology but positive by fluorescence. These were investigated further and 
found to contain cancer.65 Furthermore, it also needs to be confirmed that the 
MI agent targets the appropriate biomarker by performing immunohistochemical 
analysis. Therefore, in all of these clinical trials, the ex vivo investigation of the 
tissue should play an important role.
Imaging systems
Imaging systems are essential in optical imaging trials, and especially the 
difference between systems is important. The currently available imaging 
systems all have their own sensitivity, dynamic range, and wavelength variation. 
For now, in multicenter studies the same camera should be used until it is 
proven that the systems operate sufficiently similar, as is the case with PET 
devices. Imaging systems used in clinical trials need to be chosen based upon 
performance standards needed for that indication. In addition, issues around 
calibration, validation, and interpretation need to be established before a 
specific imaging system is picked to be used in a trial.66
Quantitative element
Currently, a major problem in optical imaging trials is the lack of a quantitative 
element compared to PET imaging trials. Quantitative results are needed to 
generate objective results and convince the regulatory agencies. For now, the 
field has mostly focused on generating images, showing fluorescent signal at 
the position of the tumor. With the described differences in imaging systems, 
those images are not comparable between different trials and it is challenging 
to place these results in the appropriate context. Currently, more groups are 
investigating the more quantitative element of optical imaging.67
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Single surgeon study to multicenter study
Another elements that needs to be taken into account in surgical clinical trials 
is the difference in surgical technique and experience between the different 
surgeons participating in the trial. In phase I trials, the decision to use only one 
surgeon could improve the reliability of feasibility data. However, multicenter 
studies with numerous amounts of surgeons are needed to show that the 
Figure 4. The design of a clinical trial determines the validity of the generated data. Here, a schematic 
representation is provided of the different trial designs that can be used for intra-operative imaging 
trials. On top of the pyramid the trial that generates the most rigorous data and can be used to show 
patient benefit: the blinded randomized controlled trial. At the bottom the trial that generates less 
rigorous data but can be used to show efficacy: the cohort study, either in multi- or single center fashion. 
All trial designs are accompanied by an example based on the pancreatic cancer MI agent. 
Successful clinical translation of optical imaging agents | 187
promising results from early phase trials persist and that eventually wide-spread 
use is justified. 
 
CLINICAL TRIAL DESIGNS
Clinical trials can be broadly divided into prospective and retrospective studies. 
In case of optical imaging studies the majority of studies will be prospective 
since the use of optical imaging with exogenous MI agents is a new phenomenon 
for which the patient needs to be injected with an investigational product. 
Only in case of clinical trials with the non-specific ICG, retrospective cohorts 
are described.68 The use of an exogenous MI agent also means that optical 
imaging studies are always interventional studies. Different clinical trial designs 
can be placed in an hierarchy based on the generated scientific rigor (figure 
4). Rigor is research is mostly defined using the criteria of validity, reliability, 
and objectivity.69 Trials with high scientific rigor are mostly also challenging to 
perform. Here, we discuss the different trial designs applied to optical imaging 
trials, with an MI agent for the detection of pancreatic cancer to serve as an 
example.
Blinded randomized controlled trial
Blind assessment ensures that treatment and analysis of outcomes are not 
biased. Also, the FDA requires that when studies are conducted with subjective 
endpoints to show efficacy, the evaluator of the results needs to be blinded. At 
this point, most optical imaging studies have relative subjective endpoints such 
as tumor-to-background ratio (TBR) to determine efficacy. TBR values are highly 
affected by the chosen background by the investigator and currently, no strict 
rules are set to determine what should be chosen as background. Therefore, 
blinding in optical imaging studies is important, yet difficult to achieve. In 
intra-operative cases as discussed here, the surgeon cannot be blinded for the 
imaging results. However, multiple blinded studies are performed in the field of 
surgery showing the possibility of this design, even in surgical trials. The most 
rigorous trial design would be a blinded RCT with two different agents of which 
one is the tumor-specific agent, R01-MG-IRDye800, and one the non-specific 
agent, ICG. Here, the surgeon, pathologist and investigator can be blinded. In 
addition, even without an second agent double blinding can be achieved in 
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optical imaging trials if the pathologist and evaluator are blinded for where in 
the tissue fluorescence was seen in the operating room. 
According to the literature, double-blind randomized controlled trials (RCT) are 
assumed to be insusceptible to bias, and are therefore accepted as the gold 
standard for clinical trial designs.70 However, there is also criticism regarding 
RCTs and its place above all other study designs in the hierarchy of trial 
designs.71, 72 Despite these criticisms, for now the main consensus is that studies 
looking at therapeutic and/or diagnostic agents should be done in a randomized 
fashion. As is known, control groups and randomization ensure that the control 
and test group are identical on average and that only the test conditions differ, 
which improves validity of the results.33, 73 One could argue that the limited 
sample size of most early stage optical clinical trials are not amendable to 
randomization. For these cases, non-random allocation methods have been 
proposed as an alternative to achieve statistical significance and distribute 
individuals better between groups in cases with a small sample size.72
Randomized controlled trial
Even in cases where blinding is challenging there are several strategies to 
perform trials a randomized fashion – including comparing judgment of the 
surgeon prior to imaging and after exposure to the fluorescent imaging data. 
Patients could be randomized between starting the surgery with inspection 
using fluorescence and without. A difference in detected tumor-positive lymph 
nodes could for example be used as outcome measure in pancreatic cancer 
patients. These and other methods to mimic blinding are recognized by the 
FDA. For example, the use of placebo which is infused in some patients (not 
necessarily half) could serve as an excellent control for randomization.
Randomization in optical imaging trials for surgical procedures are complicated 
by the variation of the surgical procedure based on stage, regional disease, 
tumor size/location, and variable anatomy. Furthermore, surgical technique and 
skill sets differ between surgeons and there is often limited agreement between 
surgeons on how to send margins (from the patient or from the specimen). 
Finally, there is to be some expected difference in tumor biology heterogeneity 
and patient variability. One strategy to accommodate this variability is to 
have each patient, tumor and surgeon serve as their own control. In this case, 
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one compares the added value of the fluorescent imaging compared to a 
conventional image on the screen in the same procedure. This can especially 
well be performed in cases of minimally invasive surgery.
Matched case-control study
To achieve rigor results, all optical imaging studies should at least be done by 
using a control group even in early phases. Third in rank, behind the randomized 
design, matched case-control study could lead to important data. In this case 
one could choose to compare patients operated on with the fluorescent agent 
and patient without an fluorescent agent matched based on demographics 
and tumor characteristics. This cannot be performed in a blinded fashion, and 
randomization could potentially lead to unethical situations, but a matched 
case-control study can be performed. In pancreatic cancer studies overall 
survival or disease-free survival of both patient groups could be used as an 
endpoint, even as the amount of tumor-positive resection margins.
Interventional study with comparison group
As mentioned above, optical imaging studies are always investigational studies 
because an MI agent is injected into or applied onto the patient. Going down 
the pyramid, the next form for a clinical trial is a study where a comparison 
group is used without matching. In these cases, historical cohorts could be 
used to compare the new data. For example, the amount of detected tumor-
positive lymph nodes or percentages local recurrence could be compared to 
results acquired over the past years in a hospital or a nation. The disadvantage 
of using historical cohorts is the mismatch between the compared groups, and 
potentially the influence of under or over reporting of the intended outcome. 
Multicenter cohort study
The first multicenter clinical trials are conducted in the field of optical imaging, 
and currently even an international study is initiated. All these trials are 
cohort studies were all patients receive the agent, and no comparison is made. 
These studies are not fit to show benefit of this technique over the standard-
of-care, and are mainly performed to proof feasibility. One could question if a 
large international multicenter study is needed just to show feasibility and if 
a comparison group would not dramatically improve the rigor of the scientific 
data coming from those kind of trials.
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Single center cohort study
On the bottom of the pyramid is the single center cohort study, were a novel 
agent is tested in one hospital. A significant amount of this type of studies are 
performed in the field of optical imaging to show safety and feasibility. For 
this purpose, this trial design is well-suited since a limited amount of patients 
are needed. However, one should question the external validity of this data, 
especially when the surgeries are performed by one surgeon only. The clinical 
relevance of the data generated in single center cohort studies could be 
improved when multiple surgeons are involved.
Other clinical trial approaches
Specific to optical imaging, there are also certain clinical trial approaches 
only applicable to this type of trials, which do not fit the above mentioned 
standard classification. For example, an approach that could be used to mimic a 
controlled trial comparing intra-operative use of optical imaging to a standard-
of-care surgery, is a trial where the surgery is performed only using white light 
and after the surgeon is finished, the NIR light is turned on and the fluorescence 
will show what is left behind. These lesions will be analyzed by pathology to 
determine the amount of additional lesions found. 
 
PHASES OF CLINICAL TRIALS
All the discussed trial designs can be applied to the different phases of clinical 
trials.
Phase IA: First-in-human studies, assessing safety and tolerability
In contrast to microdose studies that are conducted to get information on 
pharmacokinetics, -dynamics, and metabolism in humans, phase IA studies of MI 
agents should start with testing the optical imaging agent in healthy volunteers 
or highly selected patients to determine safety and pharmacokinetic properties. 
For R01-MG-IRDye800 this first step will be taken in healthy volunteers. Healthy 
volunteers have several advantages over patients: first pharmacokinetics can be 
assessed in more detail, and second all observed effects can be contributed 
to the MI agent compared to patients who mostly have comorbidities and 
potential drug interactions. In phase IB, the safety and feasibility of a MI agent 
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is tested typically through a dose-escalation study. Pharmacodynamic studies 
and studies relating drug blood levels to imaging signal (PK/PD studies) may be 
conducted in healthy volunteer subjects or in patients with the target disease. 
The pharmacodynamic data are important to guide the dosing schedule and 
timing in later studies.74 The pharmacologic requirements during clinical trials 
for MI agent development are divided into safety and efficacy goals. The safety 
thresholds for imaging agents are high since these agents are diagnostic tools 
and do no offer therapeutic advantage. The efficacy goal of early phase clinical 
trials should be to determine a “near optimal” dose - a process that is mostly 
completed in Phase II but should start at the first-in-human trial. For FDA, the 
definition of near-optimal is a dose regimen and imaging condition that are 
superior to alternatives. This will require the investigation of a dose escalation 
scheme with at least 3 cohorts, and the ability to answer if a higher dose will 
be better or if a lower dose will be sufficient. Furthermore, the optimal imaging 




Most optical imaging Phase IB studies start with a dose-escalation and timing 
study. The goal of a dose-escalation study for optical imaging should be to 
establish the recommended dose and timing in phase II trials. The guiding 
principle is to avoid exposing too many patients to suboptimal doses while 
preserving safety and maintaining rapid accrual. A dose-escalation study has 
many components, including starting dose, dose increment, dose-escalation 
method, number of patients per dose level, specification of dose-limiting 
toxicity (DLT), and recommended dose for phase II trials. As for MI agents, it 
is unusual to include language regarding the maximum tolerated dose (MTD). 
There are broadly two designs that can be used for dose-escalation studies: the 
rule-based designs, which include the traditional 3+3 design and its variations, 
and the model-based designs.75 For optical imaging, the rule-based design is 
the most applicable since the used dose is relatively low and therefore, DLT 
is not expected to be reached and there is no therapeutic effect to determine 
the optimal dose. In imaging studies, the 3+3 design focuses on identifying the 
lowest dose that will generate the optimal signal to noise ratio. In this design, 
the first cohort is treated at a starting dose that is considered to be safe based 
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on extrapolation from animal toxicological data, and the subsequent cohorts 
are treated at increasing dose levels that have been fixed in advance.76 The 
dose-escalation normally stops in imaging studies when either two patients in 
a cohort of three to six patients experience a DLT or when the higher dose 
level generates a signal to noise ratio equivalent to the lower cohort. For R01-
MG-IRDye800 a 3+3 design is chosen with a fixed starting dose of 2 mg and 
increments up to 16 mg per patient. The most optimal cohort will be expanded 
by 3 patients.
Figure 5. Detection of additional lesions in pancreatic cancer surgery. The detection of additional lesions 
with the use of NIR fluorescence is an endpoint that can be used to show efficacy of NIR fluorescent 
imaging during surgery. The MI agent is injected into the patient prior to surgery Here a schematic 
representation of this trial design is provided, with the assessment by surgeon (A) using white light 
(B), and afterwards identification of potential additional lesions on the screen when using NIR fluores-
cence (C). Clinical examples are provided of pancreatic cancer surgery, of both the primary tumor (D, 
white light, and E, NIR fluorescence) and lymph nodes (F, white light, and G, NIR fluorescence) using 
Cetuximab-IRDye800 targeting EGFR.
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Efficacy studies
Determining efficacy in optical imaging studies can be done in several ways. The 
most important assessment that needs to be done at this phase is to determine 
if fluorescence signals correlates with histological evidence of tumor. This is 
best accomplished during ex vivo imaging of the specimen and histopathologic 
analysis in combination with H&E stain. However, since this is an intra-operative 
technique, the primary clinical endpoints and efficacy assessments should be 
done in the operating room as well. In intra-operative setting there are two 
main methods to assess efficacy. In case of our R01-MG-IRDye800 agent, the 
primary endpoint to show efficacy is based on additional lesions found. This first 
method is explained in figure 5; one could let the surgeon assess the surgical 
field with standard white light for suspicious lesions and afterwards turn on 
the NIR fluorescent light to identify additional lesions. The second methods is 
shown in figure 6; here the surgeon needs to outline the intended resection 
margin based on white light assessment, and afterwards compare this outline 
to the outline determined when applying NIR fluorescence. This last method 
is beneficial in tumor types where the resection of too much healthy tissue 
Figure 6. Assessment of resection margins. The assessment of resection margins with fluorescence is 
another method to show efficacy of fluorescence imaging during surgery. The MI agent is injected into 
the patient prior to surgery. Here a schematic representation of resection margin determination by the 
surgeon (A) is shown, using white light (B), and after the use of NIR fluorescence (C). Clinical examples 
are provided were the red dotted line is the resection margin determine using only white light (D), and 
the margin after assessment with NIR fluorescence (E, white dotted line). Here, additional resection 
will be performed based on the NIR fluorescence.
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increased morbidity, such a head and neck and brain cancer. A disadvantage 
of both these methods are the missed potential lesions that are both not seen 
with white light and also not seen by the additional NIR fluorescence, since 
these lesions will not be assessed by pathology. However, until now there is not 
a method developed to assess these double false negative lesions.
Phase II trials
The goal of phase II trials should be to acquire more proof for the benefit of 
the investigated imaging technique and MI agent in a larger, but homogeneous, 
patient population, and determine the dose and regimen for phase III trials. 
When conducting a phase II trial, it is important to note that at this point 
the agent still offers no real advantage to study subjects, and therefore, 
investigators need to ensure that standard of care procedures are maintained.59 
At the end of the phase II trials, the end-of-phase-II meeting is held with 
the FDA, which is considered the most important meeting for a sponsor. This 
meeting will determine whether or not the sponsor can initiate a phase III trial. 
Phase III and Phase IV
Phase III trials are conducted in a larger population to determine efficacy, 
benefit, and compare it to commonly used procedures. In this phase the added 
value of the optical imaging agent should be determined with clinically relevant 
endpoints. A great example of a properly conducted phase III trial for the use of 
optical imaging during surgery is the previously mentioned RCT conducted by 
Stummer et al. regarding the use of 5-ALA in glioma surgery.33 Studies in phase 
III need to be blinded randomized controlled trials. However, as mentioned 
before, also the ICH guidelines and FDA encourage investigators to perform 
randomized, controlled trials to improve the validation of observations in 
earlier phases of investigation. After finishing the phase III study, the sponsor 
will submit a NDA application and have the pre-NDA meeting with the FDA to 
determine if the MI agent meets the criteria for a NDA or BLA. Phase IV trials 
are not necessary for approval of the MI agent, but are important for optimizing 
the agent in a large population. These trials look at the different effect of the 
imaging agent in various populations. Normally in this phase the side effects 
of long term use will also be determined, however that is not applicable for 
optical imaging agents since they mostly be one-time use. 
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INDUSTRY AND ACADEMIC PARTNERSHIPS
It is generally accepted that academia can generate highly innovative 
products, but successful delivery to the market where it will benefit patients 
almost always requires working with an industry partner with the appropriate 
expertise. Working with public-private partnerships (PPPs) accelerates the 
clinical translation by combining the expertise and resources of universities 
and industry. For example, industry partners would provide the facilities for 
cGMP production of the imaging agents, imaging systems, and data handling, 
while the university and hospital network regulate the clinical trials. With this 
strategy all parties bring their own field of expertise, making the process more 
efficient and providing greater quality of the achieved product.62 These kind 
of collaborations can also be achieved by international partnerships between 
different academic centers with several advantages. In the case of R01-MG-
IRDye800, a collaboration between Stanford University and Leiden University 
Medical Center ensured timely and efficient clinical translation of this novel MI 
agent due to the unique expertise of both centers. In addition, collaboration 
between industry and universities can also result in new hypothesis generating 
research, such as converting failed therapeutic drugs into MI agents. Chemical 
libraries underlying a developed drug can also provide a wealth of information for 
potential imaging agents.3 Additionally, many components of drug and imaging 
agent development are similar, and therefore the exchange of knowledge and 
experience are crucial for an efficient clinical translation process.
CONCLUSION
In summary, the use of optical molecular imaging for tumor-specific 
identification of cancer is an emerging field with the potential to change the way 
medicine is practiced. it is not surprising then that the clinical development and 
approval process of these agents has recently received considerable attention. 
However, this technique will only be approved by the FDA in patient care if 
the field can identify clinical settings that will provide clear clinical utility and 
patient benefit in well-designed clinical trials. Although the potential of tumor-
specific optical imaging is yet to be realized, several early-phase clinical trials 
have already shown safety and efficacy in specific cancer types and tumor-
specific intraoperative optical imaging is likely to play an important role in the 
identification and treatment of cancer in the near future. 
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ABSTRACT
Background: This study describes the bench-to-bedside process of developing, 
validating and translating a novel PET tracer for detection of cancer through 
molecular recognition of integrin αvβ6 receptors. Integrin αvβ6 is an 
extracellular matrix (ECM) protein that is dysregulated and overexpressed in 
pancreatic cancer. 
Methods: A cystine knot peptide was engineered to selectively bind integrin 
αvβ6. Preclinical mouse models guided PET tracer development providing 
feedback for the optimization of tracer pharmacokinetics, maximization of 
tumor uptake and minimization of background uptake in normal tissues. Toxicity 
of the non-radioactive reference standard, [19F]FP-R01-MG, was evaluated in a 
rat model. 
Results: The lead PET tracer, [18F]FP-R01-MG, was produced under cGMP 
guidelines and evaluated in 5 healthy human volunteers. Upon verification of 
its safety, [18F]FP-R01-MG was administered to pancreatic cancer patients and 
compared to [18F]FDG PET in the same patient. [18F]FP-R01-MG was produced 
in high specific activity (~5000 mCi/µmol) and purity (99%). In mouse models, 
tumor, liver, muscle and kidney uptake was ~5%ID/g, ~1%ID/g, ~0.5%ID/g and 
~30%ID/g, respectively, 1 hr p.i.. Tumor-to-muscle ratio was ~ 5:1 at 1 hr p.i. 
The reference standard [19F]FP-R01-MG did not produce any toxic effects in a 
rat model at 250x the imaging dose needed for human studies normalized to 
mass of subject. Upon clinical translation, [18F]FP-R01-MG was well tolerated 
in 5 healthy human volunteers. The tracer cleared via the kidneys, which were 
determined to be the dose limiting organ. Next, [18F]FP-R01-MG was evaluated 
for detection of pancreatic cancer. Tumor uptake was rapid and homogeneous. 
In contrast, a small focal point of uptake (SUVmean = 4, 1hr p.i.), which mapped 
precisely to an implanted stent, was observed for [18F]FDG PET. 
Conclusion: [18F]FP-R01-MG demonstrated promise in detecting pancreatic 
cancers in human subjects. Although notable uptake of the tracer resulted in 
the stomach and small intestines, pancreatic tumors were easily identifiable 
because of high uptake in tumor tissue compared to normal pancreas.
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INTRODUCTION 
Positron emission tomography (PET) imaging, using targeted agents, is an 
effective way to detect cancer. Accumulation of targeted PET tracers in 
tumor tissues provides a way to image cancer cells in vivo through proteins 
overexpressed on their cell surface. In contrast, [18F]FDG (deoxyglucose analog) 
is based on the accumulation of sugar by metabolically hyperactive cancer 
cells.1 However, [18F]FDG accumulation in non-malignant tissues, such as 
inflammation, decreases diagnostic specificity.2-6 Additionally, some small or low 
grade tumors do not accumulate sufficient levels of [18F]FDG.7, 8 In cases where 
[18F]FDG PET falls short, such as the lack of accumulation by metastatic lymph 
nodes, or with confounding uptake by benign biological processes, or when 
background accumulation occurs by surrounding normal tissues, a targeted 
approach may provide more precise information that may be useful in cancer 
diagnosis, staging, treatment monitoring or disease management.9-13 
Integrin receptors are extensively studied for the development of novel PET 
tracers.14-18 Integrins are a family of proteins that mediate cellular adhesion to 
extracellular matrix (ECM) proteins.19 In normal cells, integrins mediate contact 
events at their surface, and transduce signals to support gene expression of 
various ECM proteins that regulate differentiation, migration, proliferation, and 
apoptosis.20 In certain disease states such as cancer, the expression of some 
integrins become dysregulated.21, 22 A member of the integrin family, αvβ6, is 
overexpressed on the surface of many types of cancer cells.23, 24 In a recent 
studies, IHC analysis revealed expression of integrin αvβ6 in PDAC compared 
to cancers of other systems.23, 25 Expression of integrin αvβ6 was reported to be 
significantly higher in PDAC compared to chronic pancreatitis, and its expression 
was observed in tumor positive lymph nodes.26 In well differentiated pancreatic 
tumors, elevated levels of integrin αvβ6 were reported in 100% of the samples 
(n=34) by immunological methods.23, 25 Currently, a number of research groups, 
including ours, are developing peptide-based PET tracers to image integrin αvβ6 
for cancer detection.27-29
The cystine knot secondary structure motif stabilizes knottin peptides so that it 
is protected against many forms of biological, chemical, and physical insult. The 
topological knot is formed by 3 disulfide bonds that thread the center of the 
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molecule. Knottins are found throughout nature in plants and animals serving 
in hist defense. Here, we engineered a trypsin inhibitor knotting into a cancer 
targeting ligand that recognizes integrin αvβ6 with single digit nanomolar 
binding affinity. In this study, we developed a stabilized integrin αvβ6 knottin 
and evaluated their ability to image cancer in living systems [18F]FP PET tracers. 
In this pilot first-in-human study, we translated the lead cystine knot PET tracer, 
[18F]FP-R01-MG-F2, and determined the ability to image pancreatic cancer. 
Figure 1. Characteristics of Knottin. (A) Primary structure of lead candidate R01-MG. The engineered 
active loop-1 is shown in red. The integrin αvβ6 core binding motif, RTDLxxL, is shown in blue. The 
framework residues are shown in gray. Cysteine residues are shown in yellow and the pattern of disulfide 
bonds are indicated by the connecting lines above the sequence. (B) The insert on top left shows the 
RP-HPLC trace of R01-MG, and the top right shows the equilibrium binding curve of between R01-MG 
expressed on yeast surface and soluble human integrin αvβ6 (KD = 1.24±0.21 nM). The insert on the 
bottom left shows the radio-RP-HPLC trace of the purified clinical-grade PET tracer [18F]FP-R01-MG-F2, 
and on the bottom right the competition binding between unlabeled R01-MG (IC50 = 0.61±0.31 nM, 
circles) or the N-terminus labeled version [19F]FP-R01-MG-F2 (IC50 = 0.56 ± 0.46 nM, squares) vs. yeast 
surface expressed R01-MG, respectively. 
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RESULTS
Pre-clinical Development and Validation of R01-MG.
R01-MG emerged as the lead translational candidate (Figure 1A). It was produced 
by cGMP solid phase peptide synthesis, and its mass was verified by MALDI-
TOF-MS. The precursor, reference standard and PET tracer were purified to > 
95% chemical purity by reverse phase high pressure liquid chromatography (RP-
HPLC, Figures 1B, left side). Equilibrium binding assays indicated that R01-MG 
(KD = 1.24±0.21 nM, Figure 1B) bind integrin avb6 with high affinity that is 
comparable to the original peptide R01 (KD = 1.07±0.14 nM). Competition binding 
assays demonstrated that the FP group did not adversely affect high affinity 
binding to integrin αvβ6. The half maximal inhibitory concentration (IC50) values 
for the unlabeled precursor and FP labeled standard were 0.61±0.31 nM and 
0.56±0.46 nM, respectively (Figure 1B, right). 
Figure 2. Preclinical studies with R01-MG. (A) Comparison at 1 hr post injection of the [
18F]FP labeled 
lead candidate R01-MG in integrin αvβ6 positive (red) vs αvβ6 negative tumor models (magenta, dashed 
circle in the figure). In vivo validation of the [68Ga]NODAGA-R01-MG at 1 hr post injection (yellow). (B) 
Volume rendered PET/CT images of [18F]FP-R01-MG (cyan) and (C) [
68Ga]NODAGA-R01-MG (yellow) in 
integrin αvβ6 positive models at 1 hr post injection. The green arrows point to the tumor. The letters 
K and B represent the kidneys and bladder, respectively. (A-C) Bar colors correspond to discrete box 
legend colors that identify the images. 
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R01-MG was evaluated as a radiofluorinated PET ligand, [
18F]FP-R01-MG-F2, in 
pre-clinical models with either human integrin αvβ6 positive (~ 3.5%ID/g) or 
integrin αvβ6 negative (~0.5%ID/g) tumors (Figure 2A). Volume rendered PET/CT 
images of [18F]FP-R01-MG (red) (Figure 2B) and [
68Ga]NODAGA-R01-MG (yellow) in 
integrin αvβ6 positive models at 1 hr post injection were generated (Figure 2C). 
Selective uptake was demonstrated in the integrin αvβ6 overexpressing tumors. 
At 1 hr p.i., tumor uptake was 2.8±0.3 %ID/g. Liver, muscle and kidney uptake 
was 1.2±0.4 %ID/g, 0.6±0.1 %ID/g and 30.4±5.5 %ID/g. 
Pharmacokinetic Evaluation of [18F]FP-R01-MG-F2.
Dynamic PET/CT imaging in mice indicated that uptake of [18F]FP-R01-MG-F2 
in integrin αvβ6 expressing tumors was rapid and high. At 5 minutes p.i., the 
average tumor uptake value reached 5.4 ± 2.7 %ID/g, and plateaued at 5.7 ± 
2.8 %ID/g at 60 minutes p.i.. Immediately upon tail vein injection, the PET 
tracer quickly entered and cleared both the heart and the liver. [18F]FP-R01-
MG-F2 cleared primarily via the kidneys where maximum uptake values of 
~54 %ID/g were recorded at 4.5 minutes p.i.. Kidney uptake steadily decreased 
for the duration of the dynamic scan to ~16% ID/g at 60 min p.i., while the 
radiotracer accumulated in the bladder to ~110 %ID/g. Tumor-to-muscle ratio 
was approximately 8:1 and 5:1 at 30 and 60 minutes p.i, respectively. [18F]FP-
R01-MG-F2 did not accumulate to a great extent in liver, which gave rise to 
contrast ratios of ~7:1 to ~10:1 at time points beyond 30 minutes.
cGMP Radiosynthesis and Toxicology Studies
In order to produce the reference standard and the PET tracer, the knottin 
precursor’s sole amine, was used to couple the radioactive analog, [18F]FP, 
through the electrophilic carbonyl carbon of the active nitrophenyl ester. 
Radiochemical purity of [18F]FP-R01-MG-F2 ranged from 96.1% to 98.3%, and 
the chemical purify of the probe, for each synthesis, was greater than 99%. In 
addition, the probe remained stable in injection buffer for two radio half-lives 
after completion of the radiosynthesis. The specific activity of [18F]FP-R01-MG-F2 
was used to calculate the mass of tracer that would be administered to human 
from a PET study involving a dose of 15mCi. 
For toxicological evaluation, the reference standard [19F]FP-R01-MG-F2 was 
administered to 20 male and 20 female 7-week-old Sprague-Dawley rats at 
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250 times the anticipated clinical dose. Toxicity was evaluated on days three 
and fifteen following intravenous injection of the reference standard. All rats 
survived to the scheduled termination date and remained bright, alert and 
responsive during the course of the study. Under the conditions of this study, 
there were no treatment related findings in Sprague Dawley rats three or fifteen 
days after a single 1.1mg/kg intravenous dose of [19F]FP-R01-MG-F2.
30
Evaluation of [18F]FP-R01-MG-F2 in Healthy Human Volunteers 
The following study was conducted in the Division of Nuclear Medicine and 
Molecular Imaging at Stanford University Nuclear Medicine Clinic under US-FDA 
eIND 126374 (S.S. Gambhir). A bolus of [18F]FP-R01-MG-F2 was administered 
intravenously to five healthy male and female adult human volunteers; the 
mean ± SD injected dose of [18F]FP-R01-MG-F2 was 7.5 ± 1.3 mCi and the mean 
injected mass was 12.5 ± 4.0 µg or 0.18 ± 0.06 µg/kg. No adverse effects were 
reported by volunteers or noticed by physicians and staff for up to 7 days after 
injection of [18F]FP-R01-MG-F2. 
Figure 3. [18F]FP-R01-MG-F2 PET Imaging of Healthy Human Volunteer. (A) Representative whole-body 
[18F]FP-R01-MG-F2 maximum intensity projection (MIP) PET images of a healthy volunteer (50 year-old 
male) show the biodistribution of PET tracer at 3, 60 and 120 minutes post injection (p.i.). Focal uptake 
near the elbow and between the legs are the site of intravenous injection, and a tube containing the 
reference calibration standard, respectively. (B) Axial and coronal PET/CT images of the same healthy 
volunteer at 1 hr p.i. Close-ups of the chest and abdominal regions show the heart (SUVmean ~ 0.9), liver 
(SUVmean ~ 0.8), lung (SUVmean ~ 1.3), pancreas (SUVmean ~ 1.9), stomach (SUVmean ~ 12.6), small intestines 
(SUVmean ~ 7.8), kidneys (SUVmean ~ 14.3), and bladder (5.9). Accumulation of the tracer is evident in the 
pituitary gland (SUVmean ~ 5). (C) H&E staining and integrin αvβ6 immunohistochemical analysis of 
healthy stomach and small bowel tissue, where uptake was relatively high, shows expression of integrin 
αvβ6 on the luminal (Lu) side of these organs. Scale bars on the 1x and 10x images represent 2.5 cm 
and 250 µm, respectively. 
09
210 | Chapter 9
The pharmacokinetics and biodistribution of [18F]FP-R01-MG-F2 in a healthy 
volunteer (immediately, 1hr and 2hr after administration) are shown in Figure 
3A. Transaxial PET/CT images show tracer distribution in the abdomen and 
brain (Figure 3B). [18F]FP-R01-MG-F2 was renally cleared (SUVmean ~ 15) with 
notable uptake in the stomach (SUVmean ~10) and small intestines (SUVmean ~10) 
throughout the study. IHC confirmed the expression of integrin αvβ6 in normal 
stomach and small intestine tissues (Figure 3C). Uptake in most normal organs 
were relatively low (< SUVmean ~1) and decreased throughout study as the tracer 
steadily cleared these organs. Pancreatic uptake was slightly higher at 1 hr p.i. 
(SUVmean ~ 2). Throughout the study, tracer accumulation was also comparably 
higher for the pituitary gland (SUVmean ~ 4, 1 hr p.i.) and the large intestines 
(SUVmean ~ 3, 1 hr p.i.). The muscle SUVmean ~ 1.5 for the duration of the study. In 
agreement with pre-clinical models, the dose-limiting organ was determined to 
be kidney. 
For an adult male, the kidneys received 0.1650 rem/mCi. Secondary uptake in 
the stomach and small intestines resulted in exposures of 0.0650 and 0.1100 
rem/mCi, respectively. Dose calculations were low for the majority of organs 
including brain, muscle, liver, skin, thymus, lung and breast. The effective dose 
of [18F]FP-R01-MG-F2 was 0.0335 rem/mCi for an adult male. Using the value for 
the kidney as dose-limiting, the maximum allowable exposure to [18F]FP-R01-
MG-F2 may be 30.30 mCi/dose or 1121.21 MBq/dose based on the 5 rem limit 
described in the US-FDA Code of Federal Regulations Title 21 Section 361.31 
Comparison Between [18F]FP-R01-MG-F2 and [
18F]FDG in a Pancreatic 
Cancer Patient
Dosages of 10.2 mCi [18F]FDG and 5.1 mCi [18F]FP-R01-MG-F2 were separately 
administered on different days to a 70-year-old woman with pancreatic cancer 
scheduled for surgical resection. Imaging was conducted at the Division 
of Nuclear Medicine and Molecular Imaging at Stanford University Nuclear 
Medicine Clinic under US-FDA eIND 126374. Maximum intensity projection (MIP) 
PET, PET/CT and volume rendered PET/CT images show the biodistribution of 
[18F]FP-R01-MG-F2 (Figure 4A) and [
18F]FDG (Figure 4B) approximately 1 hour 
after tracer administration. 
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Figure 4. [18F]FP- R01-MG-F2 PET Imaging of Pancreatic Cancer. (A) [
18F]FP- R01-MG-F2 and (B) [
18F]FDG 
images, from left to right, show MIP, CT, PET/CT (axial and coronal) images of a 71 year-old female 
pancreatic cancer patient at ~60 minutes post injection. The liver, kidneys, small intestines, stomach 
and spleen are denoted by Lv, Kd, SI, St, and Sp, respectively. The green arrow points to the tumor. 
(A) Accumulation of [18F]FP- R01-MG-F2 at the head of the tumor is shown by the green arrow. PET/CT 
images demonstrate several regions of relatively high accumulation including the kidneys, the main 
clearance route, and the stomach (St), small intestines (SI) where integrin αvβ6 is expressed. (B) An area 
of focal [18F]FDG uptake which is located within the tumor coincides with a biliary stent (white tube) 
that is apparent in the CT image. The tracer is seen draining out of the kidney (Kd) through the ureter 
and collecting in the bladder in the MIP, and volume rendered PET/CT images. (C) From left to right, 
H&E staining and IHC analysis of the resected pancreatic mass, which included some healthy pancreatic 
tissue. A section of normal pancreas (left) and a section of malignant tissue (right) are shown. Scale 
bars on the 1x and 10x images represent 2.5 cm and 250 µm, respectively.
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[18F]FP-R01-MG-F2 was distributed broadly through the tumor region (ROI ~ 
8000 mm3) and resulted in a SUVmean of 6.2 at 1 hr after tracer injection (Figure 
4A). Comparatively, a region of focal uptake (ROI ~ 3000 mm3, SUVmean = 4.1) of 
[18F]FDG mapped precisely to a biliary stent that was implanted to circumvent 
the obstruction caused by the tumor (Figure 4B). Uptake of [18F]FP-R01-MG-F2 
and [18F]FDG in the liver had SUVmeans of 0.9 and 2.9, respectively, at 1 hr p.i. 
SUVmeans of [
18F]FP-R01-MG-F2 the stomach and small intestines were 22.9 and 
10.7, respectively, at 1 hr p.i. In comparison, SUVmeans of [
18F]FDG in the stomach 
and small intestine at 1 hr p.i. were 0.16 and 2.5, respectively. H&E staining and 
IHC analysis confirmed that the abnormal cells contained in the resected tissue 
expressed high levels of integrin αvβ6 as shown in Figure 4C.
 
DISCUSSION
This manuscript describes the bench-to-bedside process of developing and 
translating a cystine knot PET tracer for detection of pancreatic cancer. In both 
pre-clinical small animal models and humans, accumulation of the knottin PET 
tracers within integrin αvβ6-positive tumors was rapid and sustained compared 
to either the healthy portion of the diseased organ or to surrounding normal 
tissue. The tracers cleared rapidly from circulation via renal filtration with a 
half-life of under 5 minutes. In contrast to the way FDG accumulated in the 
tumor of a pancreatic cancer patient, the uptake of the knottin PET tracer was 
more homogeneously distributed throughout the enlarged pancreatic mass, 
which highlights the different activities targeted by the two different types of 
PET tracers (glucose transporter vs ECM protein). Accumulation of the knottin 
PET tracers in normal human tissues was generally low with notable exceptions 
in the upper gut and pituitary gland. 
Cystine knot peptides are a relatively new class of PET tracer that were first 
engineered for molecular recognition of integrins overexpressed in cancer. They 
have recently shown promise in pre-clinical models, not only as PET tracers, but 
in near infrared fluorescence imaging, molecularly-targeted ultrasound imaging, 
and in photoacoustic imaging.15, 32, 33 Though initial studies R01-MG demonstrated 
high tumor uptake with acceptable off-target accumulation in healthy tissues, 
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and emerged as the lead candidate. Toxicological testing indicated that the lead 
was not harmful to rats even at 250x the imaging dose. 
The pilot clinical trial began in healthy male and female human volunteers (n=5) 
where the knottin PET tracer demonstrated rapid renal clearance. Dosimetry 
studies confirmed our pre-clinical dose-estimations, and indicated the 
kidneys to be the dose-limiting organ. Notably, a substantial amount of tracer 
accumulation occurred in the stomach and small intestines. Tissue samples 
of healthy stomach and small intestines derived from another clinical study/
procedure were made available to us for IHC analysis. These studies indicated 
relatively high levels of integrin αvβ6 expression in these tissues. Generally, the 
tracer demonstrated low levels of accumulation in most healthy tissues. 
Afterwards, we evaluated cystine knot PET tracers (R01-MG) in pancreatic 
cancer where the initial results demonstrated promise in cancer detection. 
Accumulation of the PET tracer, [18F]FP-R01-MG-F2, was rapid and remained 
high throughout the study. Here we were fortunate to have [18F]FDG data from 
a previous study for comparative purposes. In this case, accumulation of [18F]
FDG by the tumor was concentrated at a biliary stent which was implanted to 
mitigate the pressure to the ducts caused by the tumor. Contrastingly in this 
same patient, the uptake of [18F]FP-R01-MG was more uniformly distributed over 
a greater tumor volume. The difference in uptake profiles between the two 
classes of PET tracers probably reflects the different activities that are targeted 
(glucose transporter vs ECM protein). Although, we observed high tracer 
accumulation in neighboring stomach and small intestinal tissues, pancreatic 
tumors in three patients were easily discernable in their PET/CT images. 
This pilot clinical study is limited mainly by the small sample size of pancreatic 
cancer patients that were evaluated with the knottin PET tracers. In addition, 
we found it informative to be able to directly compare the performance of the 
knottin PET tracers to the “gold standard” in PET imaging, [18F]FDG, in pancreatic 
cancer. For pancreatic cancer, the challenge has been that patients usually do 
not undergo FDG PET scans as part of their care. 
In conclusion, we have developed cystine knot PET tracers that effectively 
detect pancreatic cancer. We also begin to address an unmet clinical need 
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by providing new molecular imaging tools that can likely be coupled with 
strategies devised for earlier detection of pancreatic cancer. The knottin PET 
tracers demonstrated rapid and sustained accumulation in the tumor throughout 
the 2-hour clinical study. Low background uptake in organs or regions of the 
body prone to different cancers, together with several studies documenting 
the extent of integrin αvβ6 expression across many cancers, suggests that the 
R01-MG based PET tracers will have broad application in oncological molecular 
imaging. Taken together, the results from these pilot clinical studies encourages 
comprehensive evaluation of these new integrin αvβ6 cystine knot PET tracer 
across a broad range of indications and applications.
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ABSTRACT
Background: Operative management of pancreatic ductal adenocarcinoma (PDAC) 
is complicated by several key decisions during the procedure. Identification 
of metastatic disease at the outset and when none is found, complete (R0) 
resection of primary tumor are key to optimizing clinical outcomes. The use of 
tumor-targeted molecular imaging, based upon photoacoustic and fluorescence 
optical imaging, can provide crucial information to the surgeon. Here, the first-
in-human use of multimodality molecular imaging for intraoperative detection 
of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared 
fluorescent (NIRF) agent that binds to epidermal growth factor receptor (EGFR).
Methods: A dose-escalation study was performed to assess safety and 
feasibility of targeting and identifying PDAC in a tumor-specific manner using 
cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic 
cancer. Patients received a loading dose of 100 mg unlabeled cetuximab 
prior to infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument 
fluorescence imaging was performed throughout the surgery in addition to 
fluorescence and photoacoustic imaging ex vivo.
Results: Seven patients with resectable pancreatic masses suspected to be 
PDAC were enrolled in this study. Fluorescence imaging successfully identified 
tumor with a significantly higher mean fluorescence intensity (MFI) in the 
tumor (0.09±0.06) versus surrounding normal pancreatic tissue (0.02±0.01), and 
pancreatitis (0.04±0.01) (p<0.001), with a sensitivity of 96.1% and specificity of 
67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than 
surrounding tissue.
Conclusion: The safety and feasibilty of intra-operative tumor-specific detection 
of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the 
primary tumor and metastases was demonstrated.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, 
with an expected median survival of around 25 months for patients undergoing 
surgery with adjuvant chemotherapy.1, 2 After diagnosis of PDAC, patient 
selection for surgical resection is challenging at multiple stages during the 
procedure; detection of occult distant metastases, assessment of the extent of 
the primary tumor, peritumoral lymph nodes (LN), and the resection margins. 
There are two critical decisions that surgeons address during the procedure 
that will determine long-term survival of pancreatic cancer: the absence 
of metastatic and regional disease and cancer-free margins.3-5 However, 
margin-positive resections are a frequent phenomenon (which occurs up to 70% 
of cases),6 as is the emergence of distant metastases soon after surgery.7 Failure 
to identify small tumor extensions during surgery is not surprising, due to the 
growth pattern of the tumor and the inability of the surgeon to differentiate 
between tumor and (peritumoral) inflammation.
The use of tumor-targeted imaging probes for photoacoustic and optical imaging 
modalities has the potential to provide real-time information to the surgeon 
to aid decision making. Photoacoustic imaging can provide intraoperative or 
transcutaneous images with functional information at clinically relevant depths 
(up to 5 cm) with submillimeter spatial resolution.8 Fluorescent optical imaging, 
on the other hand, is superior for imaging of superficial lesions with a very high 
resolution.9 
Despite significant investment in systemic therapy for small incremental 
gains in survival, there has been minimal investment in improving surgical 
outcomes. And although the value of intraoperative guidance in pancreatic 
cancer resection would seem obvious, previous studies have not demonstrated 
benefit when using the non-specific imaging agent indocyanine green (ICG).10 
Rosenthal et al. showed the successful use of cetuximab-IRDye800 to image 
sub-clinical fragments of squamous cell carcinoma arising in the head and neck 
cancer patients.11 EGFR is also highly expressed in PDAC and is a good target 
for fluorescence imaging, due to its transmembrane position.12-15 This study is 
the first example of tumor-specific multimodality molecular imaging for the 
accurate detection of primary PDAC, tumor-bearing LN, and distant metastases. 
The workflow of infusion, surgery and imaging is shown in Figure 1.
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This study is a single-arm, open-label dose-escalation study, with the main 
objectives to determine safety and feasibility of tumor-specific multimodal 
molecular imaging for intraoperative detection of PDAC. Patients with suspected 
or biopsy-proven PDAC scheduled to undergo surgical resection at Stanford 
University Hospital were identified. A pretreatment dose of 100 mg unlabeled 
cetuximab was administered before the study drug to differentiate between a 
cetuximab reaction and a cetuximab-IRDye800 reaction, and to saturate the 
EGFR receptors in normal tissues with high expression (antigen sinks).16 Two to 
five days after cetuximab-IRDye800 infusion patients underwent surgery.
Investigational agent: Cetuximab-IRDye800
The cetuximab-IRDye800 was produced under cGMP conditions at the University 
of Alabama (UAB) Vector Production Facility as previously described,17 before 
shipment to Stanford University Hospital Pharmacy (see also supplementary 
methods).
Figure 1. Schematic overview of workflow of clinical trial with imaging examples. 1. Infusion. Infusion 
of a loading dose cetuximab (100 mg), and cetuximab-IRDye800 (50 or 100 mg) 2-5 days before surgical 
resection. 2. Operating room. Intra-operative fluorescence imaging. 3. Ex vivo imaging - pathology. Ex 
vivo fluorescence and photoacoustic imaging of surgical specimens. 4. Histology correlation. Histologic 
correlation between histologically proven tumor or normal tissue with H&E and fluorescent signal.
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Imaging
Intra-operative near-infrared (NIR) imaging
Imaging during surgery was performed using the laparoscopic optical imaging 
system PINPOINT 9000 modified for IRDye800 fluorescent dye imaging 
(Novadaq, Burnaby, Canada), and the wide-field SurgVision Explorer (SurgVision 
BV, ‘t Harde, The Netherlands). During surgery, imaging was performed during 
inspection of the abdomen, before resection for the primary tumor, and after 
resection for the wound bed. This procedure is described in detail in the 
supplementary materials. Subsequently, all excised tissues were imaged ex vivo 
at a separate table in the OR directly after removal. Next, the surgical specimen 
was processed by the pathologist according to standard clinical practice to 
determine tumor status. 
Ex vivo close-field NIR imaging
The Pearl Impulse imaging platform (LI–COR Biosciences, Lincoln, NE) was 
used to image fresh tissues obtained in the operating room prior to paraffin 
embedding. The procedure is described in the supplementary methods. 
Ex vivo photoacoustic imaging
After excision of the specimen, ex vivo photoacoustic imaging was performed 
on the primary specimen and breadloaf sections of the tumor using a Stanford-
build clinical hand-held photoacoustic imaging (PAI) and ultrasound transducer 
as previously described18 [Kothapalli SR, et al. Nature Communications, under 
review], see also supplementary methods.
For detailed description of the imaging analysis for both fluorescent and 
photoacoustic imaging, see supplementary methods. 
Ethics approval
This study is performed in accordance with the tenets established by the 
Helsinki Declaration of 1975, ICH-GCP guidelines, and the laws and regulations 
of the United States. The Stanford University Institutional Review Board and 
the FDA approved the study protocol. All patients provided written informed 
consent prior to the start of any study-related procedures. The study was 
registered in the Clinical Trials Database of the U.S. National Institutes of 
Health, under number NCT02736578. 
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Pathologic assessment
All resected lesions were examined for tumor status by a gastrointestinal 
pathologist with expertise in pancreatobiliary disease. A positive tumor that 
was fluorescent was considered a true positive, a negative lesion that was 
fluorescent was considered a false positive; and a positive tumor that was 
nonfluorescent was considered a false negative. Fluorescence positivity was 
determined based on the MFI of the raw data.
Histologic correlation
Formalin-fixed paraffin-embedded tumor tissues were sectioned at 4 µm 
thickness and fluorescence imaging was performed using the Odyssey NIR 
scanner (Li-COR Biosciences). All histologic sections were stained with standard 
hematoxylin-eosin (H&E). To confirm the presence of EGFR, additional sections 
underwent immunohistochemical (IHC) analysis for EGFR expression utilizing 
anti-human EGFR. In addition, Ki-67 proliferation index was determined by 
IHC. See supplementary methods for further details. Appropriate positive and 
negative controls were included and evaluated with the specimens tested.
Fluorescence microscopy
FFPE slides were prepared for fluorescence microscopy using the methods 
described in supplementary materials.
Adverse events
Adverse events were classified according to the National Cancer Institute 
Common Terminology Criteria (Version 4.0), see supplementary methods.
Statistical analysis
SPSS statistical software package (version 23.0, IBM Corp.) was used for 
statistical analyses. Differences in fluorescent signal per tissue type (tumor, 
pancreatitis, normal pancreatic tissue) were tested separately and between 
different dose groups, with One-way ANOVA with posthoc Bonferroni correction.
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RESULTS
Patient and safety data
Between July 2016 and April 2017, ten patients were screened for trial eligibility. 
Eight patients with suspected PDAC received a loading dose Cetuximab, 
and 7 were enrolled. One patient was not enrolled since he had an infusion 
reaction on the loading dose Cetuximab. The other 7 patients went on to 
receive cetuximab-IRDye800. Patient and tumor characteristics are summarized 
in Table 1; 5 received 50 mg cetuximab-IRDye800 (cohort 1) and 2 received 
100 mg cetuximab-IRDye800. There was one CTCAE grade-2 adverse event in 
cohort 1, fever, possibly related to cetuximab or cetuximab-IRDye800. No other 
possibly related adverse events occurred (Table 1). Two patients turned out to 
have neuroendocrine tumors at pathologic assessment, and one patient did 
not undergo resection due to liver metastases. Consistent with the literature 
regarding cetuximab administration for therapeutic purposes,19, 20 a small 
increase of QTc interval was seen after infusion of the loading dose cetuximab 
with no further increase after cetuximab-IRDye800. QTc interval gradually 
decreased to baseline and none of the patients had persistent increased QTc 
after the observation period.
Figure 2. Intra-operative fluorescent imaging. Lesions could be clearly identified as shown in this figure; 
bright-field (2A and E), overlay (2B and F), grayscale (2C and G), and heat-map (2D and H) fluorescence 
imaging provided clear contrast between tumor and surrounding tissues during a Whipple procedure 
for both the primary tumor (A-D) and lymph nodes (E-H). PF = peripancreatic fat.
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Figure 3. Correlation between intra-operative fluorescence and tumor-status. Identification of primary 
tumor (A) and tumor-bearing lymph node using fluorescence (B), with corresponding ex vivo fluorescence 
(C and D). Fluorescence of the primary tumor (E) is shown, and bisected lymph node on mesoscopic scale 
(F), with enhancements corresponding to the tumor on H&E, outlined in red (G + H)), and increased EGFR 
expression, also outlined (I + J). A graphic representation is shown of the mean fluorescence intensity 
(MFI) in normal pancreatic tissue, pancreatitis and tumor (K), and tumor-bearing and tumor-negative 
nodes (L). Scale bar represents 1 cm, unless indicated differently. ***; p<0.001
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Intra-operative NIR fluorescent imaging
Laparoscopic NIR-imaging was performed at the diagnostic laparoscopy prior 
to resection. All surgeries, except one, were converted to an open procedure 
and wide-field NIR imaging was performed during the subsequent procedure. 
The primary pancreatic tumor and/or LN could be clearly identified in every 
patient, as shown in Figure 2, bright-field (Fig. 2A and E), overlay (Fig. 2B and 
F), grayscale (Fig 2C and G), and heat-map (Fig 2D and H). Fluorescence imaging 
provided a clear contrast between tumor and surrounding tissues for both the 
primary tumor and LN dissection. The primary tumor could be identified in four 
of the six patients during surgical resection, with mean TBR of 2.3±0.72. In the 
other two patients, the tumor was situated below the peripancreatic fat (> 5mm 
depth) and was therefore intraoperatively not visible using NIR fluorescence. 
During surgery, tumor-bearing LN could be identified with mean TBR of 6.3±0.82. 
Back table imaging of the primary tumor in all patients demonstrated a mean 
TBR of 3.4±0.4. 
Correlation of fluorescence with histological disease
Correlation between fluorescent signal and histologic evidence of disease was 
established using close-field fluorescence imaging (Figure 3). The average 
fluorescent signal was significantly different in normal pancreatic tissue (MFI 
0.02±0.01), pancreatitis (MFI 0.04±0.02), and tumor (MFI 0.09±0.06) (p<0.001) 
(Figure 3K). This allows tumor detection with a sensitivity of 96.1% (C.I. 92.19–
98.43%) and specificity of 67.0% (C.I. 59.69–73.81%). There was no significant 
difference in MFI between normal pancreatic tissue (MFI 0.02±0.01; 0.03±0.02), 
pancreatitis (MFI 0.03±0.02; 0.06±0.03) and PDAC (MFI 0.09±0.06; 0.1±0.05) 
between the low and high dose cohort, respectively. Tumor-bearing LN (n=29) 
could be detected with significantly higher MFI (0.06±0.01) compared to tumor-
negative (n=78) LN (0.02±0.002) (p<0.001) (Figure 3L). Interestingly, liver 
metastases could be detected as well by negative contrast (Figure S1). 
Ex vivo photoacoustic imaging 
Ex vivo photoacoustic imaging of primary tumor and LN was performed using a 
custom built photoacoustic imaging system21 in order to determine the potential 
utility of this strategy for eventual in vivo use. In this study, photoacoustic 
imaging could successfully be performed in all patients (n=4). (The device was 
not available for two patients). There was a clear increase in photoacoustic 
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imaging signal in the primary tumor compared to surrounding pancreatic tissue 
(Figure S2), and in the tumor-bearing LN (Figure 4), which was consistent with 
the optical fluorescence imaging results. The mean photoacoustic signal in 
the tumor (32,286±1,660 AU) was significantly higher compared to background 
(8,651±902 AU) (p<0.001), which indicates a mean 3.7-fold increase in signal in 
the tumor compared to surrounding tissue (Figure 4B). A difference in signal-to-
noise ratio (SNR) was observed between patients, as shown in Figure 4B. This 
trend was comparable to the difference in fluorescence imaging results in the 
same patients (Figure S2, Figure 5D). 
Molecular correlation
The correlation of fluorescence on microscopic level (Figure 5, panel I) was 
performed to correlate the uptake of the antibody-dye bioconjugate in the 
tumor, but not surrounding stromal elements. To perform this analysis a grid 
was overlaid on the fluorescently scanned slides to determine the MFI per 
specific area and then mapped to the histological grid as shown in (Figure 5, 
Figure 4. Photoacoustic and fluorescence imaging of tumor-bearing lymph node. Conventional ultra-
sound image of lymph node, surrounded by white dotted line and corresponding photoacoustic image 
(A). Mean photoacoustic signal in normal pancreatic tissue and tumor, and the signal-to-noise ratio 
(SNR) in photoacoustic signal per patient (B). Corresponding bright field (C), fluorescence overlay (D), 
heat-map fluorescent (E) images, and H&E section with outlined tumor (F) of tumor-bearing lymph 
node. ***; p<0.001. Scale bar represents 1 cm, unless indicated differently. 
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panel II). The tumor could be identified with a sensitivity of 95% (CI 92.8-96.8%), 
specificity of 61% (CI 58.8-63.2%), AUC of 0.84 (CI 0.82-0.85), and a positive- 
and negative predicting values of 37.8% and 98.0%, respectively. MFI was also 
correlated with EGFR expression (Figure 5, panel III). In Figure 5D, the MFI per 
patient per tissue type is shown. A clear difference can be detected in MFI per 
patient. This is likely due to the heterogeneity of EGFR expression between 
Figure 5. Histologic correlation with fluorescent signal. Panel I: Correlation between tumor in H&E 
section (A), EGFR expression (B), and fluorescence signal in heat-map (C) using Odyssey NIR Scanner (Li-
COR Biosciences, Lincoln, NE). Panel II: The workflow to correlate histologic disease and fluorescence 
is shown here, a grid was overlayed on H&E and fluorescence slides to determine the tumor status 
and mean fluorescence intensity per area specific. Panel III: A graphic representation of the difference 
in MFI between patients in normal pancreatic tissue, pancreatitis, and PDAC, respectively (D), and the 
correlation with EGFR expression in PDAC in those patients (E). Intensity; 1-2 = low expression, 2-3 = 
moderate expression, and 4 = high expression.
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tumors. Patient 4 had relatively strong EGFR expression, patient 5 and 6 
moderate EGFR expression and patient 1-3 low expression (Figure 5E). Although 
low EGFR expression in the tumor is seen in those patients, a clear difference 
in the MFI between tumor and surrounding pancreatic tissue could be detected 
(Figure 5D).
To localize cetuximab-IRDye800 within the tumor cells we used fluorescence 
microscopy. Figure S4 shows representative images of the 800 nm fluorescent 
signal at the tumor ducts but not adjacent stromal tissues. Importantly, 
fluorescent signal (serving as a surrogate for the antibody-dye bioconjugate) is 




Here, we demonstrated for the first time the safety and efficacy of tumor-
specific multimodality molecular imaging in the detection of pancreatic cancer 
using NIR fluorescently-labeled antibody. Current metabolic and anatomic 
imaging modalities often fail to detect small tumor lesions or tumor-bearing 
LN and as a result, intraoperative identification of the disease is critical to help 
guide decision making and precision surgery.
We found a significant difference in fluorescent signal between tumor-bearing 
and –negative LN at the lower dose (50 mg), however, at the higher dose 
(100 mg) we observed an increased number of false-positive fluorescent LN. 
We hypothesize this is caused by lymphatic drainage of excess antibody to the 
primary nodal basin, which is similar to findings with cetuximab-IRDye800 in 
head and neck cancer.22 We have shown that this technique can guide tumor-
bearing LN detection and removal when used at the optimal dose, which can 
be beneficial in patients with tumor-bearing LN in the first-echelon (N1).23 
Therefore, the optimal dose Cetuximab-IRDye800 established in this study is 
50 mg, with a loading dose of 100 mg cetuximab. Due to variety of the infusion 
window in this study between cetuximab-IRDye800 infusion and surgery, no 
conclusion can be drawn if a specific timing is optimal. We can conclude that all 
Image-guided surgery for Pancreatic Cancer | 231
intervals in the infusion window, 2-5 days before surgery, provide clear tumor-
to-background ratio’s and are therefore sufficient for this purpose.
We have previously shown that EGFR has high levels of expression in the primary 
tumor and tumor-bearing LN,15 a finding which is confirmed by the results of our 
current study using EGFR as a target. A difference in EGFR expression between 
neuro-endocrine tumors and PDAC was seen, as shown in figure S3D, with lower 
expression in neuro-endocrine tumors resulting in subsequent lower absolute 
fluorescence signal. Nevertheless, in both patients with neuro-endocrine tumors 
the background signal in normal pancreatic tissue was three times lower to 
provide sufficient TBRs for detection. High expression of EGFR in the stomach 
and duodenum resulted in high levels of background fluorescence in these 
organs. We hypothesize that this is located in normal luminal epithelium since 
fluorescence correlated with EGFR and Ki-67 expression at this position (Figure 
S5). Background fluorescence from these organs, however, did not interfere 
with detection of the primary tumor or LN during surgery, partly because the 
stomach and duodenum can be retracted away from the pancreatic tumor. 
Furthermore, the potential of this technique to differentiate between PDAC and 
pancreatitis is crucial since this is a difficult distinction to make both before 
surgery and intraoperatively, leading to around 7% of pancreatic resections 
being performed for benign conditions.24 Fluorescence imaging may also add 
value for margin assessment: in one patient, a positive pancreatic neck margin 
was evident during back-table imaging with clear fluorescence being visualized 
in the pancreatic neck, also confirmed by ex vivo imaging at pathology (Figure 
S6). This preliminary observation supports the notion that this technology 
may be useful for real-time identification of close or positive margins during 
resection, but future prospective studies are needed in this direction.
The observed negative contrast of tumor in the liver may be related to the 
intensity of fluorescence in the normal surrounding liver, since it is known 
that the amount of fluorescent dye coupled to EGFR targeting antibodies will 
influence the biodistribution of the conjugate. Our conjugate has a dye/protein 
ratio of 1.8, which indicates that some molecules will have 2 or more eq of dye 
coupled to the antibody.17 Those are known to have the tendency for increased 
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liver uptake.25 Another explanation can be the difference in EGFR expression in 
the metastases, which was clearly lower than surrounding hepatocytes. 
It is worth noting that cetuximab-IRDye800 clearly penetrates the tumor and 
reaches the tumor cells. Limited success rates of phase II-III clinical trials on 
PDAC26-30 is commonly attributed to the presence of dense desmoplastic stroma, 
consisting of cellular and acellular components.31 This is thought to severely 
reduce the delivery of systemically administered therapies to the tumor and 
contribute the unresponsiveness of PDAC to systemic chemotherapy. Here we 
show at least to some extent that the EGFR monoclonal antibody can indeed 
reach the tumor successfully.
The main limitation of the study is the small sample size. However, while 
our sample size was small, it was sufficient for a proof-of-principle study 
investigating the safety and feasibility of multimodal molecular imaging in 
pancreatic cancer patients, and to identify significant results in the detection 
of tumor, and tumor-bearing LN. A second limitation is based on the limited 
depth penetration of NIR fluorescent imaging. For pancreatic cancer an imaging 
depth of 1 cm, achieved by fluorescence when used as single modality, is not 
enough to successfully capture spatial features of the tumor. The combination 
with photoacoustic imaging can overcome the limited depth penetration.
In conclusion, this is the first-in-human study evaluating the use of multimodality 
molecular imaging in patients undergoing surgical resection for pancreatic 
cancer. Our findings emphasize that the technique is safe and feasible for this 
pilot patient population. This type of tumor-specific imaging could be leveraged 
for a range of diagnostic techniques including detection of metastatic disease, 
identification of the primary tumor and tumor-bearing LN, assessment of 
resection margins, and identification of residual disease at the tumor bed after 
resection. Whether this additional information can change surgical management 
over commonly used, conventional methods remains to be determined in future 
prospective trials.
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Detection of Visually Occult 
Metastatic Lymph Nodes 
Using Molecularly Targeted 
Fluorescent Imaging During 
Surgical Resection of 
Pancreatic Cancer
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ABSTRACT
Objective: To examine the efficacy of molecularly targeted intraoperative 
fluorescent imaging in the detection of metastatic lymph nodes (LNs) during 
resection of pancreatic ductal adenocarcinoma (PDAC).
Summary Background Data: Although most patients with PDAC experience 
distant failure after resection, a significant portion still present with local 
recurrence. Intraoperative fluorescent imaging can potentially facilitate the 
visualization of involved peritumoral LNs and guide the locoregional extent of 
nodal dissection enabling staging and complete tumor clearance.
Methods: A dose-escalation prospective study was performed to assess the 
feasibility of tumor detection within peripancreatic LNs using cetuximab-
IRDye800 in PDAC patients undergoing surgical resection. Patients received 
either 50 mg or 100 mg of cetuximab-IRDye800 2-5 days preoperatively. 
Fluorescent imaging of dissected LNs was analysed ex vivo macroscopically and 
microscopically and fluorescence was correlated with histopathology.
Results: A total of 144 LNs (72 in the low-dose and 72 in the high-dose cohort) 
were evaluated in 7 patients. Detection of metastatic LNs by fluorescence 
was better in the low-dose (50 mg) cohort, where sensitivity and specificity 
was 100% and 78% macroscopically, and 91% and 66% microscopically. More 
importantly, this method was able to detect occult foci of tumor (measuring < 5 
mm) with a sensitivity of 88% (15/17 LNs).
Conclusion: This study provides proof of concept that intraoperative fluorescent 
imaging with cetuximab-IRDye800 can facilitate the detection of peripancreatic 
lymph nodes often containing subclinical foci of disease. This method holds 
promise in enhancing nodal tumor detection during surgery for PDAC, enabling 
more precise and targeted lymphadenectomy.
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INTRODUCTION
Pancreatic Ductal Adenocarcinoma (PDAC) represents a significant challenge 
in surgery and oncology. Autopsy studies have identified that although 70% 
of patients with pancreatic cancer die of widespread metastases, a significant 
portion (30%) die of locally destructive disease.1 Therefore, although PDAC is 
largely considered a systemic disease at presentation, efforts to improve local 
therapies are very important. For patients with locally contained disease, surgery 
is the mainstay of management and the only chance for cure. Thus, maximizing 
the completeness of surgical resection in this setting is critical. However, even 
following what is felt to be a curative-intent resection, up to a third of patients 
with PDAC die from disease within a year from surgery.2 This early failure is 
related mostly to unrecognized distant disease at the time of surgery, but also 
to residual disease left in situ at the resection bed. This occult residual disease 
is often below the threshold of detection by current intraoperative or radiologic 
imaging modalities. We have previously shown that tumor-specific imaging 
using a fluorescent dye targeting epidermal growth factor receptors (EGFR) on 
the tumor, especially in the form of intraoperative fluorescence imaging, has 
high sensitivity and specificity even for low-volume PDAC.3-5
The use of intraoperative fluorescence imaging can potentially improve the 
operative management of PDAC patients, since the extent of locoregional 
dissection can be expanded, to lymph node clearance. Sites of peritumoral 
lymphatics that can potentially be left behind after pancreatectomy, but are 
still considered locoregional sites of disease, are shown in Figure 1. The effect 
of additional lymph node resection remains subject to debate, as four previously 
published randomized trials have shown that extended lymphadenectomy for 
“all comers” undergoing PDAC resection does not provide therapeutic benefit.6-10 
However, these trials pertain to all presenting patients with resectable PDAC and 
it remains unclear whether precision surgery, (utilizing fluorescence guidance 
as part of the lymph node dissection to target occult nodes in the resection 
bed) could improve long-term surgical outcomes for this disease. To this end, 
we hypothesize that with intraoperative identification of occult metastatic 
lymph nodes using tumor-specific imaging, either a targeted lymph node 
dissection could be performed (should these nodes are considered regional), or 
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the resection could be aborted (if these nodes are considered M1 disease) if no 
oncologic benefit is anticipated from resection.
For tumor-specific molecular imaging, a biomarker is needed to be able to target 
tumor tissue. We have previously demonstrated in a cohort of 129 patients 
with different stages of PDAC that EGFR was abundantly expressed in up to 
70% of cases.11 To validate these results, we also tested the marker on tissues 
of patients with chronic pancreatitis and in lymph node metastases.12 These 
experiments confirmed that EGFR is an appropriate pancreatic cancer-specific 
marker, also able to differentiate between benign and malignant pancreatic 
lesions, and detect tumor-positive lymph nodes. Interestingly, only low levels of 
EGFR expression are required for imaging,13 which supports our hypothesis that 
small tumor burden in lymph nodes can be detectable by fluorescence.
We recently reported on the results of a prospective study utilizing EGFR-
targeting cetuximab-IRDye800 for intraoperative fluorescent imaging of the 
pancreatic primary tumor during resection of PDAC.5 In the current analysis, we 
Figure 1. Locoregional peripancreatic lymph nodes. Involved lymph nodes in periaortic locations or high 
up in the hepatoduodenal ligament towards the liver would be considered distant metastatic disease 
during surgery for PDAC.
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focus specifically on the diagnostic accuracy of this method for tumor-specific 




The study was performed as a single-arm, open-label, dose-escalation study, 
with the main objective of determining the safety and feasibility of tumor-
specific multimodal molecular imaging for detection of PDAC, as described 
previously.5 Briefly, patients with suspected or biopsy-proven PDAC scheduled 
to undergo surgical resection at Stanford University Hospital were identified. 
A dose-escalation model using two doses (50 mg and 100 mg) of cetuximab-
IRDye800 was chosen to identify the dose providing optimal tumor detection. 
The doses were determined based on previous findings by our group showing 
that a dose of 62.5 mg/m2 provided the optimal tumor-to-background ratio (TBR) 
for head and neck cancer.4 After informed consent, patients received a systemic 
infusion of the study drug 2-5 days before surgery. A pretreatment loading 
dose of 100 mg unlabeled cetuximab was administered before cetuximab-
IRDye800 to differentiate between an infusion reaction to the parent compound 
(cetuximab) and a cetuximab-IRDye800 reaction, and also to preload the EGFR 
receptors in the liver.14 After a 3-hour observation period, the patients were 
discharged and returned for surgery 2-5 days later.
Investigational agent: cetuximab-IRDye800
The study drug (cetuximab-IRDye800) was produced under clinical Good 
Manufacturing Practice (cGMP) conditions at the University of Alabama (UAB) 
Vector Production Facility as previously described,15 before shipment to Stanford 
University Hospital Pharmacy. During transit the temperature was monitored 
and kept stable. Briefly, cetuximab (ImClone LLC, Eli Lilly and Company) was 
concentrated and pH adjusted by buffer exchange to a 10mg/mL solution in 
50 mmol/L potassium phosphate, pH 8.5. IRDye800CW NHS ester (LI–COR 
Biosciences) was conjugated to cetuximab for 2 hours at 20ºC in the dark, at a 
molar ratio of 2.3:1.
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Optical imaging
Intraoperative near-infrared (NIR) imaging
Intraoperative imaging of the operative field in real time was performed using 
the wide-field SurgVision Explorer (SurgVision BV, ‘t Harde, The Netherlands) 
at 3 time points: during preliminary inspection of the abdomen, after initial 
dissection but before tumor resection, and after tumor resection. The surgical 
specimen was processed by the pathologist according to standard clinical 
practice for inking, sectioning and margin evaluation. During this preliminary 
study, the findings of intraoperative imaging did not inform intraoperative 
management, which otherwise followed standard contemporary practice for 
patients with PDAC.
Closed-field near-infrared (NIR) ex vivo imaging
Closed-field NIR ex vivo imaging was performed using The Pearl Impulse 
imaging platform (LI–COR Biosciences, Lincoln, NE) as previously described [5]. 
Briefly, the system was used to image fresh tissue obtained in the operating 
room prior to paraffin embedding. In addition, the system was used to measure 
mean fluorescence intensity (MFI) of the tumor and surrounding background 
tissue. MFI was defined as total counts/region of interest (ROI) pixel area, 
using integrated instrument software (ImageStudio, LI–COR Biosciences). After 
measuring the signal intensity from macroscopic images, the following formula 
was used to measure Tumor to Background Ratio (TBR) = MFI of the tumor/ MFI 
of the surrounding tissue.
Pathologic assessment
All resected specimens were examined by a single dedicated gastrointestinal 
pathologist (TAL) with expertise in pancreatic disease. Formalin-fixed paraffin-
embedded tumor tissues were sectioned at 4 µm thickness and fluorescence 
imaging was performed using the Odyssey NIR scanner (Li-COR Biosciences). The 
system was used to determine microscopic accuracy of fluorescence, correlated 
to standard hematoxylin-eosin (H&E) staining. NIR-fluorescence measurements 
were done following the same method as described above, using the integrated 
instrument software ImageStudio.
To confirm the presence of EGFR, additional sections underwent 
immunohistochemical (IHC) analysis for EGFR expression using anti-human EGFR 
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monoclonal antibodies (predilute, rabbit, clone 5B7, 790-4347, Ventana, Tucson, 
AZ). Automated immunohistochemical staining was performed with Ventana 
Benchmark XT (Ventana Medical Systems, Inc., Tucson, AZ, USA). Formalin 
fixed paraffin embedded (FFPE) tissue sections cut at 4 µm were deparaffinized 
and rehydrated. Antigen retrieval was performed by heat pretreatment at 
Standard Cell Conditioning 1 (Ventana Tris/ Borate/ EDTA-based buffer at pH 
8.5) for 60 minutes. The slides were incubated with primary antibodies at 37°C 
for 32 minutes. After primary incubation, ultraView Universal DAB Detection 
system (Ventana) was used for single brown staining with 3,3′diaminobenzidine 
chromogen. 
Ethics approval
The described study is performed in accordance with the tenets established 
by the Helsinki Declaration of 1975 (as amended in Tokyo, Venice, Hong Kong, 
Somerset West, Edinburgh, Washington, and Seoul), ICH-GCP guidelines, and the 
laws and regulations of the United States. The Stanford University Institutional 
Review Board and the FDA approved the study protocol. All patients provided 
written informed consent. The study was registered in the Clinical Trials 
Database of the U.S. National Institutes of Health, under number NCT02736578. 
Statistical analysis
SPSS statistical software package (version 23.0, IBM Corp.) was used for 
statistical analyses, and GraphPad Prism 7 (version 7.02, GraphPad Sorftware, 
Inc.). Differences in fluorescent signal between tumor-positive and tumor-
negative lymph nodes were tested separately and between different dose 
groups, with One-way ANOVA with posthoc Bonferroni correction. TBR is 
reported as the mean, SEM, and range. Graphical display was performed using 
box plot graphs, and Receiver Operating Characteristic (ROC) curves.
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RESULTS
Metastatic lymph node detection using cetuximab-IRDye800
A total of 144 lymph nodes were evaluated in the 7 patients; in the low-dose 
cohort (50 mg), there were 72 nodes evaluated of which 64 were tumor-negative 
and 8 were tumor-positive. In the high-dose (100 mg) cohort, a total of 72 nodes 
was evaluated of which 56 were tumor-negative and 16 were tumor-positive. 
Examples of tumor-positive lymph nodes detected in real-time by fluorescence 
during surgery are shown in Figure 2. 
For the entire cohort, tumor-positive lymph nodes could be detected ex vivo 
demonstrating significantly higher MFI (0.06±0.01) compared to tumor-negative 
lymph nodes (0.02±0.002) (p<0.001). This difference was more pronounced in 
the low-dose cohort, where MFI for tumor-positive lymph nodes was 0.071, 
compared to 0.018 for tumor-negative lymph nodes (p<0.001) (Figure 3A). In 
contrast, in the high-dose cohort, the difference in MFI between tumor-positive 
lymph nodes and tumor-negative lymph nodes was not significant (0.046 
vs.0.035, p=0.148) (Figure 3B). The sensitivity to detect tumor-positive lymph 
nodes in the low-dose cohort was 100% (C.I. 73.5 – 100) and specificity 78% 
(C.I. 64.0 – 88.5), with a likelihood ratio of 4.55. In the high-dose cohort, the 
sensitivity was 88.2% (C.I. 63.6 – 98.5) and specificity decreased to 32.1% (C.I. 
15.9 – 52.4), with a likelihood ratio of 1.30 (Figure 3C). 
Fluorescence intensity of formalin-fixed paraffin-embedded tissue sections were 
evaluated to validate tumor targeting of the fluorescent agent. A significant 
Figure 2. Intraoperative lymph node detection. Tumor-positive lymph nodes in the hepatoduodenal 
ligament during pancreaticoduodenectomy. Bright field image of wound bed (2A), overlay (2B), grayscale 
(2C), and heat-map (2D) fluorescence imaging provided clear contrast between tumor and surround-
ing tissue. Imaging was performed with wide-field SurgVision Explorer (SurgVision BV, ‘t Harde, The 
Netherlands).
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Figure 3. Detection of tumor-positive lymph nodes using fluorescence imaging of fresh tissue ex vivo. 
Analyzing the low-dose cohort, MFI for tumor-positive lymph nodes was 0.071, compared to 0.018 for 
tumor-negative lymph nodes (p<0.001) (Figure 3A). In the high-dose cohort, the MFI for tumor-positive 
lymph nodes was 0.046, compared to 0.035 for tumor-negative lymph nodes (p=0.148) (Figure 3B). 
Images were obtained with The Pearl Impulse imaging platform (LI–COR Biosciences, Lincoln, NE), and 
MFI was determined with integrated software (ImageStudio, LI–COR Biosciences). Test characteristics 
of fluorescence for the detection of tumor-positive lymph nodes are shown in Figure 3C.
Figure 4. Detection of tumor-positive lymph nodes using fluorescent imaging of formalin-fixed paraf-
fin-embedded tissue sections. In the low-dose cohort, a significant difference was seen between the 
MFI of tumor-positive lymph nodes (250.4±33.9) and tumor-negative lymph nodes (76.4±5.1) (p<0.001) 
(Figure 4A). The same was true for the high-dose cohort, with the fluorescence in tumor-positive lymph 
nodes being 182.5±19.0 and in tumor-negative lymph nodes 126.9±11.9 (p=0.03) (Figure 4B). Images 
were obtained with the Odyssey NIR scanner (Li-COR Biosciences), and MFI was determined with in-
tegrated software (ImageStudio, LI–COR Biosciences). Test characteristics for the detection of tumor 
using fluorescence at the microscopic level per dose group are shown in Figure 4C.
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difference in MFI was seen in the low-dose cohort between tumor-positive lymph 
nodes (250.4±33.9) and tumor-negative lymph nodes (76.4±5.1) (p<0.001) (Figure 
4A). The same was true for the high-dose cohort, but a smaller difference in 
MFI between tumor-positive and tumor-negative lymph nodes (182.5±19.0 and 
Figure 5. Detection of occult tumor deposits within lymph nodes. Figure 5A shows resected peripancre-
atic fat with an embedded lymph node ex vivo in bright light, overlay fluorescence mode, and heat-map 
fluorescence mode (respectively from left to right). In figure 5B the fluorescence part (red dotted box) is 
visualized at the microscopic level with the tumor section outlined. An overlay is created between the 
H&E and the fluorescence image in three steps showing high fluorescence only at the location of the 
occult tumor (black dotted box). In figure 5C, the two tumor foci are visualized in more detail with the 
same method of overlaying the H&E and fluorescence image, demonstrating the ability of fluorescence 
to detect tumor deposits of only 0.5 x 0.25 mm in size.
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126.9±11.9, respectively) was noted (p=0.03) (Figure 4B). The test characteristics 
for the microscopic detection of tumor using targeted fluorescence imaging 
for the low-dose cohort included sensitivity of 91.4% (C.I. 76.4 – 96.4) and 
specificity of 66.3% (C.I. 61.6 – 70.8). In the high-dose cohort, the specificity 
was relatively low due to high frequencies of false-positive detection in the 
lymph nodes (34.8%, C.I. 26.2 – 44.1), though sensitivity was higher (93.1%, 77.2 
– 99.2) (Figure 4C). 
Imaging of occult tumor in lymph nodes
For intraoperative fluorescence to augment current intraoperative techniques 
used by the surgeon (palpation, inspection), it should allow for the detection 
of subclinical/occult tumors. Therefore, it is important that even lymph nodes 
that contain “microscopic” amounts of tumor can be detected by fluorescence 
(Figure 5A). When analyzing the fluorescence data at the microscopic level, 
even sub-millimeter tumor lesions of 0.25 by 0.5 mm (e.g. 2 tumor glands in 
close proximity) were detected using fluorescence (Figure 5B and 5C). Of the 17 
lymph nodes with “occult” tumor (defined as tumor foci < 5 mm in size), 15 were 
detected by fluorescence, and 2 were not, resulting in a sensitivity of 88.2%. 
The amount of tumor in the two non-fluorescent lymph nodes was comparable 
to the fluorescent lymph nodes (0.83 mm vs 1.98 mm, p = 0.425).
Non-specific drainage of fluorescent agent
In the high dose cohort, a significant amount of false-positive lymph nodes 
were seen. Additional sectioning and pathologic analysis of these false-positive 
nodes did not reveal occult tumor not identified at initial pathological review. 
We, therefore, hypothesized that this was due to the tumor-bound cetuximab-
IRDye800 leaking non-specifically out of the tumor, into the regional lymphatic 
nodal basin. To examine this hypothesis, we looked into the localization of 
fluorescence within these false-positive lymph nodes and the relationship with 
D2-40 immunostaining (a marker of lymphatic endothelium). We identified that 
areas of high (false-positive) fluorescence corresponded to enlarged lymphatics, 
as highlighted by D2-40 staining (Figure 6).
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DISCUSSION
In this prospective dose escalation study of patients undergoing pancreatectomy 
for PDAC, we showed that in the low-dose cohort (50 mg of cetuximab-IRDye800) 
tumor-targeted fluorescent imaging identified tumor-positive lymph nodes 
ex vivo with a sensitivity of 100% and specificity of 78%. At the microscopic 
level, the sensitivity of the method was 91% and specificity was 66%. If the 
Figure 6. Non-specific drainage pattern in false-positive lymph nodes. Fluorescence and H&E over-
lays are shown with high fluorescence at position of lymphatic vessels (Figure 6A) in a patient who 
received the high-dose (100 mg) of cetuximab-IRdye800. In Figure 6B, a magnification of an area with 
high fluorescence (black dotted box) is shown, together with a D2-40 immunostain, which is a marker 
of lymphatic epithelium. In figure 6C this area is magnified further to shown co-localization of D2-40 
staining (Figure 6C). 
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high-sensitivity of this method can be replicated in vivo with improved surgical 
imaging equipment, this information can be used to improve intraoperative 
management and decision making. Specifically, if the fluorescently detected 
(but otherwise occult) node is located at distant site (and is conformed to be 
involved on frozen section), the resection can be aborted. Alternatively, if the 
detected node is considered locoregional, the resection can be extended to 
include this nodal basin and achieve a more complete resection. 
Four prospective randomized trials, two from the US,6-8 one from Europe10 
and one from Asia9 have previously tried to answer the question of whether 
an extended lymph node dissection - including periaortic, renal hilum, upper 
hepatoduodenal, celiac, and superior mesenteric artery (N2) nodes – for all 
patients undergoing surgery for PDAC is associated with oncologic benefit. In 
aggregate, these studies included 424 patients and showed that the number of 
resected lymph nodes was significantly higher in the pancreaticoduodenectomy 
with extended lymphadenectomy group compared with the standard lymph 
node dissection group. Morbidity and mortality rates were comparable. In none 
of these trials, however, was a benefit in long-term survival demonstrated 
with extended lymphadenectomy. In accordance with these studies, we do not 
advocate routine performance of extended lymph node dissection in patients 
undergoing resection of PDAC. However, we view intraoperative molecularly 
targeted fluorescent imaging as a tool to identify the subset of patients with 
tumor-positive nodes remaining in the resection bed. The surgeon can proceed 
with their resection if they are felt to be locoregional sites of disease. In two 
of the aforementioned trials,6-8 metastasis was noted in 15% and 29% of these 
second-order (N2 nodes) in the extended lymphadenectomy group. We feel that 
intraoperative fluorescent imaging may be a promising tool that can identify 
this exact subset of patients where disease would have otherwise been left 
in situ in the resection bed after a standard resection/lymphadenectomy, and 
where additional nodal dissection may ensure a more complete resection. 
Along the same lines, this “extended” lymphadenectomy does not have to 
be comprehensive to include all aforementioned N2 lymph node stations, 
but selective and targeted to include only the fluorescent nodes, thereby 
minimizing the potential complications and adverse events associated with 
more aggressive lymph node dissections. We envision this tool as a step closer 
to precision medicine in pancreatic cancer surgery. Whether this approach of 
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“precision lymphadenectomy” will be associated with improved long-term 
survival remains to be determined, however, it is interesting to note that the 
study of Pedrazzoli et al. showed improved survival for patients undergoing 
extended lymphadenectomy in an a posteriori subset analysis of patients with 
positive lymph nodes.10
Our method of molecularly-targeted fluorescent intraoperative imaging had 
relatively high sensitivity, but lower specificity for PDAC. Since fluorescent lymph 
nodes (in M1 sites) would routinely be checked with frozen section analysis 
during surgery to confirm the presence of cancer before further management 
decisions are made intraoperatively, we feel that the high number of false-
positive lymph nodes is preferred to prevent the possibility of missing occult 
disease. In addition, one can hypothesize that these nodes may serve as sentinel 
lymph nodes (the first echelon of lymph nodes to which the tumor drains) in 
pancreatic cancer surgery with several clinical applications down the line. On 
the other hand, our method’s high sensitivity is extremely important for any 
intraoperative guidance tool, as the lack of fluorescence in the resection bed (or 
other distant sites) would be highly reassuring for the absence of residual tumor 
in these areas. 
Perhaps the most novel finding of this study is the demonstrated ability of our 
method to detect subclinical, occult foci of tumor within a lymph node that 
macroscopically appears normal. The fact that this technique could readily 
identify tumor deposits of 0.5 x 0.25 mm ex vivo could potentially have 
significant implications in the surgical management of patients with PDAC. 
Obviously, the sensitivity of this method to detect such occult foci of disease 
ex vivo should be replicated in vivo before one can definitively comment on the 
potential clinical utility of this tool intraoperatively.
As noted above, the main limitation of this study is that all analyzed images to 
determine the detection threshold for tumor-positive lymph nodes were obtained 
ex vivo. In our previous study, we have shown that it is possible to detect PDAC 
intra-operatively using clinically available cameras.5 The smallest tumor size we 
could detect in vivo was a lymph node of 3.0 x 1.2 x 1.0 cm, containing several 
tumor lesions of different sizes on H&E with the largest focus being 6.8 x 5.6 
mm. At this point, the intra-operative fluorescence cameras are not sensitive 
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enough to detect small amounts of tumor like those used ex vivo. The closed-
field fluorescent PEARL camera is a highly sensitive camera for imaging of fresh 
tissue ex vivo, and together with the Odyssey NIR fluorescence scanner, these 
modalities were able to detect minimal amounts of tumor in surgical specimens. 
There is an obvious need to develop intraoperative cameras that can also reach 
this degree of sensitivity. Therefore, future development is warranted to improve 
the performance of intraoperative cameras, and to develop new imaging agents 
with higher quantum yields resulting in a more intense fluorescent signal. In 
the future, we hope to reach the aforementioned detection limits with in vivo 
imaging. An additional limitation is the small sample size of this prospective 
study. However, even though the number of patients was limited, the number 
of lymph nodes, both positive and negative, was sufficient to show statistically 
significant and clinically relevant differences.
 
CONCLUSION
In conclusion, this study provides proof of concept that molecularly targeted 
fluorescence imaging can detect tumor-positive peripancreatic lymph nodes 
ex vivo with high sensitivity, even in the case of visually occult microscopic 
disease. Therefore, we believe that this technique, if implemented in vivo, 
has the potential to enhance the surgeon’s intraoperative “visibility”, thereby 
enabling better intraoperative staging, and perhaps leading to a more precise 
and targeted lymph node dissection. Having proven the feasibility and efficacy 
of intraoperative EGFR-directed molecular fluorescence imaging on patients 
undergoing resection of pancreatic cancer with this study, and a previous study 
focusing on detection of the main tumor,5 our group is in the process of initiating 
a larger prospective study utilizing EGFR-targeted fluorescent imaging, with the 
main objective of assessing the frequency by which this intervention can change 
intraoperative management both in terms of expanding the extent of resection 
or aborting the resection due to metastatic disease. 
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ABSTRACT
Intraoperative fluorescence imaging is particularly well-suited for surgical 
applications due to its inherently high sensitivity, resolution, and ability 
to provide images in real-time. To date, the intraoperative observation of 
fluorescence has largely been subjective. With the need to show objective 
evidence in order to demonstrate the benefit of this technique, quantitative data 
needs to be provided to the overseeing regulatory bodies. Standardization in 
fluorescent imaging protocols would improve reproducibility and minimize inter- 
and intra-institution variance. This would allow studies to be conducted using 
the same injection techniques, imaging times, reconstruction methods, and 
analyses. Here, we provide recommendations for standardized methodologies 
with the goal of setting a minimum requirement for reporting fluorescence-
guided surgery results based on both qualitative and (semi-) quantitative data 
collection. Clinical trials using fluorescence-guided surgery should present 
results of three critical elements; 1) intra-operative imaging, 2) specimen 
mapping and pathology correlation, and 3) target validation. Qualitative 
analyses should consist of a bright field image, black-and-white fluorescent 
image, pseudo-colored fluorescent overlay image, and/or heat-map whereby 
fluorescent signal intensity differences are displayed on a color spectrum. 
Quantitative analyses should include 1) intraoperative data (consisting of images 
or video, raw numeric values and ratios); 2) specimen mapping, for correlation 
of fluorescence with the presence of disease (performed using fresh tissue); 
and 3) target validation (designed to determine fluorescent intensity relative 
to receptor density of a specific area). Including the aforementioned methods 
of both qualitative and quantitative analyses will ensure that trial results are 
comparable and could be collated in future studies to expedite FDA approval.
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INTRODUCTION
An incremental improvement in oncologic surgical outcomes can be obtained by 
successful identification of visually occult disease and tumor-positive margins 
during surgery, which will have a significant impact on overall cancer survival. 
Interest in cancer-specific intraoperative molecular imaging has undergone 
rapid growth. This substantial interest is not surprising considering the robust 
potential of the technique to achieve subclinical tumor-detection and improved 
surgical guidance. Fluorescence-guided surgery (FGS) is particularly well-suited 
for surgical applications due to its inherently high sensitivity, resolution, and 
ability to provide images in real-time.1 In recent years, the number of early 
phase clinical trials using FGS has drastically risen, and shifted towards the use 
of dyes emitting in the near-infrared fluorescent rather than in the visible part 
of the light spectrum. An example of a commonly used near-infrared fluorescent 
(NIRF) dye is indocyanine green (ICG). ICG achieves its tumor-targeting through 
“second window imaging,” which is based on the enhanced permeability and 
retention (EPR) effect.2, 3 While safe, ICG is a non-specific agent that is rapidly 
cleared by the liver and excreted in bile. Currently, most strategies use a NIRF 
dye which is conjugated to a targeting vehicle directed against a tissue of 
interest, such as a tumor-specific agent, and this combination permits optimal 
cancer-specific detection.4, 5 However, human testing using such novel NIRF-
guided surgical agents has thus far only been conducted in early phase trials 
to establish safety and efficacy.6-13 These trials are unable to show benefit over 
the current standard-of-care; larger phase II/III trials are needed to demonstrate 
superiority prior to obtaining regulatory approval and wide-spread adoption into 
practice. Early stage clinical trials are crucial to providing data to support in 
vivo application, surgical specimen mapping, and target validation. These three 
elements should be evaluated using a standardized methodology that can be 
used to advance these technologies through regulatory pathways into routine 
clinical use. 
Positron emission tomography (PET) imaging represents a clear precedent for 
the introduction of standardization into FGS. Since its establishment in 1984, 
numerous articles have been published describing the need for standardization 
of the technology with regards to clinical application.14-16 These studies showed 
that strict standardization of all aspects of imaging and data analysis is required 
12
260 | Chapter 12
to obtain quantitative, accurate, reliable, precise and reproducible results. 
Similarly, multiple studies have been performed investigating the concordance 
of PET results obtained at different institutions.15, 17, 18 Developing a standardized 
approach will minimize variability between studies in addition to facilitating 
the development of multicenter studies, thus allowing for direct comparison of 
results within and between clinical trials. Moreover, it can potentially allow for 
future direct translation of results to other centers.
Although often difficult to test in clinical trials, the qualitative representation of 
fluorescence imaging data is critical, as surgeons make intraoperative decisions 
based on their own interpretation of images generated and displayed by the 
imaging device. To be valuable, high-resolution images need to be generated 
in real-time, without delayed image processing. In many cases, the value and 
objectivity of qualitative data is questioned, though in the case of FGS its 
representation is of the utmost importance to the technology’s implementation 
and utility. 
Simultaneously, quantitative data plays a key role in the analysis of FGS clinical 
trials. Currently, quantitative data is difficult to generate as compared to 
qualitative data, and since FGS is primarily a visual tool for the surgeon, the use 
of quantitative data has been less emphasized in the first early phase clinical 
trials. However, with the need to show objective evidence to demonstrate the 
superiority of FGS techniques, quantitative data should also be provided to the 
regulatory bodies. 
Here, we propose a methodology for reporting results from fluorescence-guided 
oncologic surgery studies (Figure 1). Our proposed method is based on the 
minimum requirements for the presented data from all phases of a clinical trial, 
including intraoperative imaging, ex vivo imaging, and pathologic correlation, 
which should be represented using both qualitative and quantitative data.
 
QUANTITATIVE DATA
In vivo fluorescence quantification is challenging, since the measured 
fluorescence depends not only on the concentration of the imaging agent, 
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but on multiple parameters, such as intrinsic autofluorescence of tissue, the 
sensitivity of the imaging device, the absorption and scattering properties 
of the tissue, and photobleaching. All these parameters can influence the 
accuracy of quantification.19-21 Standardization of quantification in fluorescence 
imaging protocols would improve reproducibility and minimize inter- and 
intra-institution variance, and studies should be conducted using the same 
injection technique, imaging time, reconstruction method, and analysis.14 Such 
strategies are critical for reproducibility in multi-institutional clinical trials but 
are not easy to achieve. Use of phantoms will be beneficial to determine how 
well individual cameras and centers perform in the technical aspects of image 
acquisition, data processing, and analysis.22 In multicenter studies using PET 
imaging, the submission of a phantom scan is usually required periodically for 
scanner calibration and reproducibility.23
Perhaps the largest research effort to quantify fluorescence in vivo has been 
focused on the measurement of photosensitizer concentration prior to and during 
photodynamic therapy (PDT).20, 21, 24, 25 Because the effect of PDT depends directly 
on the concentration of sensitizer used, there is a high need for measuring this 
quantity quickly and noninvasively.20 Kim et. al describe a noninvasive in vivo 
method to determine fluorophore concentration in neurosurgery using 5-ALA.19 
Using a fiber-optic probe, the fluorophore concentration is calculated from the 
quantitative fluorescent spectrum, which is the fluorescent emission spectrum 
corrected for optical attenuation of the tissue, thus quantifying the observed 
fluorescence.19 These handheld fiber-optic probes need to simultaneously 
collect tissue fluorescence and diffuse reflectance spectra in vivo.26 The method 
is performed using specific fiber-optic probes that touch the tissue, which 
requires a separate device in combination with the fluorescent camera for intra-
operative navigation. Another complicating factor of this method is the need to 
identify the optical properties of tissues and the variation of these properties 
which are mostly unknown.26 
Achieving absolute in vivo quantification is unlikely, since the current 
fluorescence imaging systems are not equipped to generate quantified imaging 
data, but a semi-quantification of the fluorescent signal should be possible. 
Similar as to in PET imaging, where maximum standard uptake values (SUVmax) 
are calculated based on the administered radioisotope dose and the patient 
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weight, one can also calculate fluorescent signal uptake values by correcting 
for tissue surface area.10 In fluorescence imaging, only fluorescence arising from 
<1 cm depth will contribute to the measured signal. Therefore, signal should be 
corrected for surface area since corrections either for weight or volume will not 
necessarily generate a representative value. Consequently, it is recommended 
for fluorescence imaging to provide standardized reports on surface area-
adjusted values where feasibly measured by ex vivo imaging. For example, 
adjusted from the formula for SUV values, mean fluorescence intensity (MFI) 
could be calculated as MFIcorrected = fluorescence intensity of tissue of interest / 
(injected dose/surface area of the tissue).27 
As described above, quantification of fluorescent signal is still in its infancy. 
Ultimately, it is expected that this objective measure is going to play a major 
role in providing evidence of patient benefit. Next to the extensive investments 
in novel agents and clinical cameras, innovative solutions are being developed 
for the quantification of fluorescent imaging signals in the ex vivo setting. 
Several groups are working on the real-time detection of the actual amount and 
concentration of the fluorescent agent that accumulates in tissues. By scanning 
part of the tissue or by taking point measurements, the concentration can be 
determined leading to exact quantification.19, 28 Another method to objectify and 
automate quantification is by machine learning. Here, the software can be trained 
to identify the fluorescent cut-off value for true-positive fluorescence and true-
negative fluorescence. With a learning set, these values can be validated and 
applied to the all patients injected with the same agent and dose.29 For now, 
these methods are not commercially available, and further research is required 
to validate their applicability, but semi-quantification of the fluorescent signal 
is already possible without these novel devices using methods described below.
 
QUALITY CONTROL PROCEDURES
FGS is intrinsically linked to the sensitivity of the imaging device used. 
Currently, various imaging systems, ranging from large open-field cameras to 
minimally-invasive endoscopic cameras, are available for NIRF excitation and 
emission signal detection during surgery and ex vivo. Consequently, results from 
different imaging systems are hard to compare. This is one of the main reasons 
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that the FDA primarily reviews combination products, instead of an imaging 
agent and device separately.30 This is in contrast to PET agents and scanners, 
where the implementation of quality control (QC) procedures have led to an 
established method to verify consistency, linearity, and safety functions of PET 
scanners. For PET imaging, the National Electrical Manufacturers Association 
(NEMA) has formulated performance standards, to which manufacturers need to 
adhere.31 For fluorescent imaging devices, this is still far from standard practice, 
with only safety standards currently available. Incorporating documentation on 
performance testing can help to identify relevant characteristics (e.g., spatial 
resolution, uniformity, sensitivity, dynamic range), provide guidelines for testing 
(e.g., phantom material property range/geometry, methods for calculating 
metrics), and describe viable test methods for the validity of performance 
characteristics.30 
 
GENERAL ASPECTS OF FLUORESCENT DATA 
ANALYSIS
Ideally, all acquired FGS data should be analyzed for the correlation between 
imaging results and pathology using a quantitative and qualitative approach.
Detection threshold
Targeted agents are usually present in the tissue of interest at nanomolar 
concentrations, which requires sensitive cameras with low detection 
thresholds. Analysis of this threshold for different imaging systems and agents 
is important when evaluating agents for their intended use. If one aims to 
detect micrometastases, the sensitivity of the camera and the specificity of 
the agent should both be extremely high. DSouza et al. performed a study to 
determine the detection limit of various fluorescent imaging systems using dye 
concentrations in a phantom and showed that devices with higher bit depths, 
variable electronic gain settings, and background-light correction during 
acquisition, had the highest sensitivities.32 Previously, we have shown that small 
amounts of cancer cells can be detected in optimized ex vivo settings both 
preclinically (2.4 × 104 cells) and clinically (<5mm).33
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Quantification parameters
Significant variations can occur when reporting on fluorescent signal intensities 
since the value remains dependent on the way the images are analyzed. Below 
we discuss various methods to quantify fluorescent imaging data. 
Mean fluorescence intensity
The mean fluorescence intensity (MFI) is a measurement of the fluorescent 
signal in a region of interest (ROI) divided by the area within that ROI (either 
in pixels or cm2 ). The MFI is typically shown in arbitrary units of fluorescence 
(AU) or total number of photons detected by the device for each pixel, or per 
cm2. Arbitrary values are generally used for relative, ratiometric quantification 
to determine the fold difference or change between various samples that 
are analyzed in parallel. Devices that use a scaled algorithm for determining 
fluorescent signal also use AU. The MFI can also be shown in relative fluorescent 
units (RFU), which is a relative unit of measurement compared to a reference 
measurement using the same ROI area. In PET imaging a defined background 
is determined to compare to the SUVmax value, in order to determine the 
presence of increased uptake. As with PET imaging, it may be recommended 
to use the maximum fluorescent value, since this is independent from an ROI, 
less observer-dependent, and more reproducible compared to the mean value. 
The primary disadvantage is that a maximum value is more susceptible to noise. 
Comparing the maximum fluorescent value to that of a set background (Table 
1), may be used to correct for this noise.
Tumor-to-background ratio
When addressing the quality of an imaging agent to provide tumor-specific 
contrast, it has generally been related to a ratio such as tumor-to-background 
ratio (TBR), signal-to-noise ratio (SNR) or contrast-to-noise ratio (CNR). In the 
past, studies aimed for a TBR of >2.5, since it was thought that any lower rate 
was insufficient to identify cancerous tissue intraoperatively.2, 34 However, an 
intraoperative TBR of >2.5 is relatively hard to achieve in a clinical setting with 
currently available agents and imaging systems, although at this TBR the tumor 
can be clearly distinguished from the surrounding tissue. While a higher signal 
in the tumor when compared to surrounding tissue is preferred, there are many 
other variables that contribute to an agent’s ability to differentiate normal from 
diseased tissues. Therefore, it may not be appropriate to identify a specific 
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number as a minimum value before one can determine there is “sufficient 
contrast”. At a minimum, the difference in signal needs to be high enough for 
the surgeon to differentiate tumor from normal tissue – in our experience a TBR 
>3.0 in preclinical studies and >1.5 in clinical studies would be appropriate for 
further studies. 
Another important note is that TBR is highly dependent on the dynamic range of 
the imaging devices used in addition to the variability in properties of the chosen 
background tissue. The background will greatly influence the TBR value, and 
currently no guidelines exist regarding an appropriate background for various 
cancer types. If unrealistically high values of TBR are set as a standard, it is likely 
that only surrounding tissues with virtually no fluorescence will be candidates 
for employing these techniques. However, to ensure clinical applicability of the 
technique, the background tissue is inherently in close proximity of the tumor 
even when this tissue displays some intensity of fluorescence. For example, in 
pancreatic cancer surgery, muscle would not be an appropriate background, 
whereas for head and neck cancer, muscle would be appropriate based on the 
surgical field of view (Table 1).
Table 1. Suggestions for tissue to appoint as background for quantitative fluorescent imaging analysis
Cancer type and location Ideal background Appropriate background
Breast Uninvolved breast tissue Adipose tissue
Head and neck Muscle Skin or mucosa
Colorectal Uninvolved bowel serosa Normal bowel mucosa
Pancreas Peritumoral inflammation Normal pancreatic tissue
Lung Uninvolved lung tissue Skin
Brain Uninvolved brain tissue Uninvolved brain tissue
Hepatocellular and CRLM Immature hepatocytes Uninvolved liver tissue
Prostate Uninvolved prostate tissue Connective tissue
Parathyroid Thyroid tissue Muscle
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Signal-to-noise ratio (SNR)
The SNR is the quotient of the MFI measured in a ROI and the standard deviation 
(SD) of the signal intensity in a region outside the boundaries of the object 
being imaged (i.e. a region from which the tissue’s fluorescent signal is zero).35 
There are two forms of noise in images: random and structured. Random noise 
(or statistical noise) is directly related to the number of signals coming from 
the imaging agent. Structured noise refers to non-random variations in counting 
rates. The latter will adversely affect the interpretation and analysis of the 
images. Examples of structured noise are organ motion, and imaging instrument 
non-uniformities.36 
Contrast-to-noise ratio (CNR)
To ensure only contrast through targeted uptake is measured, and contrast 
through non-specific enhanced-permeability effect (EPR) is excluded, contrast 
can be quantified by calculating the average signal in the tumor and subtracting 
the average signal in the selected background tissue. This value can be divided 
by the standard deviation of the background to estimate the CNR.37 This 
technique may be particularly helpful to assess off-target accumulation in 
non-cancerous tissues that express the biomarker of interest. CNR is especially 
useful in situations where the background and tumor signals fluctuate widely. In 
these cases, the TBR value could be the same as compared to a situation with 
a more constant signal profile. However, the tumor would be more consistently 
clearly visible in case of a constant pattern. In situations with more fluctuation, 
CNR would show a difference in value, providing a more representative value 
that assists in distinguishing true contrast from noise.37 
When detecting lesions in the body, a high SNR alone will not guarantee that 
sufficient contrast exists to make the lesion detectable. Therefore, SNR should 
be used to assess one single image. CNR on the other hand can be used to 
identify fluctuations within one patient over time as it compares a measure of 
signal fluctuations to noise. In summary, SNR is a good measure to assess data 
quality of a single image, and CNR provides knowledge regarding how easy or 
hard it is to detect signal fluctuations over time.35 
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Sensitivity and Specificity
A topic of constant debate in the field of FGS is the reporting of test 
characteristics. Certain groups choose not to report sensitivities and specificities 
in early phase clinical trials, since the number of patients is insufficient for a 
powered calculation. Some groups use multiple separate specimens from each 
patient to generate a sufficient sample size for determining test characteristics. 
We believe that reporting on sensitivity and specificity in early trials is important 
in order to determine the potential of the fluorescent imaging agent for FGS. 
In larger clinical trials in later phases, the additional benefit of sensitivity 
and specificity should focus on improving or complementing the surgeon’s 
assessment. 
 
DEMONSTRATION OF VALUE IN EARLY PHASE 
CLINICAL TRIALS: THREE CRITICAL ELEMENTS
I. Intraoperative data collection
Real-time fluorescence tumor imaging should demonstrate sufficiently higher 
contrast enhancement in the tumor relative to surrounding normal structures 
in order to augment the current standard of care. During minimally-invasive 
and robotic surgery, this real-time detection of fluorescence is easily integrated 
as the current technology requires the surgeon to operate using a screen to 
visualize the surgical field. However, to properly interpret a positive fluorescent 
signal that will subsequently affect clinical decision-making, consensus should 
be reached regarding validation of fluorescent markers and imaging devices 
designed to differentiate tumor from peri-tumoral tissue. To date, an insufficient 
number of standardized studies have been performed to reach this type of 
consensus. 
Developers of strategies for intraoperative imaging should recognize that the 
surgical approach varies significantly by tumor type, and that each approach has 
a unique workflow. The incorporation of intraoperative FGS into the surgical 
workflow will be individualized to the type of procedure being performed, and 
the type of cancer being resected. For example, in the case of ovarian cancer, 
brain cancer or peritoneal metastases during a cytoreduction and hyperthermic 
intraperitoneal chemotherapy procedure (HIPEC), the primary goal is a more 
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complete debulking.38 In these cancer types, it is known that extensive debulking 
leads to prolonged survival for patients.39 Here, FGS has the potential to be 
beneficial in identification of subclinical disease, or occult tumor deposits.12 For 
other tumor types, complete resection is the key to prolonged survival. In these 
situations, FGS will play a crucial role in assessing the resection bed for residual 
tumor after initial resection or to assess the margins of the specimen.6, 9, 11, 13 Next 
steps in treatment could be informed by the presence of residual fluorescence, 
warranting either further resection or, for example, novel techniques such as 
applying PDT to the resection bed.40
Intraoperatively, FGS is particularly important for: 1) Identification of tumor; 
2) Assessment of resection margins, both before the resection for operative 
planning and after to assess the wound bed; and 3) Detection of tumor-positive 
lymph nodes, especially in locations that would suggest metastatic disease. In 
this case, for example, FGS could inform clinical decision making by aborting a 
surgery when there is no oncologic benefit.
Margin assessment in the OR
One of the biggest gaps in oncologic surgery remains the high rate of positive 
margins following surgical resections, which directly correlates with poor 
survival and locoregional recurrence.41-43 Both the in vivo assessment of 
the resection bed and the ex vivo assessment of the specimen are critical to 
ensure negative margins. The current approach to margin assessment in most 
tumor types is circumferential analysis of the resected specimen using frozen 
sections.44 Therefore, only a fraction of the tumor mass can be analyzed due 
to the limited sampling that is feasible with frozen sectioning. A tumor-specific 
fluorescent contrast agent can be leveraged to perform fluorescent mapping 
of the surgical specimen. Fluorescent ‘hot spots’ could be used to direct 
clinicians toward suspicious regions, and thereby reduce sampling error. The 
detection of a fluorescent signal using back-table benchtop devices could also 
result in reduction of time needed for specimen analysis, since sampling can 
be performed based on fluorescent positive areas, as opposed to sampling all 
surfaces of a large tumor specimen (i.e. hepatic tumor resections).
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Data representation from intraoperative imaging
During surgery, fluorescence imaging should be performed at multiple fixed 
time points as outlined in the clinical trial protocol and standard operation 
procedure (SOP). For example, one can identify three imaging time points to be 
used in most trials; first, while scanning the area of interest for the localization 
of the primary tumor and/or detection of metastases prior to excision. Second, 
once the tumor has been exposed while still in situ, with surrounding normal 
tissue in the field of view. And third, after resection of the primary tumor for 
assessment of the wound bed. During surgery, both endoscopic and open-field 
imaging systems can be used. In some operative cases, such as an abdominal 
laparotomy that is converted to an open procedure, both systems can be used 
at different timepoints. Since the two devices will generate data that is not 
necessarily comparable, it is important to clearly state which device’s data 
will be used in a clinical trial and document this in the SOP. Depending on the 
capabilities of the fluorescent camera, multiple images should be obtained 
in each setting; a bright field image, a black-and-white fluorescent image, 
a pseudo-colored fluorescent overlay image, and/or a heat-map whereby 
fluorescent signal intensity differences are displayed in different colors (Figure 
2). Ex vivo imaging of fresh tissue should be presented in a similar manner. 
Quantitative data of intraoperative images should consist of a numeric value 
representing fluorescent signal. This can either be reported in MFI values or in 
a ratio such as TBR. 
The development process of an optimal intraoperative imaging strategy should 
keep in mind the specific nature of the surgical workflow in order to minimize 
Figure 2. Suggested method of reporting intra-operative imaging results. This includes a bright field 
image (A), black-and-white fluorescent image (B), fluorescent overlay image (C), and fluorescent heat-
map (D). In this case, an example of a tumor-positive lymph node during abdominal surgery is shown.
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interruptions and facilitate the adoption of this technology. Early phase clinical 
trials are designed to demonstrate the safety, appropriate dose and tumor 
specificity of experimental agents. For these trials, the secondary outcomes 
primarily focus on the tumor-specific contrast that is generated between tumor 
tissue and background tissue using the agent-device combination. Regulatory 
standards ensure the workflow of these early phase trials maintain the standard 
of care, which makes it difficult to objectively assess the potential clinical value 
and patient benefit of FGS. For larger clinical trials, clinically relevant endpoints 
that necessitate experimental assessment will be needed to demonstrate 
superiority to the current standard of care. Examples of secondary endpoints 
include improved detection of tumor-positive margins, decreased morbidity, 
reduced local recurrence, or increased efficiency in the operating room.30 These 
endpoints can be directly correlated with known statistics pertaining to survival, 
thereby demonstrating clinical benefit.
It is important to recognize that the success of these trials will be influenced 
by the parameters of the clinical imaging devices employed. Not all imaging 
devices are able to show a TBR in real-time, and the significant differences 
in sensitivity among the various devices will make it challenging to achieve 
consistency and compare results regarding the clinical utility of tumor-specific 
contrast agents. Another limitation that should be recognized is the inability 
to directly correlate intraoperative images with pathology results in real-time. 
Therefore, dependence on ex vivo imaging to confirm tumor status will remain 
a critical component of FGS validation, especially in early phase clinical trials 
where confirmation of tumor specificity is critical. To circumvent this limitation, 
ex vivo imaging can be done in the form of back-table fluorescence imaging 
in the operating room using either a clinical camera, or a bench-top device, 
developed for this purpose. These results can later be directly correlated to the 
pathological assessment.6-13
II. Specimen Mapping
An important stage in the validation of FGS is the correlation of the fluorescent 
imaging-based results with the pathologic findings, which is used to determine 
if the fluorescent signal is specifically localizing to the tumor. It is recommended 
that the correlation be performed in a standardized and rigorous method as 
described in Figure 3. After analysis of the resected fresh tissue, the surgical 
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Figure 3. Detailed overview using a clinical example of the ex vivo mapping process of a surgical spec-
imen to ensure exact correlation of the surgical specimen with pathologic assessment. During step 1 
the fresh tissue specimen is imaged ex vivo to ensure images from all angles. After formalin fixation, 
the specimen is mapped and sliced into bread loaves in step 2. Fluorescence imaging is subsequently 
performed of the bread loaves separately. In step 4 cassettes are made that include one bread loaf each 
and are imaged either on a fluorescence scanner or in a closed-field imaging system. The cassettes are 
then paraffin-embedded and sectioned to produce microscopy slides. In step 5, these slides are used 
for pathologic assessment and fluorescence scanning. 
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specimen is processed into bread loaves (either before or after formalin-fixation) 
and later into blocks to be placed in cassettes (Figure 3). These cassettes are 
then imaged on a fluorescent scanner both before and after paraffin embedding. 
Finally, these cassettes are processed into microscopy slides where fluorescence 
can then be correlated with hematoxylin and eosin (H&E) histopathology. These 
steps are possible when the fluorescent capabilities of the probe are maintained 
after formalin-fixation. Additional immunohistochemical correlation of the 
target of interest and H&E should be performed to determine co-localization of 
the target and fluorescence, which will be discussed later.
Mapping process of the gross surgical specimen
To facilitate the processing of the specimen, a bright-field image of the 
gross surgical specimen can be acquired and used as a reference map as the 
specimen is sectioned and placed into cassettes. The origin of the cassette-
specific sections can be drawn on a printed or digital image of the primary 
specimen and saved for later correlation at the time of histopathologic study. 
This methodology is commonly employed during pathological processing of 
large surgical specimens. Precise imaging of the gross specimen and close 
correlation with histopathologic sections increases the efficiency and accuracy 
of pathologic assessment and enables consistent and accurate interpretation 
of the technique’s specificity. This method is anecdotally used during Mohs 
surgery and is also described in the standardized pathologic assessment of 
breast cancer specimens.45 It is important to maintain the specimen orientation 
relative to the patient so that the slide-mounted section can be registered back 
to the primary specimen, and ultimately to the wound bed. This approach will 
allow the clinician to determine if fluorescence observed on either the resected 
specimen or in the wound bed is clinically relevant and a source of potential 
recurrence.
Data representation of ex vivo imaging
After removal from the patient, the fresh specimen is imaged at the back-table 
using a benchtop device or the surgical camera. Fresh tissue should be imaged 
when possible and fluorescent intensity should be expressed relative surface 
area of the specimen. 
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After imaging the fresh surgical specimen, the tissue should be formalin-fixed 
prior to being processed into bread loaves. Formalin-fixed tissue can still be 
used for qualitative and quantitative analysis of fluorescent imaging signal, in 
contrast to paraffin-embedded tissue which is more suitable for qualitative data 
analysis. Cassetted, formalin-fixed tissues are ideal for identification of complex 
tumor-containing tissues since both the orientation and size are matched to the 
hematxoylina and eosing (H&E) stained slide of that specific block after paraffin 
embedding. 
Quantitative analysis of formalin-fixed tissue can be performed in two ways. 
First, an absolute quantitative comparison of MFI from the raw data can be 
performed between tumor tissue and normal surrounding tissue, either per 
patient or per dose cohort, as demonstrated by an example in pancreatic cancer 
in Figure 4A. Alternatively, a semi-quantitative scoring method could be used 
to determine the percentage of fluorescent tissue, compared to the percentage 
of tumor tissue per tissue block (Figure 4B). The amount of tumor tissue can be 
assessed on the H&E slide from a particular block, while fluorescence can be 
Figure 4. Quantitative analysis of ex vivo imaging. Quantitative analysis of formalin-fixed tissue can 
be performed in several ways. Two examples are shown here. (A) a quantitative comparison using the 
calculated MFI could be performed between tumor tissue and normal surrounding tissue, either per 
patient or per dose cohort. (B) a semi-quantitative scoring method could be used to determine the 
percentage of fluorescent tissue, compared to the percentage of tumor tissue per tissue block.
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measured either with a fluorescent scanner or a closed-field imaging device of 
a deparaffinized slide.Qualitative representation of ex vivo imaging preferably 
includes images of the ex vivo specimen, a bread loaf slice and the corresponding 
cassette to ensure correlation, as also shown in Figure 3. In this context, the 
bright field image, a black-and-white fluorescent image, and fluorescent overlay 
image should be shown of each specimen, and ideally also a fluorescent heat-
map image.
III. Target validation
After paraffin-embedding of the tissue, the fluorescent signal will be attenuated. 
This influences the quantification properties of the signal. This, on the other 
hand, does not influence two other key aspects of data analysis in FGS trials. 
In the pathologic assessment one should focus on (1) confirmation of tumor 
targeting using histology, and (2) confirmation of molecular targeting of the 
biomarkers to the tumor cell. Lastly, correlation of fluorescent intensity with the 
density of the target molecule can be performed (Figure 1, panel III). Other key 
factors associated with delivery of the agent can also be assessed in this stage 
including vascular density, the presence or absence of lymphatic vessels, and 
the amount of cell proliferation.
Confirmation of tumor cell targeting
As discussed above, this step allows for direct correlation between tissue 
fluorescence and tumor status on H&E. In early phase trials, this step is critical 
to ensuring the agent is indeed targeting the tumor. Confirmation of tumor 
status on the H&E slides should be performed in close collaboration with a 
trained pathologist, who is preferably blinded to the fluorescent imaging 
results. With the use of a fluorescent scanner, the location of fluorescence can 
be detected with a µm resolution. Because the tumor is often composed of 
stromal elements, it will be necessary to distinguish between tumor/cancer cell 
targeting and targeting of other structures within the tumor mass.
If the mapping process (as described above) is performed in a rigorous manner, 
the correlation generated at this step can be traced back to the images of the 
intact gross surgical specimen acquired during back-table imaging. It is even 
possible to apply this correlation back to the intraoperative findings; however, 
this is complicated by the necessary preservation of the specimen’s orientation 
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at each step in addition to the influence of ambient light on intraoperative 
fluorescence.
Confirmation of molecular targeting
In the case of a targeted agent, the confirmation of precise tumor targeting 
should be a required step of the data analysis. Here, co-localization of the 
target of interest and fluorescent signal shows that the agent truly targets the 
biomarker, as compared to fluorescent signal seen in the tumor as a result of 
the EPR effect. A (semi-) quantitative analysis can be performed to analyze the 
fluorescent intensity relative to the receptor density of a specific tissue section 
(Figure 1). Co-localization can be performed using serial tissue sections, where 
one slide is used for immunohistochemistry (IHC) to confirm the target biomarker 
and one is used for fluorescent scanning. Additional IHC may be performed to 
gain a better understanding of the behavior of the factors influencing the tissue 
target; for example, for markers that influence delivery of the agent such as 
vascular density, the presence of lymphatic vessels, and the amount of cell 
turnover. Therefore, this staining will uniquely be performed during early phase 
trials when this information is relevant to advancing the agent and further 
characterizing its potential as a fluorescent biomarker. In later phase trials, one 
could choose to perform additional staining if the imaging results of a patient 
are out of the range of what is expected but would not necessarily be performed 
routinely. Fluorescent microscopy may be introduced into future analyses in FGS 
clinical trials in order to determine the position of the imaging agent in the 
tumor, e.g. membrane-bound, internalized, or in stroma.
SUMMARY AND CONCLUSION
To ensure wide-spread use and FDA approval of FGS, the quality and 
standardization of reporting is paramount. Therefore, we present here 
recommendations for standardized reporting with the goal of establishing 
a set of minimum requirements for reporting FGS clinical trial results. In this 
approach, both qualitative and quantitative data play a major role. Three critical 
elements of early phase clinical trials can be identified and should be reported: 
1) Intra-operative data collection: FGS has the potential to play a unique role 
in the identification of tumor tissue, assessment of resection margins, and 
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detection of tumor-positive lymph nodes, especially in locations that would 
suggest metastatic disease. In early phase trials, qualitative data should consist 
of multiple images obtained in each setting which include a bright field image, 
a black-and-white fluorescent image, a pseudo-colored fluorescent overlay 
image, and/or a heat-map. Quantitative data should consist of numerical values 
reporting fluorescence, preferably both raw MFIs and a ratio such as TBR. 
2) Specimen mapping: This is critical to the validation of FGS to correlate 
fluorescent imaging-based results with the pathologic findings, preferably using 
fresh tissue. After imaging the fresh surgical specimen, the specimen should be 
formalin-fixed. Formalin-fixed tissue can be used for qualitative and quantitative 
analysis of fluorescent signal, in contrast to paraffin-embedded tissue which is 
more suitable for qualitative data analysis. 
3) Target validation: Co-localization of the target of interest and fluorescent 
signal needs to demonstrate that the agent truly targets the biomarker. A semi-
quantitative analysis can be performed to analyze the fluorescent intensity 
relative to the receptor density of a specific area. In summary, if these guidelines 
are widely accepted, trial results could be comparable and collated to expedite 
future FDA approval.
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In the field of molecular imaging, significant progress has been made over the 
last years. Tumor-specific optical imaging has entered clinical trials, and safety 
and feasibility has been shown for several cancer types. This thesis shows the 
complete roadmap from preclinical development and validation to clinical 
translation in a phase I trial for pancreatic cancer patients. Now, next steps 
need to be taken by the field to move this technique from Phase I trials to more 
wide-spread use and larger clinical trials. To be able to achieve wide-spread 
use, more specific aspects of tumor biology need to be taken into account, 
especially the effects of neoadjuvant therapy, before tumor-specific imaging can 
be applicable in all patients. Also, inter- and intrapatient tumor heterogeneity 
is a known complicating factor in the search for optimal biomarkers for tumor 
detection. 
The search for the ideal biomarker
In pancreatic cancer, it is known that tumor cells are selected by means of fitness 
and growth advantages.1 Cells that enter the blood stream from the site of the 
primary tumor and lead to metastases, are probably the cells that have achieved 
the highest fitness in the primary site. These have the greatest chance of homing 
in new microenvironments, such as the liver, lung or peritoneum, which are the 
common sites of metastasis in pancreatic cancer.1 Homing of tumor cells into 
new microenvironments will lead to novel mutations, and consequently further 
heterogeneity, both between the primary lesions and metastases, and between 
different metastases. This heterogeneity will make it almost impossible to 
identify a single biomarker that would allow, tumor-specific imaging for each 
tumor in each patient. To solve this issue, one could imagine that in the future 
multiple imaging agents directed against different biomarkers are available, 
and that prior to surgery the most optimal agent is chosen, based on biomarker 
expression from biopsy tissue. This would, on the other hand, not solve the 
problem of heterogeneity within the primary tumor, or between primary tumor 
and potential metastatic sites. An additional complicating factor in pancreatic 
cancer is that some patients do not receive a biopsy prior to surgery, and if 
a biopsy is taken, the material is not always representative for the suspected 
tumor. In those cases, it could be preferred to use a cocktail with different 
imaging agents, targeting a set of the most common biomarkers.2, 3
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Another complicating factor in the identification of the ideal biomarker, is the 
use of (neo)adjuvant therapy. This form of therapy undoubtly influences the 
biomarker expression on tumor cells. This phenomena is extensively studied in 
breast cancer patients, but little is known of the effect in pancreatic cancer 
patients.4, 5 In Chapter 4, we assessed the effect of neoadjuvant therapy on 
CEA and αvβ6 expression. There, we have shown the importance of a separate 
analysis on neoadjuvant treated tumor tissue. If neoadjuvant treated patients 
were not included in this IHC analysis. We would have concluded that CEA 
was the optimal target for pancreatic cancer, However, it was seen that CEA 
expression almost disappeared after neoadjuvant therapy, while tumor cells 
remained vital, making it impossible to target that receptor in neoadjuvant 
treated pancreatic cancer patients. Taking this into account, it was concluded 
that αvβ6 was the most ideal biomarker in all clinical relevant situations. 
In this thesis we mainly focused on tumor-specific imaging directed against the 
cancer cell, while in chapter 2, we have also described the possibility to target 
the micro-environment in pancreatic cancer. It is recognized that pancreatic 
cancer for a large part consists out of stroma tissue compared to actual 
tumor cells. Since the micro-environment plays an important role in tumor 
development and progression, it could be of additional value and potentially 
more complete targeting of the tumor could be achieved, when choosing this 
route.6 Since there is currently no experience with targeting only the stroma 
cell compartment in patients, we have chosen to focus on the tumor cells in 
this early phase work for pancreatic cancer. However, in the future, it could be 
recommended to use a cocktail of agents targeting both the tumor, and it’s 
micro-environment. 
Early detection of pancreatic cancer
As described in this thesis, pancreatic cancer has a dismal prognosis, mainly due 
to late onset of symptoms when disease is already spread to other organs, either 
distant or locally. This stresses the need for early detection. Fluorescence-guided 
surgery as described in this thesis will not be beneficial for early detection of 
pancreatic cancer, but early detection of this and other types of cancer could be 
performed in various ways; first, one could focus on identifying and validating 
a biomarker which may likely be very different compared to those of late stage 
disease. Identification of these kind of early biomarkers could be done in studies 
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like the baseline study recently initiated by Verily Life Sciences, performed in 
10.000 healthy volunteers who will be monitored daily (NCT03154346). These 
studies will generate invaluable data regarding early signs of disease, and the 
time until development of symptoms. Another method for the early detection 
of pancreatic cancer could be to develop a standardized bio-repository with 
longitudinal follow-up, established in patients with pancreatic cancer precursor 
lesions such as IPMN or with high risk for pancreatic cancer based on family 
history and established genetic risk factors. By the collection of tissues, cystic 
fluids, serum and plasma, captured prior to pancreatic cancer onset, predictive 
and early detection biomarkers can be identified. The next challenge after 
identification of biomarkers associated with early onset of disease, is the method 
to detect these markers. This can be performed in bodily fluids, such as the 
FOPT test in colon cancer, or by using imaging, such as breast cancer screening. 
In the thesis, we have focused on the improved detection of pancreatic cancer by 
targeted imaging. Both targeted ultrasound, in form of photoacoustic imaging, 
and targeted PET-CT could be used for this purpose. Photoacoustic imaging 
with targeted agents, such as microbubbles, could be a non-invasive way to 
image the pancreas for screening purposes.7, 8 Due to the costs and radiation 
used for targeted PET-CT imaging, this would not be a imaging method used 
in the general population for screening, but could be used in high-risk patients 
during periodical screening.
Other novel molecular imaging techniques
In addition to fluorescence and photoacoustic imaging, other potential novel 
molecular imaging techniques could be beneficial during surgery. In chapter 
2 of this thesis, Raman imaging is shortly addressed, together with the 
advantages and disadvantages. Raman and Cherenkov luminescence imaging 
(CLI) are molecular imaging techniques that receive tremendous attention 
in preclinical research, but currently, clinical applications are limited. In CLI, 
the visible photons emitted by Cherenkov radiation are captured, resulting in 
optical imaging of radiotracers, which could be used for intraoperative guidance 
in a way SPECT is used now in clinical trials.9 CLI could overcome the depth 
limitation of fluorescence-guided surgery, since it used radiation for visualization 
instead of emitted light. Thorek and colleagues described the successful use of 
CLI in patients undergoing FDG-PET in 2014,10 but since then no clinical studies 
are performed. The main advantage of Raman imaging is that it could be used 
Discussion and future perspectives | 287
for multiplexing. The advantage of multiplexing is that it allows simultaneous 
detection of multiple biomarkers which is ideal in case of heterogenic tumors. By 
varying the Raman active layer, different Raman particles can be created, each 
emitting a characteristic spectrum. Since each type of particles has a unique 
spectral signature they can be used for multiplexing when functionalized for 
different targets.11 For now, a disadvantage of Raman imaging is the duration 
it takes to scan a tissue surface, limiting the clinical applicability. To overcome 
this limitation, Garai and colleagues developed a clinical endoscopic Raman 
system able to rapidly scan large tissue surfaces such as colon.11 
A standard method to assess novel imaging agents
As described in this thesis, multiple early phase clinical trials are performed in 
the field of fluorescence-guided surgery. In Chapter 12, we described the need 
for a uniform set-up of these clinical trials. Currently, most trials are designed 
just to show feasibility of the technique. By now, enough proof is generated 
showing the capability of targeting tumors in a tissue-specific manner using 
optical imaging agents. At this point, the field should move one step further 
and show the world this technique helps to improve surgical care for the patient 
otherwise wide-spread use will not be reached. Furthermore, to get novel 
imaging agents approved by regulatory bodies, large trials showing patient 
benefit have to be performed. To execute these large clinical trials, extensive 
resources are needed which are mostly only possible when supported by 
industry. However, if the clinical trials would be designed in a similar manner 
and shared endpoints are chosen, results of different trials could be put together 
and collective conclusions could be drawn, leading to a more cost-efficient and 
less time-consuming strategy as described in chapter 8.
Quantification in fluorescence imaging
Another crucial aspect which is still in its infancy in fluorescence-guided 
surgery is quantification of the signal. At this point, the intra-operative use 
of fluorescence is based on binary “fluorescence yes or no”, instead of the 
numerical intensity of the signal. The problem with this way of interpreting 
fluorescence is that most imaging systems have an incorporated method to 
enhance the imaging signal even when it is weak, and therefore it is not clear 
for the surgeon how intense the signal actually is. This is important because 
depending on the imaging agent, normal tissue could express the biomarker 
13
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and therefore some fluorescence signal as well. In these cases, the intensity of 
the signal provides information on how likely it is that the fluorescent tissue 
is actual tumor. Although the potential of tumor-specific optical imaging is yet 
to be realized, tumor-specific intraoperative optical imaging is likely to play 
an important role in the identification and treatment of cancer in the near 
future. Therefore, real-time quantification should be available to provide better 
understanding of the signal to the surgeon and increasing the sensitivity and 




The future of cancer treatment
This thesis shows the great potential of tumor-specific imaging and it is 
expected that it’s use both in the diagnostic process and for intra-operative use 
will increase in the future. In the past, treatments in general, but specifically 
in oncology were based on a “one-size fits-all”-strategy undervaluing all the 
different characteristics disease and patients can have. Later on, this was 
optimized by stratification of patients by disease subtypes, clinical features 
and demographics. This method still did not lead to the preferred results in 
patient outcome, and therefore at this point there is a need to further specialize 
care based on precision medicine. Here, a doctor needs to look at the individual 
patient and has to take patient preferences, demographics, medication history, 
clinical features of the disease, biomarkers and behavior into account when 
deciding on the most optimal treatment. The call for precision medicine will 
require the need to search for treatment strategies that are focused on these 
specific characteristics of the tumor and the patient. Since the results of early 
phase clinical trials in the field of tumor-specific imaging are promising, this 
modality could help to fill part of that need. 
The future of surgery
Besides the need for precision medicine, the increasing use of minimally-
invasive surgery (MIS), such as robotic-assisted and laparoscopic surgery, 
requires a method to substitute the lack of tactile information for the surgeon. 
During open surgery the consistency of tissue gives the surgeon tremendous 
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information regarding the potential benign or malignant nature of the tissue. To 
substitute this information in MIS, novel methods are needed providing visual 
feedback to the surgeon regarding the tissue status. This visual feedback could 
come from a fluorescent imaging signal in case of tumor-specific imaging. For 
photoacoustic imaging, the second intraoperative optical imaging modality 
discussed in this thesis, this becomes more challenging. Photoacoustic imaging 
requires an ultrasound probe able to enter the abdominal cavity through 
laparoscopic trocars. At this point, such photoacoustic imaging probes are not 
available yet, however certain groups are working on this feature. Also, the 
photoacoustic signal cannot be projected on the screen already used by the 
surgeon to perform the surgery, so an additional device and screen are needed 
in the operating room.
The future of pancreatic cancer diagnostics
Precision medicine will not only change the way surgery is performed 
nowadays, also the diagnostic process needs to implement this phenomena. In 
this thesis the first steps of this transition are shown in chapter 9 using tumor-
specific PET-CT imaging to diagnose pancreatic cancer. In the case of pancreatic 
cancer, tissue-specific diagnostics could help differentiating between tumor 
and inflammation prior to resection and/or to determine resectability. Also, this 
method could potentially be used to monitor response to neoadjuvant therapy. 
A large clinical trial is about to start in the LUMC investigating this specific 
aspect. Another area of development for both diagnostic and intra-operative 
tissue-specific imaging is hybrid imaging were one agent is conjugated to both 
a radioactive label for diagnostics and a fluorescent label for intra-operative 
use. The main benefits of this method are the fact that a patient has to undergo 
only one injection with the agent, the high probability that the same lesions 
are found both on the diagnostic modality as during surgery, and the possibility 
to perform radioguided surgery together with fluorescence. In this case, both 
the fluorescent and the radioactive signal can be used during the surgery 
with a Gamma counter and a fluorescent camera. The radioactive signal can 
be used to direct the surgeon to the area of interest and the high sensitivity 
of the fluorescence for the actual resection or identification of the tumor.12 
Besides these important benefits of a hybrid agent, the use of two separate 
agents should be preferred looking at the logistics in a hospital. In case of 
a hybrid agent, the diagnostic imaging and the surgery should be performed 
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within a few days to be able to use both the radioactive and the fluorescent 
signal since both will decay after a certain amount of time. In addition, the 
radioactive signal cannot be too high during surgery, exposing the surgeon and 
the OR team to radioactivity. Therefore, a hybrid agent is an interesting idea for 
research purposes, but it remains questionable how feasible this is for actual 
patient care.
The future of fluorescence guided surgery
When looking at the future of fluorescence guided surgery, not only the 
NIR window from 700-900 nm has become of interest to the field, also 
the wavelengths in the second near-infrared window (NIR II) of 900 nm and 
above seem promising.13, 14 Preclinical research using these wavelengths show 
diminished tissue autofluorescence, reduced photon scattering, and low levels 
of photon absorption allowing centimeters imaging depth at low resolution and 
micron-scale resolution at low depths.13 Until recent, all NIR-II fluorophores 
were inorganic nanomaterials, which are excreted slowly and are largely 
retained within the reticuloendothelial system, making clinical translation 
nearly impossible due to unknown long-term toxicity concerns.15 In 2015, 
Antaris and colleagues published a study developing a small molecule dye for 
the NIR-II window of 8.9 kDa with renal excretion.16 The agent outperformed 
ICG on several levels in mouse models. The disadvantage of this small molecule 
dye is the labor-intensive and expensive synthesis, making large scale synthesis 
for human use impossible. Thus far, no clinical results using NIR-II imaging 
are shown and no clinical imaging systems are available. As seen in the past, 
it is hard to translate successful preclinical results into the human situation, 
therefore the potential benefit of NIR-II imaging for patient care with clinically 
available agents is still something that needs to be investigated in the future. 
The future of organ-sparing strategies in cancer treatment
Especially in rectal and breast cancer, another aspect that becomes increasingly 
important in the way medicine is practiced today, is the trend towards organ-
sparing treatment. For pancreatic cancer this is not a feasible treatment option 
for now, since successful neoadjuvant regimens have just been initiated in this 
disease and long term effects still need to be investigated. Studies have been 
suggesting that “organ preservation” strategies might be appropriate alternatives 
to standard resection in patients with a clinical complete response (cCR) on 
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neoadjuvant therapy.17, 18 In a so-called “Watch-and-Wait” (W&W) strategy, 
surgery is omitted and instead, patients are closely monitored with intensive 
clinical and imaging follow-up. Although several successful small cohort studies 
have been conducted in the last years, W&W is not widely adopted yet. One of 
the main reasons is because the accuracy of conventional imaging modalities 
is insufficient, resulting in reported 2-year local tumor regrowth rates of 15-
33%.19 With tumor-specific targeted imaging, a non-invasive imaging approach 
can be implemented to help improve the response monitoring during diagnostic 
imaging in these patients. This specific use of tumor-specific imaging also 
increases the need to identify a biomarker which is present on viable tumor 
cells, but not on chemotherapy-induced necrosis and fibrosis.
In the future, molecular imaging could not only be used to diagnose and treat 
patients directly. Also for the development of novel drugs molecular imaging 
could play an important role. Imaging could be used to inform physicians and 
researcher and lead to better understanding for the most optimal implementation 
of novel drugs. In drug development, imaging could provide information on 
biodistribution, the difference between individuals on pharmacodynamic and 




Pancreatic cancer remains an extremely challenging disease for a surgeon to 
tackle. Since most of the patients will not benefit from surgical resection, it is 
essential to be able the select only those patients that will benefit. Implementing 
tumor-specific imaging, both in the diagnostic process and during surgery will 
improve the detection of small lesions, assess resection margins, and help to 
identify a non-curative resection. In this thesis, we have identified integrin αvβ6 
as the most optimal target for pancreatic cancer, to distinguish cancer from 
normal pancreatic tissue and inflammation. Also, expression is retained after 
neoadjuvant therapy in vital tumor cells compared to chemotherapy-induced 
necrosis and fibrosis. In preclinical mouse models, we have shown the potential 
to target αvβ6 using a fluorescent agent, and in healthy volunteers and patients 
the possibility is shown to diagnose pancreatic cancer targeting αvβ6 with 
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PET-CT imaging. In addition, we have proven the safety and feasibility of tumor-
specific fluorescence imaging using cetuximab-IRDye800 for the intraoperative 
detection of pancreatic cancer, even in the case of subclinical disease.
Now that practicing medicine has changed to a more precision-type approach, 
tailored for each patient, tumor-specific optical imaging is likely to get an 
important role. Before this role can be claimed by the field, we have stressed 
the need to proof of patient benefit by showing improved survival and reduced 
morbidity. This can be achieved by performing large, randomized controlled, 
clinical trials, by developing a standardized way clinical trials are performed, 
and by choosing relevant clinical endpoints. Hopefully this can lead to wide-
spread implementation of this technique in the near future, and eventually to 
improved prognosis for patients with pancreatic cancer.
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For years, pancreatic cancer had a dismal prognosis with a long term survival 
of around 5%. Since the centralization of pancreatic cancer surgery and the 
introduction of systemic chemotherapy with FOLFIRINOX, the median overall 
survival increased from 6-13%, after gemcitabine therapy, to around 20%. 
However, even with the introduction of these novel treatment regimens, the 
achieved survival rates remain disappointing compared to other cancer types. 
Consequently, radical tumor-margin free resection provides the patient with 
the best potential chance for cure. However, due to late onset of symptoms, 
the majority of patients present with inoperable disease. These patients can 
benefit from neoadjuvant therapy, or palliative chemotherapy. During clinical 
practice, this means that decision-making before and during surgery is critical to 
select the most optimal primary treatment modality for the patient. Currently, 
conventional imaging modalities lack sensitivity to detect small metastatic 
lesions, and are unable to visualize treatment response on neoadjuvant therapy. 
Tumor-specific molecular imaging in the form of fluorescence and photoacoustic 
imaging aids the surgeon to accurately recognize and resect malignant tissues 
in real-time during surgery. The other form of this kind of imaging, PET-CT using 
radioactive signal, can be used in the perioperative process to assess tumor 
spread and help in the surgical planning. This thesis focuses on the challenges 
a surgeon faces during pancreatic cancer treatment, and the potential 
improvements that could be achieved by the use of tumor-specific imaging. In 
addition, the regulatory aspects of clinical translation of tumor-specific optical 
imaging agents are addressed.
Part 1: Development of Targeted Molecular Imaging for Pancreatic Cancer
Chapter 2 describes the current clinical imaging applications for the detection 
of pancreatic cancer, and the upcoming molecular imaging strategies with 
emphasize on tumor-specific intra-operative imaging. This technique has 
shown great potential in order to bridge the gap between diagnostic and intra-
operative imaging for pancreatic cancer treatment. In this chapter the need for 
an optimal biomarker to perform tumor-specific imaging is described together 
with the advantages and disadvantages of several biomarkers. 
To be able to implement a novel technique, such as tumor-specific imaging, in 
patient care and achieve actual improvement in outcomes, one needs to know 
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where this technique needs to make a difference. This element is describes 
in chapter 3, where a retrospective study is reported showing that a margin-
positive (R1) resection is a major contributor to reduced survival and early 
recurrence, especially in patients with lymph node negative (N0) disease. 
As stressed before, a biomarker is needed to be able to perform tumor-specific 
imaging. Idealy, this biomarker is able to discriminate between pancreatic 
cancer and inflammation since this is challenging both at preoperative imaging 
and during surgery. In chapter 4 of this thesis an immunohistochemistry study 
is performed identifying such a biomarker, which is also overexpressed on 
associated lymph node metastases and on vital tumor cells after neoadjuvant 
therapy. It was concluded that both integrin αvβ6 and carcinogenic embryonic 
antigen (CEA) are promising candidates, especially when used in combination. 
Integrin αvβ6 has the advantage over CEA that this biomarker retains expression 
after neoadjuvant radiochemotherapy.
Part 2: Validation of Targeted Molecular Imaging for Pancreatic Cancer
In chapter 5 a novel fluorescent imaging agent is developed targeting integrin 
αvβ6. This agent consists of an existing cysteine knottin peptide, R01-MG, 
conjugated to the near-infrared (NIR) fluorescent dye IRDye800. This agent is 
validated extensively in preclinical mouse models, showing specific targeting 
to αvβ6 and a significantly higher tumor-to-background ratio (TBR) compared 
to normal pancreatic tissue in transgenic mouse models. Chapter 6 focusses on 
early detection of cancer in preclinical models, using activatable agents. These 
agents can be used for early detection because the agent is only “turned-on” in 
the tumor microenvironment, which dramatically improves sensitivity of cancer 
detection.
Part 3: Clinical Translation of Targeted Molecular Imaging
Targeted molecular imaging is a novel technique which requires regulatory 
approval before this technique can have wide-spread use in patient. Targeted 
molecular imaging is unique in its ability to provide real-time feedback to 
the surgeon in the case of intra-operative imaging, complicating the approval 
process. In addition, this technique requires the use of both an agent and an 
imaging device, which are important considerations in this process. Chapter 7 
describes the regulatory hurdles in detail. Important here is that the proposed 
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“indication for use” will direct all future studies needed for approval, and 
therefore, should be chosen carefully. Success or failure of optical imaging 
agents will critically depend on the design of clinical trials and the chosen 
endpoints. In chapter 8 insight is given into the process of engaging the FDA 
in the evaluation of tumor-specific imaging agents, and a guide for designing 
optimal optical imaging clinical trials. 
Part 4: Clinical Application of Targeted Molecular Imaging for Pancreatic 
Cancer
This part is focused on the clinical use of this novel technique describing early 
phase clinical trials performed in pancreatic cancer patients. In the diagnostic 
process, tumor-specific PET-CT imaging could improve the detection of 
pancreatic cancer and aid the perioperative process to assess tumor spread and 
help in the surgical planning as shown in chapter 9. Targeting αvβ6 using [18F]
FP-R01-MG-F2, provided an elevated imaging signal in the tumor compared 
to normal pancreas. In chapter 10, the first-in-human use of multimodality 
molecular imaging for the intra-operative detection of pancreatic cancer is 
reported using cetuximab-IRDye800 that binds to epidermal growth factor 
receptor (EGFR). Fluorescent imaging successfully identified tumor with a 
significantly higher mean fluorescence intensity (MFI) compared to normal 
pancreatic tissue and inflammation, with a sensitivity of 96.1% and specificity 
of 67.0%. In addition, the mean photoacoustic signal in the tumor was 3.7-
fold higher than surrounding tissue. In chapter 11 a more in-depth analysis is 
performed on the ability of tumor-specific fluorescent imaging to detect visually 
occult tumor-positive lymph nodes during surgical resection of pancreatic 
cancer. With the use of cetuximab-IRDye800 peritumoral lymph nodes were 
detected with a sensitivity of 100% and specificity of 78% macroscopically. Also, 
this method was able to detect occult foci of tumor (< 5mm) with a sensitivity 
of 88%.
Part 5: Future Directions for Targeted Molecular Imaging
In chapter 12 of this thesis the future of tumor-specific optical imaging is 
discussed. To eventually achieve wide-spread use of this novel technique 
patient benefit needs to be shown as discussed in this thesis. Therefore, larger 
trials are needed with correctly chosen endpoints. To put the results of different 
studies into a broader perspective, results of different clinical trials should be 
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comparable. In chapter 12, a format is presented to standardize the way results 
of tumor-specific imaging trials are reported, which will hopefully lead to a more 
generalized method in which results can be better appreciated. Eventually, this 
will ensure that results of different trials can be pooled and hopefully used 





Tot op heden had pancreascarcinoom een zeer slechte prognose met een lange 
termijn overleving van ongeveer 5%. Door de centralisering van de chirurgie voor 
pancreascarcinoom en de introductie van het nieuwe chemotherapie schema 
FOLFIRINOX, is de mediane overleving verbeterd van 6-13% na gemcitabine 
behandeling, naar ongeveer 20%. Ondanks deze nieuwe behandelmethoden, 
blijven de behaalde sterftecijfers achter bij andere vormen van kanker. Hierdoor 
is het nog steeds zo dat radicale resectie met tumor-vrije (R0) resectie marges 
de patient de beste kans op genezing biedt. Echter, gezien het feit dat de 
symptomen van pancreascarcinoom zich pas in een laat stadium manifesteren, 
presenteert het grootste deel van de patiënten zich met inoperabele ziekte. 
Deze patiënten kunnen wel gebaat zijn bij neoadjuvante therapie, of palliatieve 
chemotherapie. Dit betekent dat het gedurende het diagnostische proces en de 
operatie van cruciaal belang is om onderscheid te kunnen maken tussen deze 
patiënten groepen, om de meeste optimale primaire behandelmodaliteit te 
selecteren voor de individuele patiënt. Op dit moment kan dat niet gerealiseerd 
worden aangezien de conventionele beeldvormingsmodaliteiten niet sensitief 
genoeg zijn om kleine metastasen te identificeren en om het behandeleffect na 
neoadjuvante therapie te monitoren.
Tumor-specifieke optische beeldvorming, zoals fluorescentie beeldvorming en 
foto-akoestische echo, heeft de potentie dit gat op te vullen. Deze techniek kan 
de chirurg tijdens de operatie helpen bij het herkennen en reseceren van tumor 
weefsel. Een andere vorm van tumor-specifieke beeldvorming is PET-CT, welke 
een radioactief signaal gebruikt voor het in beeld brengen van het beoogde 
weefsel. Dit kan gebruikt worden in het perioperatieve proces om verspreiding 
van ziekte te detecteren, zowel lokaal als op afstand, en om te helpen bij het 
bepalen van een chirurgische strategie. In dit proefschrift word de focus gelegd 
op de uitdagingen waar een chirurg mee geconfronteerd wordt bij de behandeling 
van pancreascarcinoom, en de mogelijke verbeteringen die gerealiseerd kunnen 
worden door het gebruik van tumor-specifieke beeldvorming.
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Deel 1: Ontwikkeling van tumor-specifieke moleculaire beeldvorming voor 
pancreascarcinoom.
Hoofdstuk 2 beschrijft de huidige stand van zaken rond de beeldvormingsmodaliteiten 
die worden gebruikt bij de detectie van pancreascarcinoom, en de nieuw 
ontwikkelde moleculaire beeldvormingstechnieken met focus op tumor-specifieke 
intra-operatieve beeldvorming. Deze techniek heeft de potentie om een brug te 
slaan tussen diagnostische en intra-operatieve beeldvorming bij de behandeling 
van pancreascarcinoom. In dit hoofdstuk wordt ook het belang van een optimale 
biomarker besproken voor het gebruik van tumor-specifieke beeldvorming, samen 
met de voor- en nadelen van enkele biomarkers.
Om te zorgen dat een nieuwe techniek, zoals tumor-specifieke beeldvorming, 
geïmplementeerd wordt in het huidige behandeltraject en te zorgen dat het 
tot verbetering leidt voor patiënten, is het van het grootste belang dat men 
beseft waar een dergelijke nieuwe techniek het verschil kan maken. Om dit te 
onderzoeken is in hoofdstuk 3 een retrospectieve database studie gedaan naar 
het effect van tumor-positieve (R1) resectie marges op overleving en kans op 
recidief. Hierin is aangetoond dat een R1 resectie negatieve invloed heeft op 
overleving en recidief van de ziekte, vooral als de ziekte zich nog niet heeft 
verspreid tot in de lymfeklieren (N0). 
Zoals reeds eerder werd aangegeven is een goede biomarker van essentieel 
belang als het gaat om tumor-specifieke beeldvorming. Voor pancreascarcinoom 
bestaat een ideale biomarker uit een marker die wel voorkomt op 
pancreascarcinoom, maar niet op ontstekingsweefsel of gezond pancreas 
weefsel. Dit is van belang aangezien het voorafgaand aan de operatie met 
de huidige beeldvorming niet mogelijk is dit onderscheid te maken, net als 
gedurende de operatie. In hoofdstuk 4 van dit proefschrift worden de resultaten 
van een immunohistochemie studie gepresenteerd waar een dergelijke biomarker 
is geselecteerd, die ook tot overexpressie komt op tumor-positieve lymfeklieren 
en op vitale tumorcellen na neoadjuvante behandeling. In dit onderzoek is 
geconcludeerd dat zowel integrine αvβ6 als carcinogeen embyronaal antigeen 
(CEA) veelbelovende biomarkers zijn, vooral wanneer deze in combinatie 
worden gebruikt. Het voordeel van het gebruik van integrine αvβ6 als biomarker 
ten opzichte van CEA is dat expressie behouden blijft na neoadjuvante chemo-
radiotherapie.
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Deel 2: Validatie van tumor-specifieke moleculaire beeldvorming voor 
pancreascarcinoom.
In hoofdstuk 5 is een nieuwe fluorescente tumor-specifieke contraststof 
ontwikkeld gericht tegen integrine αvβ6. Deze contraststof bestaat uit 
een peptide, de cysteine knoop R01-MG, welke is gekoppeld aan de nabij-
infrarode fluorescente stof IRDye800. De nieuwe contraststof is gevalideerd is 
verschillende muismodellen waarbij specifieke binding aan αvβ6 is aangetoond 
en een significant hoger signaal in de tumor werd gezien vergeleken met de 
gezonde pancreas in een genetisch gemodificeerd muismodel. In hoofdstuk 6 
wordt de mogelijkheid tot vroege detectie van kanker besproken door middel 
van activeerbare contraststoffen in preklinische modellen. Deze stoffen kunnen 
gebruikt worden bij vroege detectie omdat deze pas een signaal genereren 
als ze zich in de nabije omgeving van de tumor bevinden, wat leidt tot een 
dramatische verhoging van het signaal en daarmee de sensitiviteit van de 
techniek.
Deel 3: Klinische translatie van tumor-specifieke beeldvorming
Tumor-specifieke beeldvorming is een veelbelovende nieuwe techniek die 
goedkeuring vereist van overheidsinstanties zoals de FDA en EMA, voordat deze 
techniek in algemeen gebruik kan worden genomen. In het geval van intra-
operatieve tumor-specifieke moleculaire beeldvorming is een uniek aspect 
de mogelijkheid om in real-time feedback te geven aan de chirurg tijdens de 
operatie. Dit zorgt ervoor dat goedkeuring van deze techniek gecompliceerd 
is. Daarnaast is het een feit dat voor deze vorm van beeldvorming zowel 
een contraststof als een camera of echo apparaat nodig zijn, wat belangrijke 
overwegingen met zich meebrengt in het proces tot goedkeuring van zowel de 
contraststof als de camera. In hoofdstuk 7 worden de uitdagingen die komen 
kijken bij het goedkeuringsproces in detail besproken. Van belang hierbij is de 
indicatie die wordt toegekend aan de camera of de stof aangezien die indicatie 
richting geeft aan alle vervolgstudie die moeten worden verricht. Daarnaast 
hangt het succes van een contraststof af van de uitgevoerde klinische studies 
en de gekozen primaire en secundaire eindpunten. Om die reden is het van 
groot belang kritisch te kijken naar een studie design en zal men zich gedurende 
het proces bij elke stap moeten afvragen of de uitgevoerde klinische studies 
het juiste doel dienen. In hoofdstuk 8 wordt inzicht verschaft in het evaluatie 
proces van een nieuwe contraststof door de FDA en worden adviezen gegeven 
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over het optimale design voor een klinische studie met nieuwe tumor-specifieke 
contraststoffen. 
Deel 4: Klinische toepassing van tumor-specifieke moleculaire beeldvorm-
ing voor pancreascarcinoom.
Dit deel van het proefschrift richt zich op het klinische gebruik van tumor-
specifieke beeldvorming en beschrijf t de eerste klinische studies in 
pancreascarcinoom patiënten. In de diagnostische fase kan tumor-specifieke 
PET-CT de detectie van pancreascarcinoom verbeteren en kan het gebruikt 
worden in het perioperatieve proces om verspreiding van ziekte te detecteren, 
zowel lokaal als op afstand, en voor het bepalen van een chirurgische strategie 
zoals getoond in hoofdstuk 9. Met gebruik van [18F]FP-R01-MG-F2, gericht tegen 
integrine αvβ6, werd een verhoogd PET signaal in de tumor verkregen vergeleken 
met het omliggende pancreasweefsel. In hoofdstuk 10 worden de resultaten 
getoond van een klinische studie die gebruikt maakt van multimodale moleculaire 
beeldvorming voor de intra-operatieve detectie van pancreascarcinoom door 
gebruik te maken van cetuximab-IRDye800, dat is gericht tegen de epidermale 
groei factor receptor (EGFR). Door middel van fluorescentie beeldvorming kon 
tumor worden geïdentificeerd met een significant hoger fluorescentie signaal 
(MFI) vergeleken met gezonde omliggende pancreasweefsel en ontsteking, met 
een sensitiviteit van 96.1% en een specificiteit van 67.0%. Daarnaast was het 
foto-akoestische echo signaal in de tumor 3.7x hoger dan in het omliggende 
weefsel. In hoofdstuk 11 is een diepte analyse verricht omtrent de mogelijkheid 
om tumor-specifieke fluorescentie beeldvorming te gebruiken voor de detectie 
van micrometastasen in lymfeklieren bij pancreascarcinoom. Met het gebruik 
van cetuximab-IRDye800 konden peritumorale lymfeklieren macroscopisch 
worden geïdentificeerd met een sensitiviteit van 100% en een specificiteit van 
78%. Daarnaast was het met deze techniek ook mogelijk om occulte tumor foci 
(< 5 mm) te detecteren met een sensitiviteit van 88%.
Deel 5: Toekomstige perspectieven van tumor-specifieke beeldvorming
Hoofdstuk 12 van dit proefschrift richt zich op de toekomst van tumor-
specifieke beeldvorming. Om ervoor te zorgen dat deze techniek wijdverbreid 
zal worden, zal er moeten worden aangetoond dat de patiënt baat heeft bij 
het gebruik, zoals besproken in dit proefschrift. Om dit te bereiken zijn er 
grote studies nodig met zorgvuldig gekozen eindpunten. Daarnaast is het van 
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belang dat de resultaten van verschillende klinische studies vergelijkbaar zijn 
zodat deze in een breder perspectief geplaatst kunnen worden. In hoofdstuk 
12 wordt een gestandaardiseerde manier gepresenteerd voor het beschrijven 
van de resultaten van klinische studies wat hopelijk zal leiden tot een meer 
gegeneraliseerde manier van rapporteren. In de toekomst kan dit ervoor zorgen 
dat de resultaten van verschillende klinische studies samengevoegd kunnen 
worden en op die manier kunnen bijdragen aan de goedkeuring van nieuwe 
contraststoffen en camera’s. 
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Clubje Chaos, al het plezier dat wij met elkaar hebben gehad en nog steeds 
hebben, zorgt voor een goede balans tussen plezier en hard werken! Dank 
daarvoor!
Lieve Alexandra, paranimf Aal, wat ben ik blij dat ik jou in Den Haag heb leren 
kennen en dat je opeens tegelijk met mij in San Francisco zat! Ik vind het 
bijzonder dat ik dit feest met jou kan delen.
Lieve mam, dank voor je onvoorwaardelijke steun, je eeuwig luisterend oor en 
je vertrouwen in alles wat ik doe. Zonder jou was dit nooit gelukt! Lieve pap, 
dank voor al je interesse en trots bij mijn promotietraject. Jullie hebben samen 
de basis gelegd voor alles wat ik nu doe.
Lieve Quirijn, Johanneke en Fokkedien, met z’n vieren drijven wij elkaar tot grote 
hoogte en zonder jullie was ik nooit zo ver gekomen! Dank voor al jullie steun 
en ik geniet van alles wat we samen doen en hoe we er altijd voor elkaar zijn.
Lieve Twan, als ik iemand veel dank verschuldigd ben, ben jij het wel! Jouw 
eeuwige steun, je kalmte, liefde, geduld en no-nonsense houding hebben mij 
vaak geholpen. Ook voor jou was dit promotietraject niet altijd makkelijk maar 
je bent er altijd voor me geweest, ook toen ik ver weg zat! Heel veel dank!
Willemieke Tummers
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